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Abstract
A series of investigations examining the importance of genetic factors in the 
development of the inflammatory bowel diseases (IBD) namely Crohn’s disease 
(CD), Ulcerative Colitis (UC) and Indeterminate Colitis (IC) has been undertaken in 
Scottish children. This has been performed by collection of clinical details and DNA 
from children with IBD, then analysing the contribution of various candidate genes 
to both disease susceptibility and disease phenotype. In order to carry out these 
studies the presenting features of a large cohort of children from across Scotland with 
IBD diagnosed at less than 16 years were collected, both by examination of hospital 
case records and by patient interview and questionnaire.  For each patient a detailed 
analysis was made of disease phenotype at presentation including detailed 
examination of disease location, disease behaviour and growth parameters. 
A repository of clinical material (DNA, plasma and lymphocytes) was collected from 
children to accompany the detailed clinical parameters allowing genotype-phenotype 
analysis at a later stage. Additionally, DNA was also collected from parents where 
possible to facilitate family based association analysis of candidate genes by 
transmission disequilibrium testing. A previous DNA repository of healthy Scottish 
controls had been collected previously and the data generated was available for use 
in this study. The phenotypic data was collected using an established phenotypic 
classification (the Vienna classification) used in adult studies as well as a personally 
devised paediatric phenotypic classification designed for use in this thesis.
Firstly, the contribution of the three common mutations within the NOD2/CARD15 
gene (R702W, G908R and Leu1007finsC) was analysed in 247 children with IBD. 
The Leu1007finsC variant was associated with Crohn’s disease by case-control (p = 
0.01) and TDT analysis (p = 0.006). Genotype phenotype analysis demonstrated 
NOD2/CARD15 variants were strongly associated with several markers of disease 
severity in CD most notably with an increased need for surgery on multifactorial 
analysis. Then to examine the further contribution of other mutations within the 
whole NOD2/CARD15 gene, the 12 exons of the gene were sequenced in 24 
paediatric CD patients, to identify any additional SNPs that may have conferred an 
increased susceptibility to CD. Two mutations (V955I, M863V) identified in 
xii
sequencing were genotyped in a large patient cohort, but were not found to confer 
increased disease susceptibility. 
Next, the contribution of IBD5 locus was analysed in 299 children with IBD 
studying 5 SNPs, including mutations in the proposed candidate genes OCTN 1 and 
2. Allele frequencies of OCTN1/2 variants were significantly higher in IBD/CD 
cases (p<0.04). The homozygous mutant OCTN1/2 haplotype was increased in IBD 
and UC patients (p = 0.02 for both) compared to healthy controls. OCTN1/2 variants 
however were not independent of the background IBD5 risk haplotype in conferring 
disease susceptibility. Genotype- phenotype analysis demonstrated association of the 
risk haplotype with both lower weight and body mass index centiles at diagnosis as 
analysed by multifactorial analysis. 
The contribution of the 113 G/A mutation within the discs, large homolog 5 (DLG5) 
gene was examined in 296 children with IBD. TDT analysis demonstrated a 
significant association with IBD (p<0.05). Genotype-phenotype analysis 
demonstrated associations with higher social class, male sex and taller children. 
Finally, the Anti-Saccharomyces cerevisiae antibodies (ASCA) status of 301 IBD 
patients was determined. CD patients had a higher prevalence of ASCA antibodies 
compared to UC patients and healthy controls (p<0.001 for both). A positive ASCA 
antibody was more common in CD patients with markers of more severe disease and 
on multifactorial analysis in patients with CD involvement of the oral cavity (p = 
0.001).  
In summary, the candidate genes examined thus far in children with IBD in Scotland 
have demonstrated a relatively minor contribution to disease susceptibility but have 
been demonstrated to be associated with specific disease phenotypes in patients with 
Crohn’s disease. The use of a novel paediatric phenotypic classification in this thesis 
has allowed description of these novel genotype-phenotype associations.  
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1.1 Background
Crohn’s disease (CD [MIM 266600]) , Ulcerative Colitis (UC[MIM 191390]) and 
Indeterminate Colitis (IC),  the chronic inflammatory bowel diseases (IBD), are now 
common causes of chronic gastrointestinal disease in the developed world, with a 
reported prevalence rates of 1 in 250 in Northern European populations.1  Moreover, 
whereas incidence rates in adults appeared to have stabilised in recent years in the 
United Kingdom, compelling data both from within Scotland, and elsewhere in the 
United Kingdom, suggest that the incidence of early onset cases in children continues 
to rise.2-4
IBD is a major cause of morbidity costing an estimated £720 million per year for 
patients in the United Kingdom.5 The major burden of this disease impacts on 
children and young adults with a peak age of onset in the third decade of life. In 
childhood, IBD most commonly presents just before the start of the teenage years 
impacting on emotional and physical development affecting linear growth, education 
and future employment prospects. Treatment of the disease is often difficult and 
there is little evidence to base treatment on from appropriately designed trials in 
childhood with most of the “evidence” distilled from adult studies. An increased 
understanding of disease pathogenesis in childhood could lead to more appropriately 
designed treatment options not only for children but also for adults with IBD.
1.2 Incidence studies
This rising incidence of IBD has been demonstrated in many childhood populations 
across Europe and North America.4;6-11 There has been a near 3 fold increased 
incidence in Scotland initially demonstrated in 2 retrospective studies,2;6 and clarified 
in a UK wide prospective study that surveyed more than 700 new incident cases 
diagnosed at under 16 years of age over a 13 month period.4 The incidence of IBD in 
this survey carried out by Sawczenko et al. between 1998 and 1999 in Scotland was 
found to be 6.5 cases per 100,000 population having increased from 2.6 per 100,000 
in a previous study performed by Barton et al. in 1968. This Scottish incidence 
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compares to a UK average of 5.2 cases per 100,000 in 1998-99 study. The incidence 
figure in Scotland therefore is the highest in the United Kingdom and one of the 
highest rates worldwide.11
Interestingly across Scotland there is a significantly higher incidence of Crohn’s 
disease in the North of Scotland compared to the South of Scotland. In a study of 580 
incident IBD cases studied over the period 1981-95, Armitage et al. demonstrated 
that the incidence of Crohn’s disease in the North of Scotland was significantly 
higher than in the South, 3.1 compared to 2.1 cases per 100,000 population 
respectively (p<0.001).12 Additionally, the same study demonstrated the relative risk 
of developing IBD and CD analysed by Poisson regression analysis was significantly 
increased in areas of relative affluence, compared to areas of socio-economic 
deprivation (p=0.02 and p=0.03 for IBD and CD respectively).
IBD is particularly common in young people and has a major effect on quality of life 
with profound effects on growth, pubertal and sexual maturity, education and 
employment as well as psychosocial integration.13 Growth impairment is a particular 
feature of Crohn’s disease in children that has effects lasting into adult life with up to 
35% of subjects showing evidence of permanent growth failure.8
1.3 Disease definitions
Crohn’s disease is characterised by patchy transmural inflammation affecting any 
part of the gastrointestinal tract from mouth to anus and over time almost inevitably 
progresses, often leading to stricturing or fistulising complications.14 UC is 
characterised by continuous mucosal inflammation that always involves the rectum 
extending to involve a variable extent of the colon proximally. In UK children 
presenting with IBD around 60% will have CD and 30 % will have a diagnosis of 
UC.4 In around 10% of cases where IBD it is limited to the colon it proves 
impossible to distinguish between CD and UC, even after colectomy, and a diagnosis 
of IC is made. Extra-intestinal manifestations commonly involving the skin, joints, 
and the eyes occur in all forms of IBD. 
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1.4 Environmental studies
Epidemiological studies have suggested a role for many different environmental 
factors. A role for many environmental agents has been suggested to account for the 
rapid rise in the incidence of IBD previously described.  Many researchers have 
noted the rapid rise in Crohn’s disease and similar autoimmune diseases has 
paralleled a decrease in infectious diseases over the later half of the last century.15
Attempts to identify infective agents involved in disease pathogenesis have therefore 
attracted a great deal of attention in recent years. This has lead investigators to 
speculate a link in the increasing  incidence of IBD with  domestic hygiene,16
refrigeration17 and vaccination18 among many others. The specific role of 
mycobacterium paratuberculosis in the pathogenesis of Crohn’s disease remains a 
subject of impassioned debate, but conclusive evidence for a clear role in disease 
aetiology is awaited.19 The controversies regarding the Measles Mumps and Rubella 
(MMR) vaccine also been the subject of widespread media and medical interest. 
However, after a thorough review of the literature by means of a Cochrane review 
there seems to be little to base any role in disease aetiology for MMR on.20  Robust 
evidence using meta-analyses data support a  role for only two environmental in IBD 
pathogenesis, namely cigarette smoking and appendectomy.21-23
1.4.1 Smoking 
Cigarette smoking has contrasting effects in CD and UC; in CD smoking increases 
disease susceptibility but conversely is protective against the development of UC.24
As the average age at diagnosis of IBD in childhood is around 11 years it is not 
personal but passive smoking that is likely to be more relevant to disease 
pathogenesis in the childhood population. Two studies support a role for passive 
smoking during pregnancy and at birth as a risk factor for the development of CD in 
childhood25;26 with no evidence seen in a third study.18 Additionally further studies 
have demonstrated passive smoke exposure during childhood does not affect the  risk 
of  developing IBD in childhood,18;25 but has been linked to an increased risk of CD 
and decreased risk of UC in adulthood.27;28
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1.4.2 Appendectomy
The role of appendectomy and a reduced risk of Ulcerative Colitis has been 
replicated in many studies.23;29;30 In the largest study, Andersson et al. examined 
more than 200,000 patients who had undergone appendectomy in Sweden between 
1964-93.29 This study demonstrated a reduced risk of subsequent ulcerative colitis 
for patients who had proven appendicitis but not for patients who had their appendix 
removed for other indications. The greatest effect was demonstrated for patients who 
had appendicitis and appendectomy under the age of 20 years.
The most compelling evidence for the involvement of microbial agents implicates the 
gut flora.  Animal models of colitis – genetically engineered, chemically induced, or 
spontaneous – all require the presence of gut flora in order for IBD to become 
manifest.31  These data complement clinical studies with a resolution of Crohn’s 
disease with faecal diversion, and increasing evidence that antibiotic and probiotic 
therapy may attenuate disease.32-34 Diet including breast-feeding, childhood 
deprivation, and passive smoking all require to be evaluated in large well designed 
prospective studies of early onset inflammatory bowel disease populations.
1.5 Disease heterogeneity
Other epidemiological data provide evidence for heterogeneity within IBD, not only 
by age of onset but there is also evidence of widespread disease heterogeneity in 
disease phenotype (disease location, need for surgery, disease behaviour and 
extraintestinal manifestations). The sub-classification of disease by phenotypic 
characteristics remains controversial,35;36  with a notable lack of an agreed 
phenotypic classification within childhood IBD itself.37
1.5.1 Children vs. adult studies
This disease heterogeneity is perhaps best illustrated by examining the differences 
between disease presenting in childhood compared to adulthood. Crohn’s disease in 
childhood is a male dominated disease manifest as a high proportion of disease in the 
IBD Genetics in Scottish Children
Introduction 6
proximal gastrointestinal tract, contrasting with the adult onset female dominated 
disease with disease more commonly in the distal gastrointestinal tract (see chapter 3 
for a more detailed discussion).7;38  In ulcerative colitis, extensive colonic disease is 
the norm in childhood (80-90% in prospective studies) 39-41 but the exception at 
presentation in adult series (see chapter 3 for a more detailed discussion). 42;43
Inflammatory bowel disease(s) can be therefore divided into subgroups dependant on 
disease location in the gastrointestinal tract and represents a number of closely 
related multifactorial diseases. The similarities and differences highlighted by 
epidemiological data could be explained by a combination of shared environmental 
and/or genetic factors.44
1.6 Evidence for genetic predisposition in inflammatory bowel disease
1.6.1 Ethnicity
Initial evidence for a genetic predisposition to the development of  IBD stems from 
the observation of differences in the incidence of IBD between different ethnic 
groups. There is well documented evidence that Caucasians in Europe and North 
America have the highest rates of IBD followed by Afro- Americans and then 
Asians.11 Among Caucasians the Ashkenazi Jewish population have the highest 
prevalence rates of both sporadic and familial disease.45 The prevalence of IBD does 
however increase in a “low risk” population that then moves into an area of higher 
IBD prevalence demonstrating the key role of the environment.  Probert et al. 
demonstrated this by studying the prevalence of UC in Asian migrants in the UK, 
located in Leicester. They demonstrated increased rates of UC in Asians compared 
with rates in their country of origin, and rates of UC in Hindu’s and Sikhs that 
actually exceeded that of the local population in Leicester.46
1.6.2 Family studies 
It is well recognised from many studies that the greatest risk factor for the 
development of IBD is having an affected family member,47  with approximately 5-
10% of all affected individuals with IBD reporting a positive family history: first 
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degree relatives, especially siblings are at greatest risk but the risk also extends to 
more distant relatives.48 Quantification of this risk depends on a combination of 
ethnicity, the type of IBD - CD or UC and the exact relationship between the person 
at risk and the proband with IBD. 
The increased risk to relatives is difficult to quantify with precision despite many 
published studies because of the selection bias inherent within many of these studies. 
In a multi-centre study of Italian IBD patients Meucci et al. demonstrated teaching 
hospital populations will tend to have over represented IBD patients with a positive 
family history compared to studies conducted from other hospitals.49 Studies do not 
always report results in a similar manner, some will report data for all relatives or 
first degree relatives only and assign this risk to either risk of UC, CD and/or IBD. 
The studies therefore likely to give the most accurate figures for risk to relatives are 
population studies that incorporate all spectrums of disease severity. The length of 
follow up is also critically important as studies with a longer follow up period are 
more likely to include more family members with IBD.
1.6.3 First degree relatives
The first degree relatives of a patient with IBD have been studied both collectively 
and individually more than any other relatives.48 Studies have mainly consisted of 
selected hospital populations and only very few have covered whole populations. In 
each study the risk of CD and UC has been considered separately for each relative 
and some studies have given a relative risk of CD/UC/IBD compared to the 
population that the study comes from. Table 1-1 highlights studies examining these 
risks in probands with Crohn’s disease. 
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Canadian50 1000 8.7% not stated not stated not stated
Welsh51 139 5.0% 9.3% x13 not stated
Swedish52 1048 6.9% 8.9% x21 x6
USA53 522 15.1% 16.7% not stated not stated
Finnish54 257 10.9% 15.6% not stated not stated
UK55 433 not done 11.5% x15 (for 
IBD)
not stated
USA45 258 7.4% 14.0% x5-8*        
(for IBD)
not stated
UK56 424 9.4% 10.4% x17-35 x3
USA57 554 12.2% not stated not stated not stated
Belgian58 640 13.6% 14.5% x12*         
(for IBD)
not stated
Danish47 133 2.2% 5.2% x10* x4*
Dutch59 400 8% 9.5% not stated not stated
USA60 80 16.2% 22.5% not stated not stated
French61 1316 7.5% 8.4% not stated not stated
*Age adjusted figures
RR = relative risk
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The studies listed in table 1-1 are all of selected hospital populations except the 
Swedish study conducted by Monsen et al. which was an unselected population 
study.52 Also, where studied it is clear the risk of developing both types of IBD is 
increased when the proband has CD including the risk of developing CD in first 
degree relatives which is higher than that of UC.47;52;56 In studies examining UC 
probands similar findings are demonstrated with lower numbers of affected relatives 
in population based studies and increased risk of both types of IBD but with a greater 
risk of UC cf. CD.45;47;53;54;56;60;62
1.6.4 Age adjusted studies
Several studies listed have also used age adjusted figures for calculating IBD risk in 
first degree relatives.45;47;58;60 The age adjusted relatives risks  in all studies except 
Orholm's Danish study are based  on  calculations using  Strömgren’s 
methodology.63 This is a risk assessment based on patients living to age 70 years. 
Combining the results of these studies together gives a lifetime risk for first degree 
relatives of a CD proband of  4.8- 5.2% for non-Jews and 7.8% for Jews of 
developing IBD.45;58;60 The equivalent figures for first degree relatives with a  UC 
proband are 1.6% for Non Jews and 5.2%  for Jews.45
1.6.5 Sibling studies
Within  family studies results from many studies have consistently shown siblings to 
be at the highest risk of developing IBD compared to other first degree 
relatives.45;50;51;58;59;64;65 These studies clearly demonstrate that the risk of CD in a 
sibling of a CD proband is significantly higher than the average relative risk for other 
first degree relatives. Of all first degree relatives, offspring are the hardest to present 
accurate figures for as many may not have reached at age where they will manifest 
symptoms of IBD at the time of a particular study. This is reflected in the wide 
relative risks for a CD proband (2-30)55;56;66 and for  a UC proband ( 2-15).56;66
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1.6.6 Parental studies
In the relatively unusual situation of a child being born to parents who both have CD 
it is clear there is a very high risk of the children developing IBD. Laharie et al. 
studied 30 IBD couples from Belgium and demonstrated  an increasing probability of 
acquiring IBD with age such that by 28 years of age 33% of children will have 
developed IBD.67 Bennett et al. studied 19 American IBD couples and demonstrated 
a similarly high risk in offspring from UC and “mixed” IBD couples having 
children.68
In the more common situation where one parent, rather than two, has IBD the risks to 
offspring are substantially less. As studies have shown in other first degree relatives, 
the child is at greatest risk of developing the same type of IBD as their parent but is 
also at increased risk of developing the opposite type of IBD. In a population study 
examining all patients discharged across Demark with IBD between 1977 and 1992 
Orholm et al. demonstrated in offspring of UC parents that 6.2% developed IBD 
compared to 9.2% of offspring whose parents had Crohn’s disease.66
Parents of children with IBD have been consistently found to be at the lowest risk of 
developing IBD compared to the other two groups of first degree relatives.48 The 
relative risks for a parent of a child with CD and UC for developing IBD are similar 
12-16 for CD and 8-19 for UC.55;56
1.6.7 Other relatives
The risk to second degree relatives (aunts, uncles, nieces, nephews and grandparents) 
has not been as extensively studied. The risk seems to be increased only for the same 
type of IBD as the proband with little or no increased risk of the opposite IBD 
phenotype as measured against prevalence rates in the general population.47;69  
Relative risks and age adjusted risks for this group have not been published. A third 
degree relative (cousin) is also at increased risk of IBD compared to the general 
population but the risk is considerably less than the risk to first degree relatives. In a 
recent population study from Iceland only third degree relatives of CD patients were 
shown to be at increased risk of disease but not UC relatives.69
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1.6.8 Multiplex studies
In the situation where there is more than one affected first degree relative with IBD 
in the family the risk to other relatives increases e.g.  Orholm et al. demonstrated in 
UC families where at least one first degree relative had UC the relative risk of 
developing UC was doubled compared to the situation where no first degree relative 
had UC.47
1.7 Twin studies
Twin studies have been a powerful tool used to identify the different contributions of 
genes and environment to complex polygenic diseases including IBD. Twins are in 
general brought up in the same environment so differences in disease prevalence 
between monozygotic and dizygotic pairs are used to estimate the relative 
contribution of genes and environment to a disease developing. 
The early literature published on this subject contained many individual case reports
of disease concordance in both CD and UC monozygotic twin pairs and there was 
even a case report of monozygotic triplets all with CD.70 The true rate of twin 
concordance could only however be accurately estimated by large population studies.
1.7.1 Population studies
Tysk et al. published the first population survey of twins and concordance for IBD in 
1988.71 The cases were selected from the Swedish twin registry and were then 
matched with hospital inpatients records. They identified 80 twin pairs with IBD. 
The twins were diagnosed with IBD at an average age of 30 years old, with a follow 
up period of around 20 years. This original cohort was followed up 15 years later and 
3 further cases of IBD were diagnosed.72 All of the “new” cases had been 
symptomatic at the time of the original survey but did not fulfil the diagnostic 
criteria. In the monozygotic CD concordant pairs these authors were also able to 
demonstrate that 77% of pairs were concordant for disease location and that 67% of 
pairs were concordant for age at diagnosis within 2 years of each other. 
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A second population study was performed in Denmark that produced similar results 
to the Swedish study.73 Orholm et al. studied 103 twin pairs again from a national 
registry using a postal questionnaire to identify affected twin pairs. The twins were 
diagnosed at a mean age of 23 with IBD with an average follow up of 8 years. In CD 
concordant pairs 2/5 were concordant for disease location and 2/5 were diagnosed 
within 2 years of each other. The authors were also able to calculate relative risks in 
this study: a monozygotic co-twin of a CD proband had a relative risk for developing 
CD of 667 and a UC proband had a relative risk of 71 for developing UC. 
The third large published study was undertaken in the UK by Thompson et al. and 
examined 143 twin pairs.74 In this study, patients from an IBD support group, the 
National Association for Colitis and Crohn’s disease (NACC) were sent a 
questionnaire to identify IBD twin pairs. The selective nature of this study could 
potentially be a source of bias. In contrast to the other two studies the results showed 
similar concordance rates for CD and UC in monozygotic twin pairs at 20% and 16% 
respectively. The concordance rate for CD is much lower than that of the two 
population studies. In a later extension of  this study population, a total of 249 twin 
pairs were studied. The extension study did show similar concordance rates to the 
two Scandinavian population studies.75 Interestingly in this follow up study the 
concordance rate in dizygotic twins with CD was double that of siblings but similar 
concordance rates for dizygotic twins and siblings were found in UC. No information 
was given on concordance rates for disease characteristics. A summary of published 
twin studies appears in table 1-2.
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Table 1-2: Summary data from the 3 published IBD twin studies 
Population CD MZ CD DZ UC/MZ UC/DZ Total
Danish73 5/10 0/27 3/21 3/45 103
British74 5/25 3/46 6/38 1/34 143
Swedish71 9/18 1/26 3/16 0/20 80
European 19/53 4/99 12/75 4/99 326
MZ=monozygotic; DZ = dizygotic
1.7.2 Concordance rates
Combining the results of these studies makes the overall concordance rates  for CD 
36% and 4% (for monozygotic and dizygotic pairs respectively), with the 
corresponding figures for UC 16% and 4%. In a similar manner to family studies, 
IBD co-twins are also at increased risk of the opposite IBD phenotype to their twin. 
The finding of twin pairs one with CD and the other with UC has been described for 
one set of monozygotic twins and in at least 5 sets of dizygotic twins.73;75
The concordance rates in twin studies allow an estimate to be made of the relative 
contribution of genetics to overall disease aetiology, an estimate that is expressed as 
the coefficient of heritability. The derived co-efficient of heritability in Crohn’s 
disease is equivalent to that reported for type 1 diabetes, multiple sclerosis and 
asthma.76
This evidence from twin studies therefore confirms a significant role for genetics in 
disease development in IBD with a stronger genetic influence in CD compared with 
UC. There is however evidence of shared genetic susceptibility with both diseases 
occurring in some sets of twin pairs. 
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1.8 Familial Phenotypes
The similarity or difference between family members with IBD has been compared 
in familial (anyone with another family member with IBD) against sporadic disease 
(no family history of IBD) and in multiplex family studies where many members of 
the same family group have IBD. There are high rates of concordance for disease 
type in family studies with concordance rates between 78-100% in CD49;58;77;78 and  
81-86% for UC.49;62;77;78 The difficulty in extending these studies to compare disease 
characteristics is that there were no standard definitions of disease phenotype agreed 
upon when many of the studies were performed making direct comparisons between 
studies difficult. The adoption of guidelines for CD phenotyping had the advantage 
of setting a phenotypic benchmark allowing comparison between studies,35;36 but 
unfortunately most of the reported studies were performed prior to these 
classifications being adopted.
The phenotype characteristics of CD that have been studied are: age at disease onset, 
location of disease, disease behaviour, extraintestinal manifestations and the need for 
surgery. 
1.8.1 Age at disease onset
The age at disease onset/diagnosis has been compared between familial and sporadic 
disease and been found to significantly younger in familial disease in some 
studies45;52;62;65;79 but an equal number of studies show no difference.49;50;54;58;61;77
Polito et al. in a retrospective study of 552 patients with Crohn’s disease 
demonstrated stratification for age at diagnosis (<20 years at diagnosis compared to 
> 40 years at diagnosis) demonstrated age specific phenotypes. Younger age at 
diagnosis was associated with more ileal disease, more stricturing disease together 
with a greater frequency of surgery for intractable disease.79 Small bowel disease 
became less frequent with older age at disease diagnosis contrasting with colonic 
disease location and inflammatory disease behaviour that became more common 
with older age. 
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1.9 Evidence for genetic anticipation
Following on from studies suggesting a younger age at diagnosis in familial cases of 
IBD researchers including Polito et al. went onto explore the evidence for genetic 
anticipation in IBD. The term “anticipation” describes a genetic phenomenon in 
which disease severity increases and age of onset decreases in subsequent 
generations affected by the disease in question. Anticipation has been clearly 
demonstrated in a range of monogenic neurological disorders including 
Huntingdon’s chorea, Friedrich’s Ataxia, Fragile X syndrome and myotonic 
dystrophy.80 The common mechanism unifying these diseases is expansion of 
nucleotide triplet repeats, with the more repeats that are present the earlier the 
disease presents and in turn the more severe the disease is. If anticipation was 
demonstrated in IBD populations this would giving an insight into the genetic 
mechanisms underpinning IBD.
Polito et al. in a follow on  study examined 59 parent child parent IBD pairs and 
demonstrated an average difference of 15 years earlier diagnosis in the children 
compared to their parents, with 91% of children diagnosed at younger age than 
parents.81 The children also showed more extensive disease than their parents in most 
cases. Numerous replication studies followed, all universally showing a younger age 
at symptom onset/ diagnosis in children with IBD compared to their parents (see 
table 1-3 for study details). 
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Table 1 3: Studies supporting evidence for genetic “anticipation” in IBD
Author Type of IBD Number of 
parent/child 
pairs






Polito79 CD 59 91% 15
Satsangi64 IBD 77 90% 16
Grandbastien82 CD 57 84% 16
Peeters58 CD 31 not stated 17
Heresbach83 CD 61 90% 14
Lee84 IBD 137 89% 18
Hampe85 IBD 99 not stated 19
Freeman50 CD 46 100% not stated
Faybush86 IBD 136 76% 16
Annese78 IBD 36 93% 23
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Heresbach et al. were also able to demonstrate “anticipation” in not only 61 child-
parent pairs but also in 17 aunt/uncle nephew/niece pair’s showing a mean difference 
of age at diagnosis of 14 and 16 years in favour of the younger generation 
respectively.83 The age difference at diagnosis effect in their study was significantly 
more marked in father child pairs at 21 years compared with 12 years in mother child 
pairs. 
However before this apparent “anticipation” in IBD is accepted, the studies 
describing this phenomenon merit further scrutiny. Firstly, from first principles IBD 
is not the same as other diseases where anticipation has been previously described. 
The diseases in which anticipation has been demonstrated are monogenic diseases
where as IBD from all other evidence from family and twin studies are likely to be 
polygenic diseases. After Polito’s initial publication describing anticipation two 
groups independently criticised the data.  Inskip et al.  and Frisch et al. both ascribed  
the apparent anticipation to an effect of follow up time bias based on a retrospective 
study design.87;88  Follow up bias describes children who are unaffected by IBD at 
the time of a cross sectional survey but who later develop disease with failure to take 
this into account skewing the results toward apparent anticipation.
To analyse whether anticipation is truly present, IBD birth cohorts have been 
followed up to remove any effect generated by follow up time bias. Picco analysed 
928 consecutive patients with Crohn’s disease diagnosed at the Mayo clinic: in 
analysis unadjusted for follow up time bias, he demonstrated age of diagnosis 
decreased by 5 years in each successive 10 year birth cohorts giving preliminary 
evidence of anticipation.89 However, by adjusting the analysis to only include 
patients who were 40 at the time of study entry and had a diagnosis before age 40 
this effect was reduced to around 1 year difference in successive cohorts. They 
suggested anticipation does not occur in IBD and is merely caused by failure to make 
statistical corrections to the data.89 Hampe et al. analysed 2007 IBD patients with 
sporadic disease and 472 patients with familial disease and after adjustment for 
confounders between parental and child diagnosis no significant difference in age at 
diagnosis was demonstrtaed.85 In a similar study from St Marks hospital Lee et al. 
examined 137 parent-child pairs and compared them with 214 patients with sporadic 
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IBD.90 Comparison between the two cohorts using regression lines based on date of 
birth and diagnosis demonstrated no difference between the two groups despite an 
apparent age difference between parents and children analysed of 17 years. The 
difference in these results can be explained by ascertainment bias rather than 
anticipation. Faybush et al. replicated the findings of previous studies for 136 parent 
child pairs and also for 142 aunt/uncle nephew/niece pairs.86 Uniquely they were able 
to show a difference in the mean age of onset of symptoms to be doubled in 40 
grandparents – grandchild pairs compared to parent child pairs. They concluded from 
this again this apparent anticipation was due to follow up time bias and possible 
temporal changes effecting many generations at once. 
1.10 Disease concordance for disease phenotypes
There is evidence of concordance not only of disease type but also for disease 
location in within CD families. In a study of 35 Italian families Annese et al. 
demonstrated 46% concordance for disease location.78 Colombel et al. demonstrated 
concordance for disease location in 56% of patients in a study of  72 French 
families.65 Satsangi et al. demonstrated a high degree of concordance for disease 
location in both 39 parent-child pairs and 82 sibling pairs with concordance rates of 
75% and 80% respectively in a UK study.64 Peeters et al. replicated  this high 
concordance for disease location in sibling pairs in a Belgian CD study.58 In a study 
of 60 CD families from the USA concordance for disease location was seen in 86% 
of those studied.57 Lower disease concordance rates of only 16% for disease location 
were described in a small study of 25 UK families.84
In studies that have examined other Crohn’s disease characteristics varying rates of 
concordance have been demonstrated: disease behaviour 17-82%,57;61;78;84
extraintestinal manifestations 67-80% and rates of surgery 29-56%.64;78
Satsangi et al. demonstrated concordance for disease extent in 53% of 37 parent child 
and  68% of 69 sibling pairs with Ulcerative colitis.64 In the same study of ulcerative 
colitis relative pairs there were similarly high degrees of concordance for 
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extraintestinal manifestations at 74% and 89% and in need for surgery at 77% and 
67% respectively.64
1.10.1 Early onset disease 
In early onset disease there is a stronger familial and therefore perhaps genetic 
contribution to disease development. In studying early onset populations the power 
to detect a difference between cases and controls for a given sample size will 
therefore be increased.91   In a study of families with type 2 diabetes, Frayling et al. 
demonstrated that diabetes diagnosed under the age of 55 years had a much stronger 
genetic influence compared to those diagnosed over the age of 55.92 In this study an 
increased number of genetic loci were identified in families with an earlier age of 
onset despite there being a smaller total number of families studied (245 in the early 
onset group compared to 328 in the later onset). 
In families with IBD, Farmer et al. studied 838 patients with onset of IBD under the 
age of 21 years and found a positive family history in 35% of cases, higher than that 
recorded in most other series (table 1-1).53 Comparing familial with sporadic disease 
familial disease tends to be associated with an earlier age of onset compared to 
sporadic disease.48 Monsen et al. demonstrated a younger age at diagnosis in familial 
CD compared to sporadic CD at ages 25 and 33 years respectively,52 with similar 
data produced by the same author in a second study of patients with UC.62 The same 
trends in the data reported by Monsen et al. have been described by several other 
groups.45;65;79 There is some evidence to indicate that disease starting earlier in life 
has a stronger genetic influence  in patients with IBD in studies examining the IBD1 
locus.93;94
Additionally, there are obvious advantages for family association studies as parents 
are more likely to be available for recruitment if younger patients are studied.  Using 
a family based association approach in turn avoids some of the problems of 
population stratification encountered in case-control studies and reduces risk of 
population heterogeneity when comparing different study populations.95 Furthermore 
the childhood IBD population is often considered to be free of the strong influences 
of the environment present in adult patients e.g. tobacco.21;22
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1.11 Genetic models of disease in IBD
From the evidence presented thus far it is clear that both genes and environment are 
important in the pathogenesis of IBD. There is clearly a genetic risk for both types of 
IBD but it appears CD carries a higher risk than UC. The data discussed for twin and 
family studies however are not explained by simple Mendelian genetics. The risk to 
first degree relatives of developing disease is between 5-10% arguing against either 
an autosomal dominant or autosomal recessive inheritance pattern in the majority of 
patients. Exceptions to this would appear to exist in the rare situations where both 
parents have IBD with rates approaching up to 50% in the offspring suggestive of a 
dominant inheritance model.67;68 Orholm et al. formally tested a model of autosomal 
inheritance patterns in familial disease in 637 Danish patients and their relatives 
using complex segregation analysis.96 The results generated suggested an autosomal 
recessive pattern of inheritance was present in only 7% of familial disease in Crohn’s 
disease and proposed an autosomal dominant model was present in 10% of familial 
cases of Ulcerative Colitis. In response to the publication of Orholm’s data, Farrall
argued that the presence of increased risk of both CD and UC in relatives and the 
increased risk when more than one relative had IBD, strongly argued against a 
recessive model of inheritance.97
The data suggest therefore that a complex pattern of inheritance is present in IBD in 
common with other common complex diseases, with the rates of inheritance 
described similar to those in multiple sclerosis, type 1 diabetes and schizophrenia and 
much higher than rates of inheritance in the common malignancies.98 Ahmad et al. 
have proposed a disease model for IBD that describes CD and UC as related 
polygenic diseases that may share common susceptibility genes but also have disease 
specific susceptibility genes.76 In addition, genes are likely to influence not only 
disease susceptibility but also disease phenotype. 
Nonetheless it seems likely that the phenotypic heterogeneity reflects extensive 
genetic heterogeneity. The term "Crohn’s disease” can be divided into subgroups 
dependant on disease location in the gastrointestinal tract and represents a number of 
closely related multifactorial diseases, sharing some but not all genetic and 
environmental determinants of susceptibility and behaviour.44
IBD Genetics in Scottish Children
Introduction 21
1.12 Findings genes involved in IBD
At the outset of this thesis, two complementary methods were traditionally employed 
by investigators searching for susceptibility genes in complex diseases using either 
candidate gene analysis or genome wide analysis.99 The genome wide analysis until 
recently involved non-parametric linkage analysis of informative SNPs in relative 
pairs with IBD. More recently genome wide association studies involving hundreds 
of thousands of SNPs in patients and healthy controls have been utilised to identify 
further IBD susceptibility genes (see chapter 9). Other methods such as yeast two-
hybrid studies and microarray studies and have also been used to identify further 
genes important in IBD susceptibility (these are also discussed in detail in chapter 
9).100  
1.12.1 Candidate gene studies
The analysis of candidate genes relies on an understanding of disease 
pathophysiology.  In inflammatory bowel disease for example, the immuno-
pathology of the disease has led to examination of genes involved in the regulation of 
the immune system, genes involved in the maintenance of mucosal integrity, and 
genes involved in cell-cell interactions.101  The genes in question have then been 
further analysed by genetic “association” studies where the frequency of allelic 
variants of one or more polymorphisms of the genes in question are studied in 
patients with inflammatory bowel disease and compared with allelic frequencies in a 
well-matched control populations.95  A significant distortion of frequencies between 
cases and controls under comparison would provoke further investigation of the gene 
of interest. Direct association describes the situation where association studies 
implicate a polymorphism that is likely to result in an amino acid change, in contrast 
to indirect association where the polymorphism is not likely to result in an amino-
acid change and may or may not be in linkage with the causal variant. Many 
candidate genes have been subject to analysis in inflammatory bowel disease –
notably the genes of the HLA system, genes involved in the regulation of cytokine 
production, mucin synthesis, and other aspects of epithelial barrier function.102
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Candidate gene studies however are limited by the fact they rely on an assumed 
knowledge about the pathogenesis of IBD. The selection of genes for study is based 
on an a priori hypothesis about disease causality. A good case can usually be made 
to study many of the 30,000 genes on the human genome so, in the context of a 
disease that is complex and polygenic, candidate gene analysis based merely on a 
“scientific hunch” is a rather naive and approach that will be rarely successful.
1.12.2 Genome wide scanning
However, in contrast to candidate gene analysis it is the complementary technique of 
genome wide scanning (GWS) in which success has become most apparent in 
narrowing down the number of candidate genes for analysis and providing new 
insights into disease pathogenesis.103 In GWS, genetic (non-parametric) “linkage” in 
relative pairs is used to identify broad regions of the genome that predispose to 
disease susceptibility and may at a later stage be shown to contain a disease specific 
gene.104 They therefore reduce the potential number of candidate genes but do not 
identify these genes specifically. This technique is superior to candidate gene studies 
alone as it allows researchers the advantage of being able to identify genes in a 
“hypothesis free” manner, rather than selecting candidate genes on the basis of 
preconceived scientific ideology. This technique has been successfully applied in 
IBD to identify genes important both in disease susceptibility and disease 
phenotype.101
The technique of GWS evolved with the development of a linkage map of the human 
genome, involving informative microsatellite markers providing a framework for the 
systematic analysis of the human genome in both single gene disorders, and complex 
diseases.105  Studies in complex diseases have required access to large numbers of 
multiply affected families (typically sibling pairs), semi-automated technology for 
genotyping, and particularly the evolution of statistical techniques for data analysis 
produced after running the scan.  The technique of GWS has been applied by 
investigators in many common disorders – encompassing metabolic, respiratory, 
cardiovascular, endocrine, and neuropsychiatric disease.104
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The candidate genes studies performed to date have been prioritised on the basis of 
functional and pathobiological relevance of the genes in question, in addition to the 
results from these linkage studies. In each disorder, a number of linkages with 
regions throughout the genome have been described.  However, proceeding from the 
initial observation of linkage through replication to gene identification had not been 
achieved by many groups of investigators. Progress in gene identification following 
on from GWS in IBD relative pairs has been greater than in many similar complex 
polygenic diseases.101  Several chromosomal regions along the genome have been 
replicated, with sufficient strength to satisfy stringent criteria laid down by the 
statistical geneticist as demonstrated by significant logarithm of odds (LOD) scores 
(see table 1-4).76
Table 1-3: The Lander and Kruglyak criteria 
Criteria* LOD score p value
Suggestive linkage 2.2 7x10-4




*These criteria apply only to analysis of genome wide scans using sibling pair 
studies, other relative pairs will have different significance thresholds; for confirmed 
linkage to be achieved a replication study in a separate population from the initial 
cohort with a nominal p value of < 0.01 would be required.
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1.12.3 IBD loci identified in genome wide scanning
The success of the GWS in CD, in common with other complex diseases has been 
related to the size of the population sample in the scan and to a lesser extent the 
number of microsatellite markers used. There have been eleven scans in IBD patients 
since 1996 and a much larger number of replication studies. These scans have 
predominantly been performed in CD patients and a summary of the GWS for these 
patients appears in table 1-5.













European106 110 270 1.3 (16q12) nil
UK107 81 260 5.47(12q13) 3p21,7q22
European108 162 358 2.3(10) 16q, 12q
USA109 65 350 2.8 (14q11) 5q
USA110 175 377 2.17 (1p36) 3q,16q,3p26,16#
USA111 127 751 3.6(14q11) 18q22
Canadian112 131 312 3.9(5q31-33) 19p13*
Canadian113 105 307 1.9(11q) 16q#, 17p,11p
USA114 108 358 2.26(6p13) 5q31,15q
Belgian115 106 323 2.97(1p13) 6q16,14q11,4
UK116 137 404 2.1(3q) X
* 3p and 6p achieved suggestive linkage in this study for IBD but the contribution of 
CD to the LOD score was not stated. 
# Linkage on chromosome 16 distinct from IBD1 region
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Thus far, numerous susceptibility loci have been implicated in inflammatory bowel 
disease with varying degrees of replication and statistical support demonstrated for 9 
of such loci, termed IBD 1-9.117 Each of these loci represent chromosomal regions 
each of which contain many potential IBD susceptibility genes.101 Whilst some loci 
appear specific to Crohn’s disease (e.g. IBD1 on 16q- OMIM 266600 )118 or 
ulcerative colitis (e.g. IBD2 on 12q- OMIM 601458),119 others seem to confer 
susceptibility to IBD overall (e.g. IBD3 on 6p- OMIM 604519 )120 supporting the 
previously discussed hypothesis that Crohn’s disease and ulcerative colitis are related 
polygenic disorders sharing some, but not all, susceptibility loci.
1.12.3.1 IBD1
Hugot et al. used a two stage approach to demonstrate the first CD susceptibility 
locus on chromosome 16q12 subsequently named IBD1 (MIM 605956).106 These 
investigators performed initial genotyping in 40 IBD sibling pairs from 25 French 
families using a total of 270 microsatellite marker SNPs situated at regular intervals 
throughout the genome. This first stage of the investigation identified significant 
linkage (p value of<0.01) for three areas on chromosome 16 and one area on 
chromosome 1. In the second stage of the investigation a separate group of 53 
families containing 70 sibling pairs provided supportive evidence for linkage with 
the region on chromosome 16 only, with a LOD score of 1.3.  
Despite this relatively low LOD score in the initial study, this locus was then 
successfully replicated in different populations throughout the world. Ohmen et al. 
examined the IBD 1 locus in a replication study using 17 microsatellite markers 
across the region of the locus. In this study of 80 North American families (48 CD 
families with 75 sibpairs) the highest LOD score achieved for one of these markers 
was 2.41.121 In another North American replication study, Brant et al. demonstrated 
linkage at the IBD1 locus in 148 relative pairs with a highest LOD score of 2.5 in 
both Jewish and non-Jewish CD patients.122  Further support for this locus was 
provided by linkage analysis in a cohort of 58 Italian families that demonstrated 
linkage in CD patients and uniquely linkage in UC patients with LOD scores of 1.97 
IBD Genetics in Scottish Children
Introduction 26
and 2.44 respectively at a microsatellite marker located within the  IBD1 locus.123  
Cavanaugh et al. studied 54 multiplex IBD families and demonstrated a remarkably 
high LOD score of 6.3 for the IBD1 locus in these Australian CD patients. The 
largest replication study contained 581 sibling pairs carried out by the international 
IBD consortium using a combination of previously reported studies, generating a 
maximum LOD score for the  locus of 5.79 in CD patietns.118  The international IBD 
consortium study reported no significant linkage at the IBD1 locus for UC patients.  
1.12.3.2 IBD2
In the only UK genome wide scan, Satsangi et al. demonstrated  an IBD  
susceptibility locus on chromosome 12p13 named IBD2 (MIM 601458).107 This scan 
was performed in 160 IBD families with a total of 186 sibling pairs with the 
strongest evidence for linkage found for a region spanning 41 centimorgans on the 
long arm of chromosome 12.  Five adjacent microsatellite markers within in the 
region showed distortion of allele sharing, with the most significant evidence for 
linkage being seen at the marker D12S83 with a highly significant LOD score of 
5.47. The same GWS also provided provisional evidence for disease susceptibility on 
areas of chromosomes 7 and 3. The IBD2 locus was also identified in a second 
genome wide scan performed by Duerr et al. in a North American IBD population 
(122 families with 208 relative pairs) achieving a LOD score of 2.0.109 A 
combination of a number of international studies (pooled data on 613 families) has 
failed to show strong support for linkage at this locus for Crohn’s disease.118  In this 
IBD consortium study that presented convincing evidence for IBD 1 locus, the IBD 2 
locus achieved a LOD score of only 1.2 for CD.118
It is now generally accepted that the IBD2 locus may be more strongly involved in 
UC than CD.119 Parkes et al. in a large study of 581 relative pairs, demonstrated a 
LOD score of 3.91 in the 138 UC relative pairs studied compared with a LOD score 
of 1.66 for the 252 CD pairs and a LOD score of 1.29 for the 191 mixed IBD pairs. 
Further analysis of this by locus in 904 IBD relative pairs by Achkar et al, has 
demonstrated the highest LOD score in patients with extensive ulcerative colitis 
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(LOD 3.27) suggesting this locus influences both disease susceptibility and disease 
phenotype in UC patients.124
1.12.3.3 IBD3 
This locus is located at chromosome 6p21 and incorporates the major 
histocompatibility complex, has been designated IBD 3 (MIM 604519). Prior to the 
application of genome wide scanning, the major histocompatibility complex was the 
candidate gene region subject to most attention in inflammatory bowel disease.  
Allelic association studies had demonstrated association of HLA class II variants 
with susceptibility to both ulcerative colitis and Crohn’s disease.125 In the two meta-
analyses that have been performed of GWS in the IBD population the IBD 3 locus 
was ranked as the most consistent CD susceptibility locus in both analyses.113;120  
Van Heel et al. analysed a total of 1952 IBD relative pairs (1068 CD, 457 UC and 
427 mixed) from 10 GWS and demonstrated IBD3 met genome wide significance for 
IBD only.120 In a smaller meta-analysis of 709 IBD families containing 822 sibling 
pairs, Williams et al. analysed their own GWS data together with data from four 
other GWS.113 They demonstrated IBD3 linkage from their meta-analysis for IBD 
and additionally CD.
Individual GWS have also suggested a role for IBD3. Hampe et al. in a large 
European GWS of 353 relative pairs demonstrated a peak LOD score of 4.2 for IBD 
in the IBD3 locus with an equal contribution from all types of IBD.108  The 
individual LOD scores generated in other GWS have been relatively modest : Rioux 
et al demonstrated a LOD score of 2.3 for IBD patients and Barmada et al. a LOD of 
2.26 for CD.112;114 A LOD score of 3 for this locus was demonstrated in a UK 
replication study of 284 siblings pairs performed by Dechario et al, again with an 
equal contribution from all types of IBD.126 Further linkage analyses had also 
suggested an important contribution of the histocompatibility complex to 
susceptibility to both Crohn’s disease and ulcerative colitis.127
Interestingly in a study of 428 relative pairs Fisher et al. analysed the IBD3 locus by 
sex of the patient and demonstrated that IBD 3 may be a male sex specific locus.  
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Stratification for sex achieving a LOD score of 5.91 in males with IBD with equal 
contributions from UC and CD was demonstrated in Fisher’s study.128 Phenotypic 
analysis of the IBD3 region suggests it predisposes to a “colonic” IBD phenotype 
showing association with extensive and severe ulcerative colitis ,127;129-131 and 
colonic Crohn’s disease.131-133  
The contrasting phenotypic predictors of the IBD1 and IBD3 loci determinants have 
been examined by Ahmad et al.132 These authors have used the data generated to 
propose a molecular classification of Crohn’s disease contrasting the population 
attributable risk of the IBD1 and IBD3 loci in Crohn’s disease of the ileum (40%, 
and 19%, respectively), with colonic Crohn’s disease (0%, and 39%, respectively). 
1.12.3.4 IBD4
IBD 4 (MIM 606675) is located on chromosome 14q11 and matches the criteria for 
confirmed linkage in CD only. The IBD4 locus was first identified in the GWS by 
Ma et al. in North American CD relative pairs with a LOD score of 2.8.109
Replication of the initial study was provided in another North American CD 
population by Duerr et al. in a GWS of 127 relative pairs from 62 CD families that 
generated a LOD score for the IBD4 locus of 2.8.111 In a third GWS scan performed 
in the Flemish population analysis of 149 relative pairs with IBD, the IBD4 locus 
achieved the highest LOD score in this population but did not reach the criteria for 
significance set out by Lander and Kruglyak.115 In a large international study of 792 
IBD families consisting of 892 relative pairs mean allele sharing was increased in 
markers spanning the IBD4 locus.134 The allele sharing was higher in those sibling 
pairs in whom at least one sibling was a smoker compared to pairs where neither 
sibling smoked.
1.12.3.5 IBD5
The IBD5 (MIM 606348)  locus on chromosome 5q31-33 was first described in a 
relatively small CD only GWS of 65 sibling pairs achieving a LOD score of 2.2 in 
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this scan.109  In a larger Canadian GWS containing 158 IBD sibling pairs (104 sib 
pairs with CD) Rioux et al. demonstrated a LOD score of 3 for this locus.112
However, further stratification of patients by age at disease onset demonstrated 
significant linkage in the subpopulation of patients with onset of disease below the 
age of 16 years achieving a maximum LOD score of 3.9. Fine mapping of this area 
performed by the same group in 256 IBD trios has identified a single, highly 
conserved 250-kb haplotype of 11 SNPs spanning a cytokine gene cluster that is 
associated with Crohn’s disease.135 Further, more detailed discussion of this locus, 
can be found in chapter 6 where it is analysed in detail in Scottish early onset 
patients.
1.12.3.6 IBD6
IBD6 (MIM 606674) on 19p13 awaits replication as a confirmed IBD locus. This 
locus was identified in Rioux et al. in the genome wide scan of the Canadian IBD 
population. In this analysis of 158 sibling pairs the IBD6 locus achieved of LOD 
score of 4.6 for IBD.112 This locus however does not strictly fulfil the Lander and 
Kruglyak criteria, as independent replication has not been achieved after this initial 
GWS. In an attempted replication study Low et al. studied marker SNPs at the IBD6 
locus in 284 IBD sibling pairs but achieved a LOD score of only 1.59 for CD.136 Van 
heel et al. performed a GWS in 137 relative pairs with CD and subsequently 
stratified the scan results based on markers at the IBD1 and IBD5 loci.116 The results 
did not identify the IBD6 locus in the initial scan but after stratification for 
NOD2/CARD15 status (IBD 1 gene), CD patients who were not carriers of 
NOD2/CARD15 variant alleles demonstrated a LOD score of 2.9 for the IBD6 locus. 
In the same analysis, and in contrast to the findings for IBD1, patients who possessed 
markers on the IBD5 risk haplotype demonstrated a LOD score of 2.4 for IBD6 
providing provisional evidence for epistasis between the IBD5 and IBD6 loci.  
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1.12.3.7 IBD7
The IBD7 locus (MIM 605225) is located at chromosome 1p36. This was suggested 
as an IBD locus by Cho et al. in GWS performed on  297 IBD relative pairs from 174
families from North America,  37% of whom were of Ashkenazi Jewish origin.110 In 
analysis of all subjects included in the scan a LOD score of 2.65 was seen at the 
IBD7 locus, with a LOD score of 2.17 for CD. In a separate extension study by the 
same group of investigators analysis of markers at this locus was performed in a 
small Chaldean population originally of Iraqi origin.137 In total, 13 family members 
with IBD were studied (11 had UC) with the maximal linkage marker at the IBD7 
locus generating a LOD score of 3.
1.12.3.8 IBD 8
Initial genome wide scans identified the IBD1 locus on chromosome 16 as conferring 
susceptibility to IBD1,106;118 but subsequent investigation has suggested the 
possibility of a second IBD locus on chromosome 16 that has been designated IBD8 
(MIM 606668). In an extension study of the chromosome 16 region performed by 
Hampe et al. in 522 IBD relative pairs, a triple peaked linkage curve was seen on 
chromosome 16.138 Once the contribution of IBD1 was excluded, linkage peaks were 
still seen for the 2 other CD peaks located at 16p (LOD 2.7) and 16q (LOD 3.1). This 
finding is yet to be replicated in other IBD datasets.
1.12.3.9 IBD 9
In the GWS performed by Satsangi et al, a linkage region was identified on 
chromosome 3p26 as well as regions on chromosome 12 and 7, with this area 
subsequently designated IBD9 (MIM 608448). In Satsangi’s scan of 186 IBD sibling 
pairs suggestive linkage was demonstrated for the IBD9 locus with a LOD score of 
2.69.107 In a follow up extension study, Hampe et al. studied markers at the IBD9 
locus in 353 sibling pairs demonstrating a LOD score of 1.65 for IBD predominantly 
from a CD linkage peak.139 TDT analysis of one of the markers in the IBD9 locus 
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demonstrated significant over transmission in IBD trios. In a similarly designed 
replication study, Duerr et al. demonstrated significant over transmission of markers 
at this locus in 324 IBD sibling pairs with a maximum LOD score of 3.78.140
1.12.3.10 Genome wide scans in children with IBD
Although children have been part of many of the GWS, none to date have been 
exclusively paediatric.103 The most exciting data relating to paediatrics were 
presented in the Canadian GWS which stratified patients by age at diagnosis and 
demonstrated CD patients under the age of 16 had the highest LOD score (3.9 cf. 
3.0).112  
Brant et al. studied markers on the IBD1 locus in two groups of patients, one group 
of early onset patient with severe disease, (age less than 22 years at diagnosis taking 
immunosuppressants or those who had surgery) and compared them to a group with 
neither of these characteristics.94 The first group had a significantly higher LOD 
score for the 16 markers analysed at the IBD1 locus with a LOD score of 3.84. In a 
similar study by Akolkar et al. of marker SNPs at the IBD1 locus there was initially 
minimal evidence of linkage in the whole cohort  (LOD 1.63) of  53 Ashkenazi 
Jewish families studied, but when the analysis was stratified to only include patients 
diagnosed under the age of 21 years the LOD score increased to 3.02.93
1.12.4 GWS- applications and limitations 
The 11 GWS scans that have been performed over the past 10 years in IBD patients 
have produced exciting data but this enthusiasm has been tainted by the lack of 
subsequent gene identification for the majority of these loci. Aside from the notable 
success of transition from linkage to gene identification at the IBD1 locus, none of 
the other loci have provided conclusive evidence resulting in the causal candidate 
gene within the locus being identified. Gene identification has initially been 
hampered by lack of replication of some loci in extension studies. The size of an 
individual GWS is limited usually by the number of sibling pairs available in a 
specific population so these scans have been based on pragmatic numbers available 
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for recruitment rather than based on pre-calculated power calculations. This has 
meant some of the areas identified on scans may be false positives which may 
explain the lack of replication of some loci. 
The relatively small numbers of relative pairs in some of these scans has meant 
statistically meaningful results have only been demonstrated by combining studies. 
Two groups have done this by performing meta-analyses of genome wide 
scans.113;116 The combination of data after a loci has been identified has also been a 
very powerful way of making best use of results e.g. the international IBD 
consortium collaboration on the IBD 1 and IBD2 data.118 The relative lack of power 
in these individual studies also makes the identification of genes of modest effect 
difficult using this method of gene identification.
Even when the genetic data for the loci in question has been proven robustly, there 
have then been difficulties narrowing down the regions of linkage identified on 
GWS. This problem of gene identification is highlighted by the IBD5 locus where 
tight linkage disequilibrium over a gene dense region has made gene identification 
very difficult even when the studies have involved several thousand patients.141 The 
scans performed to data have also been CD dominated so this method has not been
able thus far to identify genes important in UC susceptibility. 
The study of patients, families and populations with IBD has therefore highlighted a 
key role for genetics in the pathogenesis of IBD. GWS have moved IBD genetics 
onto a stage of hypothesis driven candidate gene studies but this has not yet resulted 
in widespread success in identifying many of the candidate genes contained within 
these IBD loci. The role of the individual candidate genes and their influence in the 
Scottish childhood population is described in the subsequent chapters. The exciting 
data evolving from GWAS looks to hold more promise in moving on from 
identifying regions of interest to gene identification.
1.12.5 Thesis plan
The genetic background to inflammatory bowel disease underpinning this thesis has 
been presented in this chapter including where relevant, studies that have involved 
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children. The nine IBD loci identified are exciting step forward in the further 
understanding of the genetics of IBD but widespread identification of genes involved 
in IBD has yet to materialise from these studies. 
The hypothesis proposed in this thesis is that childhood IBD therefore characterises a 
disease group with a stronger genetic influence and represents a group with a distinct 
disease phenotype. Apriori this hypothesis has been tested by the examination of 
candidate genes implicated in adult studies by first examining their contribution to 
IBD susceptibility in Scottish children and then analysed in detailed genotype 
phenotype studies that focussed on associations that may be present only in the 
paediatric population including post hoc analysis of several factors that were 
identified as areas of interest as the thesis was being performed.
To test this hypothesis, a cohort of patients with early onset IBD, diagnosed with the 
disease at less than 16 years of age were collected from across Scotland. Blood was 
collected for subsequent DNA extraction from patients with IBD and their parents. 
Data was collected by questionnaire and examination of a patient’s case notes to 
rigorously characterise the patient’s disease phenotype both at disease diagnosis and 
later follow up. Statistical analysis was performed by transmission disequilibrium 
testing (TDT) in the family trios as well as case control analysis. The controls were 
collected from parallel studies performed in the Scottish adult IBD population. In 
comparison of disease phenotype, phenotypic classification used for defining adult 
Crohn’s disease (Vienna) was used with an additional classification for use in 
children’s studies was designed specifically for use in this thesis. The Montreal 
classification was used for direct comparison between the childhood and adult 
populations.
In chapter 3 the similarities and differences between childhood onset and adult onset 
IBD phenotype were analysed, justifying why independent studies in the childhood 
onset population were important.
Chapter 4 analysed the role of the most widely implicated gene to date 
(NOD2/CARD15) in the Scottish early onset IBD population. The specific 
contribution of the common three disease susceptibility mutations implicated in 
previous studies were analysed in 247 Scottish IBD patients aged <16 years at 
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diagnosis and 414 parents by intrafamilial studies. The NOD2/CARD15 variants 
were also analysed in a case control study using 245 healthy controls, before 
genotype phenotype analysis was undertaken. 
In chapter 5 a comprehensive analysis of the whole NOD2/CARD15 gene was 
performed after sequencing the 12 exons of the gene in 24 early onset patients with 
Crohn’s disease. Then, 2 SNPs were analysed in greater detail assessing their 
contribution to disease susceptibility in a larger of population of more than 500 
Scottish Crohn’s disease patients consisting of both children and adults, which were
then compared to results in 253 healthy controls. 
The role of a second candidate gene (OCTN) within the IBD5 haplotype was 
analysed in Chapter 6. The role of this gene together with 3 SNPs from within the 
IBD5 haplotype were analysed in 299 childhood onset IBD patients assessing the 
contribution to disease susceptibility and phenotype. The controversies surrounding 
the role of OCTN genes in disease susceptibility were then discussed examining 
whether they are truly independent of the background IBD5 haplotype.
The role of a single SNP 113 G/A within the DLG5 gene, another putative IBD 
susceptibility gene was discussed in chapter 7. The SNP was assessed for both its 
contribution to disease susceptibility and phenotype in 296 IBD patients, before 
discussing the potential controversies surrounding this genes role in disease 
susceptibility from all studies to date as well as exploring potential genotype 
phenotype interactions.
Chapter 8 switches focus from genes to serological markers. The frequency of Anti-
Saccharomyces cerevisiae antibodies (ASCA) antibodies in 301 children was 
analysed and frequencies compared between the 197 CD, 76 UC and 28 IC patients 
as well with 78 healthy population controls. Further analysis of ASCA status and 
disease phenotype was then performed in patients with CD at diagnosis.
In chapter 9 the implications of the data presented throughout the thesis are 
discussed. The results are placed in the context of current work performed during and 
after the completion of the experimental work of the thesis. The way forward to 
identifying new genes in the Scottish IBD population and a plan for continuation of 
the work is then discussed.
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2 Patients, materials and methods
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2.1 Definitions
2.1.1  “Early onset” patients
The age at which childhood ends and adulthood begins represents a continuum and 
the age limits that define childhood or meet a definition of early onset IBD are 
somewhat arbitrary. The definitions used for early onset patients in IBD have varied 
between studies and have included <16 years,112 <18 years, <19 years,142 <20 years,79
<21years,53 < 22 years94 and even less than 40 years!36 The only scientifically 
defined age cut off is at less than 16 years and was derived from the study of the 
IBD5 locus by Rioux et al (see chapter 1) in the Canadian IBD population. This 
study demonstrated a bimodal age distribution of patients with IBD and used 
statistical evidence from Gaussian distribution curves to set this age limit.112 For the 
purposes of this thesis we have targeted children with an age at diagnosis of IBD at 
less than 16 years at diagnosis. This decision was based pragmatically on the best 
available evidence and also represented an age at which it could be estimated a 
critical number of children could be recruited to allow for meaningful genetic 
analysis within the allocated study period.
2.1.2 Disease definition
The diagnosis of IBD was based on standard criteria as set out by Lennard-Jones.143
After enteric infection was excluded the criteria were used to classify a patient as 
having either ulcerative colitis or Crohn’s disease. A checklist based on these criteria 
was constructed to ensure each patient entering the study definitely fulfilled the 
criteria for having Crohn’s disease (appendix 1). Using this checklist patients were 
defined as fulfilling the criteria for Crohn’s disease if they met the definitions in 
three or more section criteria. If a given patient scored less than 3 in three separate
section criteria then he/she was considered not to have Crohn’s disease. The only 
exceptions to this standard were patients who had isolated colonic Crohn’s disease 
who had granulomas and a pancolitis with inflammatory type disease behaviour; 
using these criteria a score of only 1 or 2 may be generated by such patients but the 
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presence of epitheliod granulomas in these circumstances was deemed enough to 
classify the patient as having Crohn’s disease, as noted in the classification itself. 
Patients were diagnosed with ulcerative colitis when they had uniform inflammation 
that commenced in the rectum and continued for a varying extent more proximally. 
In addition to chronic inflammation on histology the patients had evidence of 
ulceration, cryptitis, crypt abscess formation together with goblet cell/mucin 
depletion without any epitheliod granulomata. 
A patient was categorised as having “indeterminate colitis” if definite evidence of 
chronic inflammatory bowel disease affecting the colon only  was present, but the 
patient remained unclassifiable as either CD or UC, after considering all clinical, 
radiological, endoscopic and pathological findings.
2.2 Study participants
2.2.1 Patient and parents
Patients and parents were recruited from the three tertiary paediatric gastroenterology 
centres in Scotland based in the specialist childrens’ hospitals in Edinburgh, Glasgow 
and Aberdeen between 2002 and 2005. Further study participants who were 
diagnosed with IBD under the age of 16 but who had transitioned to adult services at 
the Western General Hospital in Edinburgh were also recruited to the study. 
Information about the purpose of the study was supplied to all patients and parents 
prior to approaching them for study enrolment (appendices 2 and 3 respectively). In 
those patients and families who agreed to take part written consent was then obtained 
from patients and parents prior to participation in the study (appendices 4 and 5 
respectively). The information sheets and consent forms shown in the appendices are 
examples of the type of forms used. The exact details of each form were all slightly 
different having been adapted to a style acceptable to the local research ethics 
committee.
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2.2.2 Blood collection 
Each patient had up to 10 millilitres (mls) of blood collected into EDTA and lithium 
heparin tubes. The blood was usually collected when the patients were having blood 
taken as part of their on going clinical care as requested by their supervising clinician 
and not merely for participation in the research study. A topical local anaesthetic 
cream [Eutectic Mixture of Lidocaine and Prilocaine (EMLA Astra-Zeneca) or 
Amethocaine base 4.0%w/w (Ametop Smith & Nephew)] was applied if requested 
by the patient or family, prior to venesection. Parents each gave 10mls of whole 
blood collected into an EDTA tube collected in a Vacutainer (Nu-care) system. In 
the case of “parents” who were not the genetic parents of the child, as disclosed in 
confidence by the guardian to the researcher, “sham” blood taking was undertaken by 
placing a plaster on the carer’s arm, to avoid disclosure of any potentially sensitive 
information to the child in the course of the family agreeing to take part in the study. 
2.2.3 Healthy control recruitment
Healthy adult controls were recruited from healthy volunteers and from volunteers 
recruited from the Scottish blood transfusion service. The number of controls used in 
each of the genetic studies varied and the exact number used in the study of each of 
the candidate genes is listed individually in the subsequent chapters. 
2.2.4 Ethical approval
Ethical approval was given for all participating centres (Edinburgh, Lothian Research 
Ethics Committee (LREC) Reference Number: LREC/2002/6/18; Aberdeen, 
Grampian Research Ethics Committee (GREC) reference number: GREC 03/0273; 
Glasgow, Yorkhill Research Ethics Committee (YREC) reference number: YREC 
number P12/03).
2.2.5 Data collection
Retrospective data were collected on patients using case note review and a patient 
/parent questionnaire). All patients with IBD completed a questionnaire, collecting 
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information on patient and parental smoking details, ethnicity and a detailed family 
history of IBD and other diseases (see appendix 6). Additional clinical data was 
collected on patient demographics, age at IBD symptom onset and diagnosis, 
medications, extraintestinal manifestations, history of atopic disease and need for 
surgery after the patient questionnaire was combined with examination of patient 
case notes.  
2.3 Disease phenotype 
All patients recruited to the study were phenotyped personally or with data entry 
assistance from Hazel Drummond (database manger). Proforma sheets were designed 
to collect the data in a consistent manner and to further reduce the chances of inter-
observer error for Crohn’s disease and Ulcerative/Indeterminate Colitis (Appendices 
7 and 8 respectively). The phenotypic criteria used were the Vienna classification for 
patients with Crohn’s disease 36 and a paediatric specific phenotypic classification for 
use in all types of IBD. The Montreal classification was used to directly compare 
childhood and adult onset IBD patients in chapter 3 only. Phenotypic information 
was collected at diagnosis and reassessed in 2 yearly intervals for CD patients for the 
first 10 years post diagnosis and then collected at 5 year intervals subsequently. In 
patients with UC/IC phenotypic details were collected at diagnosis and the time of 
last follow. 
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2.3.1 The Vienna classification
A summary of the classification appears in table 2-1.
2.3.1.1 Disease location
This classification divided disease location into four different disease locations 
prefixed by the letter L for location; L1 was used to represent Ileal disease and was 
defined as disease in the distal third of small bowel, with or without caecal 
involvement; L2 was used to represent colonic disease activity only and disease 
could be present nowhere else within the GI tract; L3 Ileo-colonic represented a 
combination of the first two disease location categories and was defined by disease in 
the Ileum i.e. the distal third of the small bowel plus at any location within the colon; 
L4 represented disease in the upper gastrointestinal tract anywhere proximal to 
terminal ileum with the exception of the mouth, with or without ileal and/or colonic 
involvement. Disease locations were exclusive i.e. each patient could only have a 
disease location in one category and once a patient was classified in the L4 location 
they could not move from that category at further disease follow up. Patients who 
had oral or perianal Crohn’s disease, or a combination of both in the absence of 
disease activity elsewhere in the GI tract, did not fit into this classification system. 
For the purposes of analysis they were classified as disease location “none” and were 
analysed as a 5th disease location not forming part of the original classification.
Disease extent was defined as the maximum disease involvement prior to the first 
surgical resection. The minimum criteria for involvement of a disease location were 
ulceration or the presence of an aphthous lesion. If only erythema and/or oedema 
were present that was not deemed enough to signify disease at that site.
2.3.1.2 Disease behaviour
The classification divided disease behaviour into three different categories prefixed 
by the letter B. B1 represented inflammatory disease behaviour and was represented 
by non-stricturing, non-penetrating disease as defined in the B2 and B3 behaviour 
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categories; B2 was used to represent stricturing disease that was defined as a constant 
luminal narrowing on radiology, at the time of endoscopy  or surgery with a pre-
stenotic dilatation or if accompanied by obstructive signs and symptoms clinically; 
B3 represented penetrating disease that represented intra-abdominal or perianal 
fistulas, or inflammatory masses plus or minus abscess formation at any time 
excluding complications arising in the immediate post operative period.
Like disease location each behaviour category can never be down graded which 
meant that patients who are in the B3 category cannot move from that category. In a 
patient who has stricturing and penetrating disease, classification is to the category 
B3.
2.3.1.3 Age at diagnosis
The age (A) category simply refers to the patient’s age at diagnosis; either as A1 < 
40 years or A2 > 40 years old. All of the patients in this study were in the A1 
category so analysis was performed using age at diagnosis as a variable.
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2.3.2 Proposed paediatric phenotypic classification 
In the absence of a recognised paediatric classification a paediatric phenotypic 
classification was devised for use in this thesis. In patients with Crohn’s disease, 
location was categorised and analysed according to individual disease locations, 
regardless of disease involvement elsewhere in the gastrointestinal tract in contrast to 
the hierarchical model used in the Vienna classification. This model was adopted to 




This phenotype therefore recorded the presence or absence of evidence for CD 
activity in each anatomical location (based on findings from endoscopy, biopsy, 
surgery or barium follow through) within the gastrointestinal tract, namely: oral, 
oesophageal, gastric antrum and body, duodenal, jejunal, ileal, caecal, ascending, 
transverse, descending and sigmoid colon together with rectum and peri-anal disease 
(table 2-2). In addition to these general disease definitions some further specific 
definitions were made for specific disease sites.
1. Oral Crohn’s disease was defined by macroscopic changes (mucosal tags, deep 
linear ulceration, cobblestoning, lip swelling and fissuring) after examination by a 
paediatric dentist/oral medicine specialist only.  The presence of epitheliod 
granulomata on buccal biopsy was also classified as oral Crohn’s disease. The term 
oral CD was preferred to the term oro-facial granulomatosis.
2. Patients were diagnosed with Crohn’s disease of the upper GI tract (oesophagus, 
stomach, duodenum or jejunum) when biopsies from any of these sites confirmed the 
presence of epitheliod granulomas (not merely in the presence of chronic 
inflammation) and/or when features of macroscopic disease were present. The 
presence of a chronic gastritis in the absence of other features of Crohn’s disease was 
not sufficient to indicate disease involvement of the gastric body/antrum. 
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3. Perianal disease was defined by the presence of fissures, fistulae, abscess 
formation or perianal ulceration but not by the presence of skin tags alone. 
4. The presence of granulomata was assessed by endoscopic biopsy at diagnosis or at 
the time of surgical resection. 
2.3.3.2 Disease behaviour
The definitions for disease behaviour were the same as those used in the Vienna 
classification.36 The reason why a patient was analysed as penetrating disease was 
recorded but not analysed separately.
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2.3.4 Ulcerative colitis 
2.3.4.1 Disease location 
No widely recognised disease classification for patients with Ulcerative colitis was 
widely accepted at the time of commencing the scientific work of this thesis in 
September 2002, either in children or in adults. For the purposes of the study disease 
extent was dived into 6 categories depending on the maximum disease extent defined 
by either macroscopic appearance or histology (rectum, sigmoid, descending, 
transverse, ascending and pancolitis when inflammation involved the whole colon) as 
listed in table 2-3. It was also noted whether the patient had a full assessment i.e. 
Colonoscopy or a limited assessment i.e. sigmoidoscopy and a subjective assessment 
of whether the examination was adequate i.e. good bowel preparation or not. Details 
of where the examination stopped were also recorded i.e. in patients undergoing 
colonoscopy whether the examiner reached the terminal ileum or whether the 
examination stopped prior to this at a specific colonic location.
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2.3.5 Surgery
Surgery was defined as any operative intervention for IBD except for examination 
under anaesthesia without any other surgical intervention. This definition was further 
adapted during the course of the study dividing surgical procedures for Crohn’s 
disease into resections, drainage procedures or other types of operations.
2.3.6 Growth data
The basic anthropometric information collected in all patients were weight (in 
kilograms) and height (in metres). All patients had their height measured on a wall 
mounted stadiometer and weight measured on regularly calibrated scales. A body 
mass index (BMI) was calculated thereafter by dividing the patients weight by their 
height squared. The data were then plotted on a standard UK centile chart using the 
UK 1990 population data (© Child Growth Foundation 1996) and one of ten centile 
bands was then allocated. The centile band allocated was one of the following: 
<0.4th, 0.4th-2nd, 2nd-9th, 9th-25th , 25th-50th, 50th-75th, 75th-91st, 91st -98th,98th-99.6th
and >99.6th. 
During the course of the study the anthropometric data collected were also defined 
using z-scores (British 1990 Growth Reference for height, weight and BMI ©Child 
Growth Foundation, 2 Mayfield Avenue, London W4 1PW). A z score for an item 
indicates how far and in what direction, that item deviates from its distribution's 
mean, expressed in units of its distribution's standard deviation prefixed by a + or -. 
A correlation of the patient’s growth with their pubertal status was also recorded. 
The collection of pubertal staging however was abandoned during the study as it 
became apparent this data was poorly and inconsistently recorded in the patient’s 
case notes, making it unsuitable for further detailed analysis. 
2.3.7 Haematological and biochemical disease markers
Data were collected, using proforma sheets, for all patients who had blood tests 
performed at the time of diagnosis and at designated times of follow up i.e. 2 yearly 
for patients with CD and at diagnosis and last follow up for patients with UC/IC 
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(appendix 9). The values used to signify abnormal blood tests were as follows: 
Albumin <35 g/l, Erythrocyte sedimentation rate (ESR) > 10mm in the first hour. C-
reactive protein (CRP) was recorded as normal or high (the specific units used varied 
between various laboratories used by the participating centres in the study). 
Abnormal values for haemoglobin concentration were age dependent: age 1-3 years 
<110 g/l, 3-6years <117g/l, >6 years <120g/l and platelets >400 x109/l. The normal 
ranges for vitamin B12 were 193–982 nanograms/l
-1 and for serum folate 3–7g/l-1.
Faecal Calprotectin was considered abnormal at > 50 g/g. 
2.4 Patients
2.4.1 Crohn’s disease
The location of Crohn’s disease in individual disease locations are listed in table 2-4. 
This table demonstrates that ileal and colonic disease locations are the commonest 
disease sites at disease presentation in children at 64% and 75-78% respectively. In 
patients with oral disease (15%) there were an equal number of cases diagnosed by 
expert clinical opinion and by buccal biopsy. The number of patients with 
oesophageal Crohn’s disease is notably small at <3%. The oesophagus was the 
commonest disease site not to be biopsied and so this may be an underestimate of the 
true prevalence of oesophageal Crohn’s disease. 
Gastric Crohn’s disease is a relatively common disease site with similar disease 
prevalence in both the gastric body and antrum at around 25% for each site. The 
higher prevalence in the antrum reflected the fact this site was preferred for gastric 
biopsies and that body biopsies were not always taken. Duodenal and jejunal CD 
were equally common at around 15%
Ileal disease entailed disease involving the terminal ileum in the majority of cases. 
This was demonstrated equally by changes found at endoscopy and on barium 
studies. The colon was the commonest site of disease and despite surveying regular 
sites throughout the colon disease prevalence in all sites was equally common at 75-
78% of samples taken. At 2 year follow up there was no significant change in disease 
location at all sites.
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2.4.2 Vienna classification
The location and behaviour of CD according to the Vienna classification are listed in 
table 2-5. In contrast to the findings of individual disease sites, ileal and colonic 
disease categories were the least common category in this disease classification, with 
the presence of isolated ileal disease in less than 5%. The L4 category of upper GI 
disease was the most common (46%), being at least twice as common as any of the 
other disease sites. It should also be noted that in 6% of patients with a diagnosis of 
CD the patients did not have a disease site that was recognized by the classification.
Children less than 8 years at diagnosis were proportionally more likely to have 
isolated colonic disease (L2) than those children diagnosed at more than 8 years of 
age 37.2% vs. 20.0%, p=0.02 OR=2.37[1.14-4.93]. 
At diagnosis, the majority of patients had inflammatory disease behaviour (81%), but 
there were a notable number of patients (14%) with penetrating disease behaviour, 
predominantly reflecting patients with peri-anal abscesses and fistulae.
At 2 year follow up, disease location as defined by the Vienna classification had not 
significantly changed compared to location at diagnosis. Disease behaviour was 
progressing with more stricturing and penetrating disease. Penetrating disease was 
present in 26% of patients at 2 years post diagnosis compared to 14% at diagnosis 
(p=0.02, OR= 2.09 [1.13-3.87]). 
2.4.3 Ulcerative colitis
The disease locations for Ulcerative colitis at disease diagnosis and time of last 
follow up are shown in table 2-6. The median time of follow up was 2.33 years (IQR 
1.33-4.17 years). Data on disease location was available for 96 children at diagnosis 
and 71 at follow up. Pancolitis was the commonest disease phenotype at diagnosis 
and follow up with prevalence close to 60%. Proctitis was the least common disease 
extent found in less than 2% of cases at follow up. There was no significant change 
in the distribution of disease location at the time of last follow up. There were 18 
children diagnosed at <8 years of whom 8 (44%) had a pancolitis at diagnosis.
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2.4.4 Indeterminate colitis
The disease locations for patients with indeterminate colitis are shown in table 2-7. 
The median time of follow up was 2.33 years (IQR 1.33-4.17 years). Data on disease 
location was available for 37 children at diagnosis and 21 at follow up. As for 
patients with ulcerative colitis, pancolitis was the commonest disease extent affecting 
66.7% of patients at follow up. The median age at diagnosis was 9.9 years (IQR 7.7-     
11.9years) and median time of follow up was 2.2 years (IQR 1.6-3.9 years).There 
were 10 children diagnosed at <8 years of whom 8 (60%) had a pancolitis at 
diagnosis.
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Table 2-4: CD Disease location at diagnosis and 2 year follow up
Disease Location Diagnosis 2 year follow up
Oral 20/152 (13.6%) 14/98 (14.3%)
Oesophageal 4/142 (2.8%) 1/90 (1.1%)
Gastric antrum 39/145(26.9%) 12/84 (14.3%)
Gastric body 30/138 (21.7%) 18/94 (19.1%)
Duodenal 23/137 (16.8%) 9/88 (10.2%)
Jejunal 22/136 (16.2%) 14/90 (15.6%) 
Ileal 91/142 (64.0%) 63/94 (67.0%)
Caecal 91/119 (76.5%) 58/79 (73.4%)
Ascending 92/122 (75.4%) 56/74 (75.7%)
Transverse 99/129 (76.7%) 60/79 (75.9%)
Descending 104/134 (77.6%) 61/81 (75.3%)
Sigmoid 115/147 (78.2%) 67/92 (72.8%)
Rectum 117/151 (77.5%) 67/93 (72.0%)
Perianal 66/158 (41.8%) 37/100 (37.0%)
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Table 2-5: CD Vienna classification at diagnosis and 2 year follow up
Disease Location At Diagnosis 2 year follow up
Terminal Ileum (L1) 8 (4.8%) 5 (4.8%)
Colon (L2) 38 (22.8%) 28 (26.9%)
Ileocolon (L3) 34 (20.3%) 22 (21.2%)
Upper gastrointestinal (L4) 77 (46.1%) 45 (43.3%)
None* 10 (6.0%) 4 (3.8%)
Disease Behaviour 
Inflammatory (B1) 136 (81.4%) 66 (63.5%)
Stricturing (B2) 7 (4.2%) 11 (10.6%)
Penetrating (B3) 24 (14.4%) 27 (25.9%)
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Table 2-6: UC location at diagnosis and last follow up
Disease location Diagnosis Last follow up 
Rectum 4 (4.2%) 1 (1.4%)
Sigmoid colon 12 (12.5%) 7 (9.9%)
Descending colon 9 (9.4%) 5 (7.0%)
Transverse colon 12 (12.5%) 10 (14.1%)
Ascending colon 3 (3.1%) 6 (8.5%)
Pancolitis 56 (58.3%) 42 (59.1%)
Table 2-7 IC location at diagnosis and last follow  up 
Disease location Diagnosis Last follow up 
Rectum 5 (13.5%) 0
Sigmoid colon 3 (8.1%) 1 (4.7%)
Descending colon 2 (5.4%) 1 (4.7%)
Transverse colon 4 (10.8%) 2 (9.5%)
Ascending colon 2 (5.4%) 2 (9.5%)
Pancolitis 19 (51.4%) 14 (66.7%)
Unknown 2 (5.4%) 1 (4.7%)
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2.4.5 Growth
The mean z scores for weight, height and BMI for 235 children with Crohn’s disease 
at diagnosis were -0.67 (SD 1.43), - 0.51(SD 1.62) and -0.66 (SD 1.55) respectively. 
The equivalent figures for 85 children with ulcerative colitis were -0.07 (SD 1.15), -
0.37 (SD 2.92) and -0.02(SD 1.07) respectively. When comparing results for CD 
with UC using a t-test the respect values for weight, height and BMI were (p<0.0001 
95% CI [-0.91 to -0.29], p=0.7[-0.84, 0.57] and p<0.0001 (-0.95, -0.31].
2.4.6 Surgery 
Of the 256 CD patients with surgical details available 64 (25%) had at least one 
surgical intervention. Of those needing surgery, drainage operations were the most 
common in 30 (47%) patients, followed by resection in 25 (39%) with the remaining 
patients having combined operations or other surgical procedures. The median time 
to the first surgical resection was 1.92 years (IQR 0.33-4.54 years). The median time 
of follow up of these patients as a whole was 4.75 years (IQR 2.08-10.17 years).
In patients with ulcerative colitis details of surgery at follow up were available in 70 
patients who had been followed up for a median time of 2.33 years (IQR 1.33-4.17 
years). In this group of patients 15 (21.4%) had a colectomy with a median time to 
surgery from diagnosis of 1.5 years (IQR 0.7-3.1 years). In the 21 patients followed 
up with a diagnosis of IC only 1 had a colectomy.
2.5 Database
All study data were entered into a Microsoft Access 2000© database. Anonymised 
data were stored in this password-secure Access database, which was designed and 
maintained for the purpose of this study and the parallel genetic studies in adult IBD 
patients. The early-onset database was personally conceived and constructed for the 
thesis incorporating all of the data collected in the course of the study. All data were 
entered personally or by Hazel Drummond (database manager). All data were backed 
up on compact disc weekly, or after a period of large data entry before being stored 
IBD Genetics in Scottish Children
Patients, materials and methods 55
in secure fire-resistant container.  A dedicated computer solely used for research 
studies without connection to the internet was used for storage of the study data.
2.6 Statistics
2.6.1 General statistics
Minitab statistical software version 13 (Minitab ltd, Coventry, UK) and GraphPad 
Instat (version 3.06 for Windows 98, GraphPad Software, San Diego California 
USA, www.graphpad.com) was used to analyse genotype- phenotype associations 
using Chi squared or Fishers exact test where appropriate for unifactorial analysis. 
Non-parametric data were analysed using the Mann Whitney U test in Minitab. In 
chapter 8 statistical analyses was performed using SPSS© (version 11.5, SPSS Inc. 
Headquarters, 233 S. Wacker Drive, 11th floor, Chicago, Illinois 60606). 
Multifactorial analysis was performed using Minitab software. 
2.6.2 PedCheck
The PedCheck programme (Department of Human Genetics, University of 
Pittsburgh, Pittsburgh, PA) was used to check for genotyping error and potential 
cases of non-paternity.144 Any family trios with inconsistent results incompatible 
with normal patterns of inheritance were excluded from further genetic analyses. 
2.6.3 Population attributable risk
The population attributable risk percentage (PAR %) was defined as the excess rate 
of disease in individuals with a mutation compared to those without. As described by 
Schlesselman, the PAR% is calculated from the attributable risk as a function of the 
prevalence in the exposed population, divided by incidence of IBD in the 
population.145 To calculate this, the prevalence of CD was estimated at 100/100,000 
and the frequency of all alleles in the control population was assumed to reflect that 
of the general population.
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2.6.4 Transmission disequilibrium testing
Transmission disequilibrium testing analysis was performed using the TRANSMIT 
package (Version 2.5, David Clayton, Cambridge, UK).146 This method makes full 
use of the data available using inferred genotypes if genotypic data from both parents 
are not available. Assistance with data analysis with the TRANSMIT programme 




Genomic DNA was extracted from blood using a modified salting-out technique 
(appendix 10).147 The optical density of the resultant DNA was then measured using 
a Gene Quant Pro instrument to estimate the actual DNA concentration.  The 
solution was then re-suspended in an appropriate volume of 1xTE (10mM Tris 
(pH8.0), 1m EDTA (pH8.0)) to give a final DNA concentration of 100ng/μl.
2.7.2 Lymphocyte and Plasma extraction
Peripheral blood lymphocytes were extracted from the lithium heparin samples 
collected from patients with IBD. The lymphocytes then underwent subsequent 
cryopreservation and remain in this state currently. Plasma was isolated at the time of 
peripheral blood lymphocytes extraction and samples were stored at -80oC until use. 
The lymphocyte extraction and separation of plasma was carried out by the staff in 
the Wellcome Trust clinical research facility, University of Edinburgh.
2.7.3 PCR 
All standard Polymerase chain reactions (PCR) were run on a Techne Touchgene 
Gradient machine. The reagents used and reaction conditions are detailed for the 
individual SNPs in subsequent chapters.
IBD Genetics in Scottish Children
Patients, materials and methods 57
2.7.4 DNA sequencing
In Chapter 5 primers for sequencing the NOD2/CARD15 gene were designed using 
data from Ensembl (www.ensembl.org). Direct sequencing was performed on the 
7900 HT sequence detection system (Applied Biosystems, Foster City, Ca, USA) by 
the Technical Services section of the MRC Human Genetics Unit, Edinburgh. DNA 
sequences were analysed using Sequencher v 4.5 (Gene Codes Corporation, Ann 
Arbor, MI, USA). An example of the sequence produced for analysis is shown in 
figure 2-1.
Figure 2-1: An example of genomic sequence from Sequencher
The arrow marks sequence demonstrating heterozygote, homozygous wild type and 
homozygous mutant respectively, reading from top to bottom.
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2.7.5 TaqMan
The majority of genotyping was performed using TaqMan® (© Biosystems) and was 
performed in the Welcome Trust Clinical Research Facility (WTCRF) located within 
the Western General Hospital, Edinburgh. This PCR-based assay uses laser scanning 
technology that excites fluorescent dyes present in specifically designed probes. The 
system includes a built-in thermal cycler, a laser to induce fluorescence, CCD 
(charge-coupled device) detector, real-time sequence detection software, and 
TaqMan® reagents for the fluorogenic 5' nuclease assay. The cycle-by-cycle 
detection of the increase in the amount of PCR product is quantified in real time as 
the special probes, "reporter dye", fluoresces when the "quencher" is removed from 
the fragment during the PCR extension cycle.
2.7.5.1 SNP design
TaqMan genotyping was ordered using primers from an Assay on Demand Assay for 
SNPs that had previously been genotyped or, the target sequence for each SNP was 
submitted to the Assay by Design Service for Custom SNP Genotyping Assays. The 
Assays from these services consist of a mix of unlabelled primers and TaqMan 
Minor Groove Binder probes. Genotyping was performed using DNA plated in 384 
(4x96) well-plates, using the TaqMan polymerase chain reaction-based method. . In 
each plate, negative control wells are used to check the quality of reaction.
2.7.5.2 PCR reaction
The final volume PCR reaction was 5 micro litres (µl) using 20 nanograms of 
genomic DNA, 2.5 µl of TaqMan Master Mix and 0.125μl of 40x Assay By design 
Genotyping Assay Mix, or 0.25µl of 20x  if using Assay On Demand Genotyping 
Assay. The cycling parameters were as follows: 95° for 10 minutes, followed by 40 
cycles of denaturation at 92° for 15 seconds and annealing/extension at 60° for 1 
minute. PCR plates were then read on ABI PRISM 7900HT (Applied Biosystems) 
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instrument with Sequence Detection System (Applied Biosystems) version 2.1 
software. 
2.7.5.3 Allele discrimination
Allelic discrimination using this chemistry is based on the design of two TaqMan 
probes, specific for the wild type allele and the mutant allele separated using laser 
scanning technology. Each of the two probes is labelled with a different fluorescent 
tag 6-carboxy-fluorescein (FAM) and VIC®. Each probe is designed with the gene 
mutation affecting the middle part of the probe sequence. The binding efficiency of 
the wild type TaqMan probe to the mutant allele and vice versa is low, due to the 
mismatch within the TaqMan probe and the target sequence; therefore, mismatched 
binding is highly reduced. 
2.7.5.4 Results
Allocation of allele status as homozygous wild type, heterozygote or homozygous 
mutant was made by personnel in the WTCRF blinded to the study aims. The results 
from TaqMan studies were then collected onto an Excel 2000© spreadsheet before 
being entered onto the Access 2000© study database, with results matched using pre-
assigned unique study numbers. An example of the raw data plot generated from a 
TaqMan assay is shown in figure 2-2.
IBD Genetics in Scottish Children
Patients, materials and methods 60
Figure 2-2: Example of allelic discrimination using TaqMan
Blue and red diamonds represent homozygotes binding to FAM and VIC 
respectively. The green diamonds represent heterozygotes. The black crosses 
represent samples where no allelic status can be assigned.
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2.8 Primers 
The primers used in analysis of the NOD2/CARD15 gene, IBD5 haplotype and 
DLG5 gene are listed in the relevant chapters.
2.9 Haplotypes
Haplotypes were calculated using Haploview version 3.2.
2.10 Gels used for PCR reactions                                       
2.10.1 Preparation
Multipurpose agarose (2.25g) was added to 150 millilitres (ml) of half strength TBE 
into a 250 ml beaker. This was then microwaved on full power for between 2 and 3 
minutes agitating half way through until all of the agarose had dissolved into 
solution. The agarose was then cooled to around 50C by running under a cold water 
tap, before 10 microlitres (µl) of ethidium bromide was added and then agitated 
further to ensure even distribution. The agarose solution was then poured into a 
transparent gel-casting tray, which was sealed at each end using autoclave tape. Four 
combs containing either 12 or 16 wells were then inserted into the gel. The gel was 
then left to cool and solidify at room temperature for at least 30 minutes.
2.10.2 Electrophoresis
The gel was removed from its tray and case removed before being placed into an
electrophoresis tank filled with half strength TBE. Before loading the PCR mix in 
question 5 µl of orange G loading buffer had been added to 20 µl of PCR mix. The 
mixture was then pipetted into the wells in the gel before running the electrophoresis. 
The running time varied dependent on optimal conditions for the PCR reaction in 
question but a standard running time of 30 minutes and 150 watts of power was used
for most gels.
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2.10.3 Interpretation 
After the gel had completed electrophoresis it was then removed from the tank and 
placed in a covered ultraviolet hood. Images were then recorded using a digital 
camera image loaded onto a designated computer. The results were then read for 
each sample manually and recorded onto the Access© database. Each gel was run 
with controls for homozygous wild type and mutant as well as a heterozygote. If any 
of the controls failed then the gel was not used for genotype analysis. 
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3 Phenotypic characteristics of childhood onset IBD: 
Comparison with adult onset disease using the Montreal 
classification
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3.1 Summary 
Aims: To describe phenotypic characteristics of childhood-onset compared to adult-
onset IBD in Scottish patients.
Setting: 353 children with IBD (256 CD, 97 UC) were recruited from the three 
paediatric gastroenterology centres in Scotland. 1234 adults (617 CD, 664 UC) 
patients were recruited from the Western General Hospital, Edinburgh.
Methods: All patients were phenotyped using the Montreal classification. 
Phenotypic comparisons were then made between childhood and adult populations 
using the Montreal classification.
Results: Unless stated p ≤0.0001. Childhood onset IBD was characterised by more 
familial disease (34% vs. 20% OR=2.1 [1.6-2.8]) and less smoking (1% vs. 18% 
OR=0.05[0.02-0.14]). Childhood onset CD featured a male predominance (60% vs. 
38%, OR=2.5 [1.8-3.3]). More extensive Crohn’s disease was present at diagnosis in 
children with more combined colonic/upper GI and more combined ileo-
colonic/upper GI (L2+L4, 18% vs. 2% OR=14.3 [6.6-30.8] and L3+L4, 37% vs. 4% 
OR=16.2[9.6-27.3] respectively). There was also less isolated ileal and less isolated 
colonic disease (L1, 4% vs. 30% OR=0.09[0.04-0.17] and L2, 16% vs. 37% 
OR=0.3[0.21-0.46] respectively). There was less stricturing and penetrating disease 
at diagnosis (B2, 4% vs. 9% p=0.007 OR=0.38[0.18-0.79] and B3 p=0.02 
OR=0.45[0.2-0.9] respectively). There were also less extra-intestinal manifestations 
(18% vs. 28%, p=0.004 OR=0.58[0.4-0.85]. Childhood onset UC was characterised 
by more extensive colitis (E3, 74% vs. 41%, OR= 4.1[2.5-6.7] and conversely less 
proctitis (E1, 4% vs. 21%, p=0.0001, OR=0.2(0.06-0.5).
Conclusions: Childhood IBD has distinct phenotypic characteristics in comparison 
to adult IBD. Children with CD were more likely to be male, have more extensive 
disease (more upper tract disease, less isolated ileal and colonic disease) and less 
stricturing/penetrating disease at diagnosis. Children with UC have more extensive 
disease at diagnosis. The reasons for the phenotypic differences will be explored by 
examining patient genotypes between the two populations in subsequent chapters. 
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3.2 Introduction
The only established phenotypic classification available at the start of the thesis was 
the Vienna classification, an established phenotypic classification for adults with 
Crohn’s disease.36 No phenotypic classification was available for children, and 
additionally there was no consensus classification available for Ulcerative Colitis in 
adults or children. 36 In devising the Vienna phenotypic classification for Crohn’s 
disease, a working party was convened in Vienna in 1998 and then after reviewing 
the evidence from five IBD populations in Europe and North America; their joint 
findings were subsequently published in 2000. The consensus that emerged based a 
phenotypic classification of Crohn’s disease on: age at diagnosis, disease location 
and disease behaviour as described in detail in chapter 2. 
Subsequently, the classification system was refined taking into consideration some of 
the difficulties encountered in applying the Vienna classification to Crohn’s disease 
populations while performing clinical studies. A working party met in Montreal in 
2005 and published their revised findings in the same year.35 This classification 
provided a disease categorization that could be used for patients with both Crohn’s 
disease and Ulcerative colitis.
Could the adult classification therefore simply be applied to children? This is 
addressed in this study by first examining disease phenotype in children and then 
addressing whether the IBD phenotype is different between childhood and adulthood 
populations.
3.3 Materials and Methods
Patients were recruited from paediatric gastroenterology centres in Scotland and 
compared to adult onset patients recruited from the Western General Hospital, 
Edinburgh. 
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3.3.1 Montreal classification
In 2005 a second “adult” phenotypic classification was proposed providing a disease 
classification for both Crohn’s disease and Ulcerative Colitis (tables 3-1 and 3-2 
respectively). This newer Montreal classification addressed the shortcomings of the 
Vienna classification which included specific recognition of a separate early onset 
disease category (<17 years).35  The outline of the classification provided in the 
following text will concentrate only on the modifications to the Vienna criteria.
3.3.1.1 Disease location
In addition to the four disease locations described in the Vienna classification (ileal, 
colonic, ileo-colonic and upper GI, L1-4) the Montreal classification added three 
further subcategories; these were the first three categories (L1-L3) with the addition 
of L4 where the disease sites coexisted, meaning the L4 disease location was no 
longer an exclusive disease location allowing for more in depth phenotypic analysis. 
In patients with Ulcerative colitis disease extent was divided into three categories. 
The first category (E1) was for patients with a proctitis i.e. inflammation limited to 
the rectum, the second (E2) was for patients with left sided disease distal to the 
splenic flexure and the last category (E3) described patients with extensive disease 
proximal to the splenic flexure.
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3.3.1.2 Disease behaviour
The classification proposes waiting 5 years post diagnosis before allocating a specific 
disease behaviour. This is because of the dynamic nature of Crohn’s disease 
demonstrated in several adult studies.148-151 There is also a suggestion of 10 years 
post diagnosis for studies examining genotype-phenotype relationships! However, 
within the proposed framework leeway is also given, in that investigators are free to 
adapt a time line for disease behaviour that is suitable to the individual study 
population.
 Recognition is also given to the fact that enteric and perianal fistulae may represent 
different disease phenotypes. Thus perianal disease is removed from the B3 category 
and instead added as a suffix “p” to any of the disease categories, B1-3. Perianal 
disease behaviour is defined as the presence of perianal abscesses or fistulae. There 
are no published studies suggesting the best time line for changes in disease 
behaviour in paediatric CD. So, within the present study behaviour is only analysed 
at the time of diagnosis, when comparing disease in children compared to adults.
3.3.1.3 Age at disease diagnosis
There were now three age categories instead of the two in the Vienna classification. 
The original <40 years was divided into an age <17 years at diagnosis (A1) and a 17-
40 years category (A2). The >40 years category remained and was known as A3 in 
the new classification.
3.3.2 Parental smoking
Details were also collected on parental smoking and in a limited number cases 
smoking data was available from control children and their parents. Pairs of cases 
(IBD) and controls were matched for sex, age (within 2 years) and geographical 
location (attending same GP practice).
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Table 3-1: The Crohn’s disease Montreal classification
Age at diagnosis
A1 16 y or younger
A2 17 – 40 years
A3 Over 40 years   
Disease location
L1 Terminal Ileum L1 + L4 TI + Upper GI
L2 Colon L2 + L4 Colon + Upper GI
L3 Ileocolon L3+L4 Ileocolon + Upper GI






B2 Stricturing B2p Stricturing + Perianal
B3 Penetrating B3p Penetrating + Perianal
Table 3-2: The Ulcerative colitis Montreal classification
Disease extent
E1 Proctitis
E2 Left sided (distal)
E3 Extensive (pancolitis)
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3.4 Results 
3.4.1 Childhood compared to adult disease
Data on 353 children with IBD (256 CD, 97 UC) were compared to 1234 adults (617 
CD, 664 UC) with the results presented in table 3-3. The median age at diagnosis in 
children with IBD was 11.4 years (IQR 9.0-13.1 years) and for adults was 32.1 years 
(IQR 24.5-46.2 years). 
3.4.2 Time to diagnosis
The time from the onset of symptoms to diagnosis of was available for 337 children 
(242 CD, 94UC) and 1042 adults (494 CD, 548UC). The median time to diagnosis 
was faster in patients with ulcerative colitis compared to Crohn’s disease in both 
children (0.33 years vs. 0.58 years, p=0.0009) and adults (0.25 years vs. 0.50 years, 
p<0.0001). In adults with ulcerative colitis the median time to diagnosis was faster 
than children (p=0.01) but there was no difference between children and adults with 
Crohn’s disease (p=0.26).
3.4.3 Sex
In children with CD there was a clear male predominance of disease with the 
opposite being true in adult onset disease (60% vs. 38%, p<0.0001, OR=2.5[1.8-
3.3]). In patients with UC the disease was equally likely to occur in both sexes both 
in child and adulthood.
3.4.4 Smoking
Smoking was uncommon in children with IBD in contrast to adults (1% vs. 18%, 
p<0.0001, OR=0.05[0.02-0.14]). In adults, smoking was more common in those with 
a diagnosis of CD compared to those with UC (27.2% vs. 10.6%, p<0.0001, OR = 
3.13 [2.29-4.29]). 
In total, 62 pairs of paediatric IBD cases and paediatric controls were compared. 
Parental smoking during pregnancy and around the time of birth was more common 
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in parents of IBD cases compared with control parents (54% vs. 29%, p=0.01; 
OR=2.87 [1.23–6.66]). Maternal smoking during pregnancy and at birth was also 
more common in the parents of IBD cases and CD cases than in parental controls 
(23% vs. 6.2%, p=0.04; OR=4.46[1.16–17.1]) and (27.8% vs. 8.3%, p=0.03; 
OR=4.23[1.05–16.97]). There was no significant effect seen when paternal smoking 
in pregnancy and at birth was analysed in IBD cases versus controls (p=0.27). 
3.4.5 Family history 
A family history of IBD was more common in children than in adults (33.9% vs. 
19.6%, p<0.0001, OR=2.1[1.6-2.8]).
3.4.6 Disease Location
There was more extensive “panenteric” disease present in children compared to 
adults demonstrated by significantly more upper GI tract disease in children in 
combination with colonic or ileo-colonic disease than was present in adult patients, 
(L2+L4, 18% vs. 2%, p<0.0001 OR=14.3[6.6-30.8] and L3+L4, 37% vs. 4%, 
p<0.0001 OR=16.2[9.6-27.3]respectively). This data was complemented by there 
being significantly less isolated ileal disease and less isolated colonic disease in 
children compared to adults (L1, 4% vs. 30%, p<0.0001, OR=0.09[0.04-0.17], L2 
16% vs. 37%, p<0.0001 OR=0.3[0.21-0.46] respectively. Isolated upper GI tract 
disease was uncommon in both children and adults. There were 12/52 (23.1%) 
patients with isolated colonic disease (L2) under 8 years of age compared to 29/218 
(13.3%) diagnosed at 8 years and older showing a strong trend towards statistical 
significance (p=0.07, OR=1.96 [0.92-4.16]).
In patients with a diagnosis of UC (table 3-4) extensive colitis was more common in 
children: (E3, 74% vs. 41%, p<0.0001 OR=4.1[2.5-6.7]). Contrastingly left sided 
disease and proctitis were less common (E2, 21.9% vs.38.7%, p=0.001 OR=0.44 
[0.27-0.74] and E1, 4% vs. 21%, p<0.0001 OR=0.2[0.06-0.5] respectively). 
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3.4.7 Disease behaviour
Inflammatory disease combined with perianal disease (B1p) was more common in 
children compared to adults (11.5% vs. 6.9%, p=0.03 OR=1.77 [1.05-2.97] with 
inflammatory disease alone (B1) showing a strong trend towards significance (80.2% 
vs. 73.8%, p=0.05 OR=1.43 [0.99–2.07]). Contrastingly stricturing (B2) and 
penetrating disease (B3) were less common in children at presentation compared to 
adults (B2, 4% vs. 9%, p=0.007 OR=0.38[0.18-0.79] and B3 4% vs. 8%, p=0.02 
OR=0.45[0.2-0.9]).
3.4.8 EIMS
Extra intestinal Manifestations (EIM’s) of IBD (skin, liver, eye and joint EIM’s 
combined) were less common in children compared to adults (18% vs. 28%, p=0.004 
OR=0.58[0.4-0.85]) at presentation. 
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Table 3-3: The presenting CD phenotype in children compared to adults
Children Adults p value Odds Ratio
Male: female 155/101 236/381 <0.0001 2.47 (1.83-3.33)
Smoker 5/252 (2.0%) 145/534 (27.1%) <0.0001 0.05 (0.02-0.13)
Family history 89/250 (35.6%) 126/588 (21.4%) <0.0001 2.03 (1.46-2.81)
Disease  location
L1 9/249 (3.6%) 158/526 (30.0%) <0.0001 0.09 (0.04-0.17)
L2 39/249 (15.7%) 195/526 (37.1%) <0.0001 0.32 (0.21-0.46)
L3 53/249 (21.3%) 109/526 (20.7%) 0.85
L4 3/249 (1.2%) 15/526 (2.8%) 0.15
L1+L4 6/249 (2.4%) 22/526 (4.2%) 0.21
L2+L4 45/249 (18.1%) 8/526 (1.5%) <0.0001 14.28 (6.62-30.83)
L3+L4 94/249 (37.7%) 19/526 (3.6%) <0.0001 16.18 (9.57-27.35)
Disease behaviour
B1 202/252(80.2%) 366/496 (73.8%) 0.05 1.43 (0.99–2.07)
B1p 29/252 (11.5%) 34/496 (6.9%) 0.03 1.77 (1.05-2.97)
B2 9/252 (3.6%) 44/496 (8.9%) 0.007 0.38 (0.18-0.79)
B2p 2/252 (0.8%) 1/496 (0.1%) 0.22
B3 10/252 (4.0%) 42/496 (43.7%) 0.02 0.45 (0.22-0.91)
B3p 0 9/496 (1.8%) -
Bp 31/252 (12.3%) 44/496 (8.9%) 0.13
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Table 3-4: The presenting UC phenotype in children compared to adults
Children Adults p value Odds Ratio
Male: female 48/49 329/335 0.99
Smoker 2/96 (2.1%) 69/649 (10.6%) 0.007 0.18 (0.04-0.74)
Family history 28/95(29.4%) 116/649 (17.9%) 0.007 1.92 (1.18-3.12)
Disease extent
E3 71/96 (74.0%) 232/569 (40.8%) <0.0001 4.13 (2.54-6.70)
E2 21/96 (21.9%) 220/569 (38.7%) 0.001 0.44 (0.27-0.74)
E1 4/96 (4.1%) 117/569 (20.6%) 0.0001 0.17 (0.06-0.47)
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3.5 Discussion
This most notable finding of this study is that it has demonstrated clear differences 
between children and adults with IBD in terms of disease phenotype. There are clear 
sex differences between children and adults with CD, being a male predominant 
disease in childhood and a female predominant disease in adulthood as has been 
confirmed again in this study. Kugathasan et al demonstrated in a North American 
CD population (<18 years at diagnosis) 62% of 129 patients studied being male.40  
Sawczenko et al. described the same male predominance of 62% in a study of 431 
UK CD patients (diagnosed <16 years).39 A number of further paediatric studies have 
also replicated this finding.7;9;152;153 The only study to report the opposite trend was 
from Canada where a “paediatric” population (under the age of 20 at diagnosis) 
demonstrated a female predominance in 57% of the 224 cases described.38
The transition between male and female dominated Crohn’s disease seems to happen 
in most studies in the late teenage years causing speculation about both 
environmental and genetic influences at this age. The increased use of the oral 
contraceptive pill at this age has been suggested as a possible contributory 
environmental agent.11 Godet et al.  performed a meta-analysis combining the  results 
of two cohort studies (30,379 unexposed and 30,673 exposed patients to oral 
contraceptive pill) and seven case-control studies involving (482 CD, 237 UC, and 
3198 controls) after excluding studies of poor methodological quality.154 The results 
demonstrated a modest increased risk for the development of both CD and UC but 
only CD being statistically significant (relative risk (RR) =1.44 (95% CI 1.12- 1.86 
and RR=1.29 (95% CI 0.94-1.77) for CD and UC respectively. 
This age/sex effect could also be influenced by genetic factors. Fisher et al. analysed 
the IBD3 locus by sex of the patient and demonstrated IBD3 is male sex specific 
locus.128 There also appears to be a male specific effect in studies of the DLG5 gene, 
as discussed in more detail in chapter 7.155;156 Interest in the role of the X 
chromosome in IBD susceptibility has been generated from an association with 
Turner’s syndrome and IBD.157
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There also appear to be distinct differences in disease location between children and 
adults, with children having more extensive disease. This study has highlighted that 
when the Montreal classification is applied to childhood and adult cohorts stark 
contrasts exist in disease location, with less isolated ileal and less isolated colonic 
disease but more upper GI tract disease in children combined with other disease sites 
compared to adults. In a large study in the Canadian CD population, Freeman 
demonstrated upper GI tract disease as defined by the Vienna classification was 
significantly more common in a cohort of 224 children (age <20years) compared to a 
cohort of 622 adults (20-39 years old) at 18% vs. 10 % respectively.38
It is unclear how much of this recognized difference in disease phenotype between 
children and adults results from differences in investigations used to diagnose IBD 
and how much represents a true phenotypic difference. Children in Europe at IBD 
diagnosis are now recommended to be investigated by upper GI endoscopy, ileo-
colonoscopy and small bowel follow through.158 Although these criteria defined by a 
working group of European paediatric gastroenterology, Hepatology and nutrition 
society (ESPGHAN) that met over several years in Porto and have only recently been 
published, this model of investigation has been employed by many paediatric 
gastroenterologists over many years, prior to the publication of these “official” 
guidelines. By contrast, adult patients will often undergo a more limited examination, 
which often omits an upper GI endoscopy,159 despite published recommendations.160
Thus the well recognized increase in upper gastrointestinal disease in paediatric 
patients may be partly artifactual due to: differences in the investigation of patients, 
publication bias with a limited amount of published data available or may represent a 
true disease distinction. The true differences can only be addressed in population 
wide prospective studies employing the same methods of diagnostic investigations in 
patients of all ages.  This study has demonstrated however that the differences in 
phenotype are not explained in patients with Crohn’s disease by a difference in time 
from symptom onset to diagnosis.
This study data is limited in the fact comparisons are only made at disease diagnosis, 
but other studies have demonstrated disease location is a relatively stable phenotype 
with little change over time. Louis et al. followed 125 adult patients with Crohn’s 
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disease and found at 10 years following diagnosis only 15% had changed disease 
location (location was defined using the Vienna classification).150 In a prospective 
study of Norwegian adult patients followed up at 5 years post diagnosis, Henriksen et 
al. demonstrated disease location defined using the Vienna classification had 
changed in 13.5% of patients.161
In this current study inflammatory disease was more common in children compared 
to adults at diagnosis. There are no prospective studies in the paediatric population 
that have studied the evolution of disease behaviour over an extended period of time 
in paediatric Crohn’s disease. In this study, a significant increase in the frequency of 
penetrating disease was demonstrated at 2 years post diagnosis (chapter 2). The study 
population examined in this thesis would need to be followed up for at least 5 years 
and probably 10 years to get a true indication of the rate of disease progression in 
paediatric Crohn’s disease based on published data from adult studies. 
Interestingly, in a study of disease behaviour in 2000 CD patients Cosnes et al. 
demonstrated 40% had penetrating disease as defined by the Vienna criteria at 5 
years and 70% by 20 years.14 Contrasting with the findings of the present study 
where adults had a higher rate of penetrating disease at diagnosis, the authors also 
noted penetrating disease was more common in disease diagnosed at a younger age 
(<40 years at diagnosis) although this population was not stratified into further age 
groups. Louis et al. studied 297 CD patients again using the Vienna classification and 
demonstrated disease behaviour had progressed significantly by 1 year post 
diagnosis.150 This study did not show any effect of age at diagnosis.
It is now well recognized that rates of pancolitis, in patients with Ulcerative colitis, 
demonstrated in prospective childhood studies (80-90%)39-41 are far higher than those 
documented from prospective adult studies (24% pancolitis42 or 33% extensive 
colitis43). This study provides further replication of this data although the data was 
not collected prospectively it is the first study to directly compare a child and adult 
population using the Montreal classification. Sawczenko et al. demonstrated a 
pancolitis rate of 81% in 211 UK UC patients and  Kugathasan et al, a rate of 90% in 
60 UC patients from Wisconsin.39;40 In the study from Heyman et al it was noted the 
very youngest children (diagnosed < 5 years of age) had the highest rates of 
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pancolitis at 96%.41 These data suggest for Ulcerative colitis at least, that a true 
difference in phenotype really does exist. 
There is also proxy evidence that UC starting in childhood is more severe disease 
phenotype. Eaden et al. in a meta-analysis of 116 studies examining UC and colo-
rectal cancer demonstrated a doubling in the rate of colorectal cancer complicating 
UC, independent of the increased risk conferred from pancolitis with a risk of 15.7% 
at 30 years post diagnosis in children compared to 8.7% in adults.162
Within childhood onset disease itself, very early onset IBD (age<8years old) appears 
to be a colonic predominant disease. This current study has mirrored the data for 
colonic Crohn’s disease, demonstrating that disease at diagnosis in children less than 
8 years, defined using the Montreal classification was more common than in children 
more than 8 years old at diagnosis (although did not quite reach statistical 
significance). In published studies to date almost all under 5 year olds will have 
colonic only disease, with a higher proportion of UC and  IC than children diagnosed 
at an older age.41;163 In a very large study of nearly 1400 North American early onset 
patients, Heyman et al demonstrated by multivariate analysis that a colonic 
predominant phenotype exists in IBD diagnosed under the age of 8 years.41 In 
parallel studies from Europe, Meinzer et al. demonstrated that the acquisition of ileal 
Crohn’s disease is an age dependent phenomenon that is rare at age 8 years and 
becomes increasingly more common year on year towards the age of 16 years.164  
This suggests a colonic predominant phenotype in children who are diagnosed in 
early childhood which then changes throughout the childhood years as children grow 
older.  
Using the Montreal classification does impose limitations in the anatomical sites of 
disease that can be compared. As the individual disease locations in this study for 
Crohn’s disease (chapter 2) fit generally with those published by other groups they 
would appear to be typical of a paediatric onset Crohn’s disease population. 
Therefore if a more extensive disease location categorisation was used the distinct 
differences between childhood and adult disease may become more apparent. In the
UK prospective survey performed by Sawczenko et al. of 167 CD patients with 
details of disease phenotype at diagnosis all the disease location categories had very 
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similar proportions to those reported in this study.39 The only exception was a 
decrease in the frequency of disease moving distally through the colon culminating 
in rectal disease in 49% of patients. 
It would seem that clearly the adoption of an adult classification for the many 
reasons outlined in this chapter would not be appropriate for children, so a separate 
classification is needed. This question was previously highlighted by a working 
group at the first world congress of paediatric gastroenterology that met in Boston, 
USA in 2000 when it was conceded that there was no recognised disease 
classification system for children with IBD but that one was needed.37 The 
hierarchical disease classification adopted in the Vienna classification would mean 
most paediatric patients, based on data from previous studies would have a disease 
location that fell into the upper GI (L4) category, potentially disguising any 
underlying genotype phenotype relationships.36 Although the Montreal classification 
has improved on the “benchmark” classification proposed by the working group in 
Vienna it still does not address some of the specific issues relating to disease 
phenotype in children. However despite these limitations the Vienna and Montreal 
classifications allow uniformity of reporting for genotype–phenotype analysis in 
paediatric genetic studies in the interim period prior to the development of a widely 
accepted paediatric phenotypic classification.
In conclusion, disease phenotype in children differs markedly from patients who are 
diagnosed in adulthood. The possibility that this can be explained by a patient’s 
genotype will be explored in subsequent chapters. 
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4 NOD2/CARD15: The influence of the three common 
variants on disease susceptibility and phenotype
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4.1 Summary
Aims: To investigate the contribution of the three common NOD2/CARD15 
mutations - R702W, G908R and Leu1007finsC to disease susceptibility and disease 
phenotype in the Scottish early-onset IBD population.
Subjects: 906 individuals including 247 Scottish IBD patients aged <16 years at 
diagnosis, 414 parents and 245 healthy controls.
Methods: Genotyping for the R702W and Leu1007finsC was performed by TaqMan 
and G908R by Restriction Fragment Length Polymorphism (RFLP). Transmission 
disequilibrium testing (TDT), case-control analysis and detailed genotype-phenotype 
analysis were then performed.
Results: The Leu1007finsC variant was associated with susceptibility to CD by case-
control analysis (4.2% vs. 1.4% respectively, p=0.01) and TDT analysis (2=4.42,
p=0.006). The Population Attributable Risk (PAR) for the 3 NOD2/CARD15 
mutations was 7.9%.Unifactorial analysis of NOD2/CARD15 carriage demonstrated 
carriage of NOD2/CARD15 variants was associated with, at diagnosis: decreased 
albumin (31.0% vs. 9.0%, p=0.001) and raised CRP (25% vs. 9.5%, p=0.04) and at 
follow up with: need for surgery (39.5% vs. 12.8%, p=0.0002) jejunal involvement 
(50% vs. 18.4%, p=0.01)  jejunal and ileal involvement (50% vs. 10.7%, p=0.009),  
raised CRP (57.1% and 12.8%, p=0.0009), lower weight/height centile (75.0% vs. 
20.2 %, p=0.03, 50.0% vs. 16.0 %, p=0.001 respectively) and stricturing disease 
(45.5% vs. 19.4%, p<0.05). Multifactorial analysis demonstrated variant carriage was 
associated with the need for surgery (p=0.004, OR 4.9 [1.5-14.7]).
Conclusions: The three common NOD2/CARD15 variants have a relatively small 
contribution to CD susceptibility in Scottish children but a major impact disease on 
phenotype. In particular NOD2/CARD15 variants are strongly associated with 
several markers of disease severity in paediatric CD, most notably with the need for 
surgery. 
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4.2 Introduction
4.2.1 IBD1
The aetiology of IBD is complex with strong supporting evidence for the importance 
of interaction of  environmental agents and genetic factors in disease pathogenesis.76
Genome wide scanning has led to the identification of several confirmed loci (IBD 1-
9) as discussed in detail in chapter 1;165 of these loci further data suggest that  IBD1 
and IBD5 loci may be particularly important in early onset disease.99 As discussed in 
Chapter 1 direct comparison in non-Jewish and Jewish North American populations 
suggested that the IBD1 locus may confer a high risk particularly in early onset cases 
compared to late-onset disease in the same population.93;94
4.2.2 NOD2/CARD15
4.2.2.1 Gene Discovery
One of the major successes in IBD genetics in the 21st century has been the 
narrowing of the IBD1 region, leading to gene identification. The first susceptibility 
gene for CD was identified in 2001, on chromosome 16  and was initially named 
Nucleotide Oligomerisation Domain (NOD)2 and later renamed Caspase Activating 
Recruitment Domain (CARD) 15 (MIM 605956).166;167 Hugot et al. in their seminal 
publication in Nature narrowed the region of linkage in the IBD1 locus using a 
collection of 26 densely packed microsatellite markers spaced at 1 centimorgan 
intervals in the pericentromic region of  chromosome 16. An area within this region 
between 2 of these markers had the highest LOD score of 3.49 and the investigators 
then went on to construct a physical map of this narrowed region.  Within the region 
one marker SNP (D16S3136) located within the NOD2 gene demonstrated 
borderline association with CD in TDT analysis of 108 family trios. Association with 
a second allele within the NOD2 gene was replicated in a second set of 76 families. 
Further analysis of the gene was then undertaken by genotyping 11 SNPs located 
throughout the gene together with 2 marker SNPs identified in construction of the 
physical map of the region, in 235 CD families. Several SNPs (numbered 8, 12 and 
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13 in this original publication) then demonstrated significant association when 
analysed by disequilibrium testing.
From the results of the case-control analysis (457 CD patients, 159 UC and 103 
healthy controls) three common polymorphisms were identified by Hugot et al. that 
conferred increased susceptibility to CD: two missense mutations Arg702Trp and 
Gly908Arg and a frameshift mutation Leu1007fsincC that were named SNP 8, 12 
and 13 respectively (see figure 1). The relative risk of CD increased for 
heterozygotes by a factor of 2-3 whereas homozygotes or compound heterozygotes 
had a 28-40 times increased risk.166 There was no increased risk of Ulcerative colitis 
in patients possessing these NOD2/CARD15 mutations.
4.2.2.2 Concurrent replication
Ogura et al. chose NOD2/CARD15 as a positional candidate based on its position 
within the IBD1 locus and as a functional candidate gene based on the description of 
NOD proteins as being important in the recognition of bacteria.168 In the first stage of 
their study, Ogura et al. sequenced the NOD2/CARD15 gene in 12 patients with 
Crohn’s disease and 4 healthy controls. In three of the 12 patients they identified a
frameshift mutation that truncated the NOD2/CARD15 protein from 1040 amino 
acids to 1007 (this was SNP 13 described in the Hugot et al publication).167 In further 
analysis they then went onto further genotyping of this mutation in family trios 
containing an affected child with CD, demonstrating preferential transmission by 
TDT analysis. This finding was then replicated in 416 CD cases and 287 population 
controls demonstrating the NOD2/CARD15 frameshift mutation was associated with 
increased susceptibility to CD with a similar effect seen in both Jewish and non-
Jewish patients.
4.2.2.3 Association with disease phenotype
In subsequent studies by Ahmad et al. it was suggested that earlier onset disease was 
characterised by a higher rate of NOD2/CARD15 mutations especially those carrying 
IBD Genetics in Scottish Children
NOD2 susceptibility and phenotype 83
double dose mutations. These patients carrying double dose mutations were 
diagnosed with Crohn’s disease at age 23 years compared to those without double 
dose mutations who were diagnosed at 28 years of age  (a statistically significant 
difference).132 This study also described an association between NOD2/CARD15 
variants and ileal Crohn’s disease. 
In a summary of the early NOD2/CARD15 publications Hugot described patients 
who were homozygous for the three common NOD2/CARD15 mutations as 
representing 34% of those with an age of onset of CD at less then 10 years, compared 
with only 3% who had an onset of 40 years or more,169 justifying the need to conduct 
studies of these NOD2 /CARD15 mutations in exclusive paediatric populations. 
Figure 4-1: Structure of the NOD2/CARD15 gene and protein
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4.2.2.4 Expression
In original experiments using a  HEK293T kidney cell line Ogura et al, described 
NOD2/CARD15  as being expressed exclusively in monocytes, unlike family 
members NOD1 and APAF -1 which were widely expressed in most adult tissues.170
However, subsequent studies from the same research group and replicated by others 
clearly show that NOD2/CARD15 is also expressed in primary epithelial cells in 
culture and intestinal epithelial cells (IEC) in the small and large bowel.171;172 Lala et 
al. demonstrated NOD2/CARD15 mRNA is expressed in Paneth cells both in healthy 
controls and patients with CD, but with higher concentrations found in CD 
patients.173
Paneth cells are specialised epithelial cells located in the crypts of the small intestine 
and secrete a number of anti-bacterial substances in response to Muramyl dipeptide 
(MDP) a peptidoglycan motif commonly found in bacterial cell walls, and other 
bacterial products, most notably they secrete the defensins.174
Expression of NOD2/CARD15 is upregulated by Tumour Necrosis Factor-alpha 
(TNF-α) and interferon- gamma (IFN-γ), but IFN-γ has no effect in the absence of 
TNF-α.172 Both cytokines act directly on NF-κβ making it more response to 
Lipopolysaccharide (LPS). The TNF-α response is dependent on NF-κβ binding sites 
in the NOD2/CARD15 promoter region and deletion of two of these binding sites 
results in diminished TNF-α activity.
4.2.2.5 Structure 
The NOD2/CARD15 protein contains 1040 amino acid residues, separated into 3 
functional domains: two N-terminal CARDs which are involved in protein – protein 
interactions, a central nucleotide binding domain (NBD) which mediates self 
oligomerisation and at the C-terminus a leucine rich repeat region (LRR), which 
interacts with MDP (figure 4-1).132;175
NOD2/CARD15 is a member of a family of intracellular cytosolic proteins NOD-like 
receptors that act as pattern-recognition receptors (PRR’s) which recognise microbial 
components, also called pathogen-associated molecular patterns (PAMP’s).176 Other 
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family members are NOD1/CARD4 (MIM 605980) and Apoptotic protease 
activating factor (APAF) 1 (MIM 602233). Despite functional similarities, 
NOD1/CARD4 mutations have not been consistently been shown to be involved in 
susceptibility to CD.177
The NOD family share structural homology with R proteins in plants and Toll like 
receptors in mammals which form part of the innate immune response to bacterial 
products. NOD2/CARD15 shares sequence homology in the NBD and LRR domains  
with a wider family of around 20 proteins that are involved in apoptosis and 
inflammation collectively known as the CARD transcription enhancer, R [purine]-
binding, pyrin, lots of leucine repeats (CATERPILLER) family.178
4.2.2.6 Function
NOD2/CARD15 is involved in the activation of nuclear factor-kappa beta (NF-κβ) 
within the cell after bacterial products bind to the LRR.170 Specifically, it is the MDP 
moiety, the minimal essential structure of bacterial peptidoglycan (PGN) that is 
recognised by NOD2/CARD15 pathway.175;179 The NOD proteins combine with the 
serine threonine kinase receptor-interacting CLARP- associated kinase (RICK) to 
activate NF-κβ.180 Wild type NOD2/CARD15 can be activated by either 
Lipopolysaccharide (LPS) or peptidoglycan (PGN) in transfected cells to activate 
NF-κβ.181 The cell surface receptor, TLR2 is activated by peptidoglycan in the extra-
cellular space, resulting in NF-κβ activation.182
All three of the common NOD2/CARD15 mutations identified result in the same 
functional consequences, with marked hypo-responsiveness of NF-κβ to LPS or PGN 
compared to wild type NOD2/CARD15.181 The R702W and G908R mutations show 
diminished activity of NF-κβ in response to LPS/PGN stimulation whereas the 
Leu1007fs mutation shows no activity at all. These experiments suggest a uniform 
loss of function as their common mode of action which specifically, for the 
Leu1007fsincC mutation in Caco2 cell line results in an inability to clear Salmonella 
typhimurium from cells in contrast to wild type NOD 2/CARD15.183
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In this study we have investigated the contribution of the three common 
NOD2/CARD15 variants in the Scottish paediatric IBD population and examined 
genotype-phenotype relationships. 
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4.3 Patients and Methods
4.3.1 Patients
Two hundred and forty seven paediatric patients with IBD were studied. There were 
167 children with CD, 60 with UC and with 20 IC. 
4.3.2 Parents and controls
414 parents (232 mothers and 182 fathers) were analysed resulting in 180 complete 
family trios (73% of total). A total of 245 healthy Scottish adult controls  were 
available for case-control analysis, with the detailed characteristics of this group 
reported previously by Arnott et al.184
Of the 167 CD patients in the study 91(54.5%) were male, 163(97.3%) were 
Caucasian, 57(36.1%) had a positive family history and 3 (1.9%) were current 
smokers. The median age at CD diagnosis was 11.5 years.
4.3.3 Disease Phenotype
CD disease location and behaviour using the Vienna classification are shown in table 
4-1. Data using the paediatric phenotype developed for use in this thesis are shown in 
table 4-3. The data shown are for 167 CD patients analysed at diagnosis and 104 
patients at 2 year follow up, unless stated in the tables.
4.3.4 Blood parameters
The results of blood results for patients at diagnosis and 2 year follow up are shown 
in table 4-2.
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Table 4-1: Vienna classification of CD patients
Disease location At Diagnosis 2 year follow up
Terminal Ileum (L1) 8 (4.8%) 5 (4.8%)
Colon (L2) 38 (22.8%) 28 (26.9%)
Ileocolon (L3) 34 (20.3%) 22 (21.2%)
Upper gastrointestinal (L4) 77 (46.1%) 45 (43.3%)
None* 10 (6.0%) 4 (3.8%)
Disease behaviour 
Inflammatory (B1) 136 (81.4%) 66 (63.5%)
Stricturing (B2) 7 (4.2%) 11 (10.6%)
Penetrating (B3) 24 (14.4%) 27 (25.9%)
Table 4-2: Blood results in CD patients at diagnosis and follow up
Blood Parameters At diagnosis 2 year follow up
Raised ESR 121/137 (88.3%) 41/63 (65.1%)
Thrombocytosis 100/152 (65.8%) 26/75 (34.7%)
Raised CRP 76/118 (64.4%) 14/53 (26.4%)
Hypoalbuminaemia 71/138 (51.4%) 9/68 (13.2%)
Anaemia 112/164 (68.3%) 49/84 (58.3%)
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Table 4-3:  Paediatric disease location for CD patients
Disease Location At diagnosis 2 year follow up
Oral 20/152 (13.6%) 14/98 (14.3%)
Oesophageal 4/142 (2.8%) 1/90 (1.1%)
Gastric antrum 39/145(26.9%) 12/84 (14.3%)
Gastric body 30/138 (21.7%) 18/94 (19.1%)
Duodenal 23/137 (16.8%) 9/88 (10.2%)
Jejunal 22/136 (16.2%) 14/90 (15.6%) 
Ileal 91/142 (64.0%) 63/94 (67.0%)
Caecal 91/119 (76.5%) 58/79 (73.4%)
Ascending 92/122 (75.4%) 56/74 (75.7%)
Transverse 99/129 (76.7%) 60/79 (75.9%)
Descending 104/134 (77.6%) 61/81 (75.3%)
Sigmoid 115/147 (78.2%) 67/92 (72.8%)
Rectum 117/151 (77.5%) 67/93 (72.0%)
Perianal 66/158 (41.8%) 37/100 (37.0%)
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4.3.5  Genotyping
The NOD2/CARD15 mutations R702W and 1007fsInsC were genotyped using 
TaqMan (© Biosystems) using assay on demand methodology. The G908R was 
analysed using Restriction Fragment Length Polymorphism (RFLP). The primers 
used for the genotyping are shown in table 4-4.
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4.3.5.1 G908R RFLP
The PCR reaction was carried out in final volume of 25μl with the reaction 
conditions as follows for a total of 60 reactions: 150μl of 10x PCR buffer (160mM 
(NH4)2SO4, 670mM Tris- HCl, 0.1% Tween-20), 150μl of each primer (10mM), 45μl 
50mM MgCl2, 15μl 25mM dNTPs, 19.5μl Taq polymerase (5U/μl) (Bioline) and 
970μl of water. 1μl (100nanograms) of DNA was added to each 25μl reaction. 
The reaction was then run on a programme of 5 minutes 94°C, 30 seconds 92°C, 30 
seconds 60°C, 45seconds at 72°C and 35 cycles of 5minutes at 72°C.
The PCR reaction was digested overnight at 37C after the addition of 1 unit of the 
restriction enzyme CfoI and 3 µl of manufacturers’ restriction buffer plus 2 µl of 
water.
The PCR product was then run on a 4% NuSieve 3:1 agarose gel (6g of gel added to 
150 of 1 x TBE) with other methods as described as in the standard gel preparation 
listed in chapter 2. The PCR reactions were loaded onto the gel with a control wild 
type homozygote and control heterozygote. No homozygous mutant was available to 
run on the gels. If the controls were not identified when viewing the gel then the 
results were declared void and re-run. The samples were then were then subject to 
gel electrophoresis for 25 minutes (150 Volts, 150 milliamperes, 150 Watts).
Each variant allele was analysed for association with CD by case-control study and 
transmission disequilibrium testing. Genotype-phenotype analysis was performed by 
correlating NOD2/CARD15 carriage rates with disease phenotype, both at diagnosis 
and at 2 year follow-up. All data derived from patients and controls were consistent 
with Hardy-Weinberg equilibrium.
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4.4 Results
4.4.1 Disease susceptibility
4.4.1.1 Allele frequencies 
The results are summarised in table 4-5. Allelic frequencies for Leu1007fsInsC were 
higher in CD patients compared to both UC patients (4.2% vs. 0%, p=0.02 OR=∞) 
and healthy controls (4.2% vs. 1.4%, p=0.01 OR 3.0 [1.2-7.6]). Allelic variants of 
G908R were significantly higher in CD patients compared to healthy controls (2.2% 
vs. 0.2%, p=0.006 OR 10.5(1.3-85.5]). No significant difference was demonstrated in 
the allele frequencies of R702W in CD patients compared to either UC patients or 
healthy controls.
4.4.1.2 Carriage rates
The results are summarised in table 4-6. In total, one or more of NOD2/CARD15 
allelic variants were present in 33 (19.8%) of the 167 CD patients, with 27 (16.2%) 
simple heterozygotes and 6 (3.6%) double dose carriers (2 homozygotes, 4 
compound heterozygotes). This carriage rate in CD patients was higher than UC 
patients (19.8% vs. 8.3%, p=0.04 OR 2.7[1.0-7.3]) and demonstrated a trend towards 
higher carriage than in healthy adult controls (19.8% vs. 13.1%, p=0.07).
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Table 4-5: NOD2/CARD15 variant allele frequencies in cases and controls
R702W G908R Leu1007fsInsC Combined
CD (n=167) 6.2% 2.2% 4.2% 12.6%
UC (n=60) 4.2% 0% 0% 4.2%
p-value* 0.41 0.11 0.02 0.01
Odds Ratio* 1.52 (0.55-4.2) ∞ ∞ 3.31 (1.27-
8.61)
HC (n=245) 5.5% 0.2% 1.4% 7.1%







3.02 (1.21-7.56) 1.91 (1.18-
3.09)
* CD vs. UC;  ** CD vs. HC 
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Table 4-6 NOD2/CARD15 variant carriage rates in cases and controls 
R702W G908R Leu1007fsInsC Combined
CD (n=167) 11.3% 3.0% 8.4% 19.8%
UC (n=60) 8.3% 0% 0% 8.3%
p-value* 0.72 0.18 0.02 0.04




HC (n=245) 9.8% 0.4% 2.9% 13.1%
p-value** 0.63 0.03 0.01 0.07




3.11 (1.23-7.88) 1.64 (0.96-
2.79)
* CD vs. UC;  ** CD vs. HC
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4.4.1.3 Transmission disequilibrium testing 
The results are summarised in table 4-7. Transmission disequilibrium testing 
demonstrated significant over transmission of the Leu1007fsInsC allele (χ2=4.4, 
p=0.006). The R702W and G908R alleles were not significantly higher in CD 
patients when analysed by TDT analysis. The TDT analysis for the 3 common 
NOD2/CARD15 variants was performed in a total of 156 families of children with a 
diagnosis of Crohn’s disease.
The overall population attributable risk for NOD2/CARD15 carriage in Crohn’s 
disease patients was 7.9%. 
Table 4-7: TDT results for 3 common NOD2/CARD15 variants 
Mutation Observed1 Expected2 Variance3 Chi-square p value
R702W 18 15.63 6.50 0.86 0.42
G908R 7 6.5 2.98 0.08 0.72
1007fsInsC 14 9.80 3.96 4.42 0.006
1. Observed transmissions to affected offspring. 
2. Expected transmissions to affected offspring based on Mendelian Inheritance 
patterns. 
3. Variance of observed–expected transmissions.
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4.4.2 Genotype- phenotype analysis: Unifactorial analysis 
4.4.2.1 Age at diagnosis
The median age at diagnosis was 11.0 years in carriers of NOD2/CARD15 variant 
alleles and 11.3 years in non-carriers (p=0.38).
4.4.2.2 Family history
A history of IBD in first degree relatives was more common in children possessing a 
mutant copy of the G908R allele (9.1% vs. 1.4%, p=0.002, OR=7.0 [1.7-29.1]) but 
not for the other two NOD2/CARD15 alleles studied. Of those with a positive family 
history, carriage of one or more of the 3 NOD2/CARD15 variants was higher but did 
not reach statistical significance (26.3% vs. 16.8%, p=0.15).
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Table 4-8: Genotype – phenotype analysis using the Vienna Classification
At diagnosis* p-value  2 year follow up p-value
Disease location
Colonic 15.8% vs. 20.9% 0.48 10.7% vs. 26.7% 0.08
Ileal 50% vs. 18.2% 0.05 60% vs. 20.4% 0.07
Ileo-colonic 17.6% vs. 20.3% 0.73 22.7% vs. 22.2% 0.96
Upper GI 20.1% vs. 18.9% 0.76 26.7% vs. 19.0% 0.35
None 10% vs. 20.4% 0.42 0% vs. 23% 1
Disease behaviour
Inflammatory 16.9% vs. 32.2% 0.05 16.7% vs. 31.6% 0.07
Stricturing 42.9% vs. 18.7% 0.14 45.5% vs. 19.4% 0.05
Penetrating 29.2% vs. 18.1% 0.21 25.9% vs. 20.8% 0.58
* Comparison of carriage of one or more NOD2/CARD15 variants in each parameter 
under consideration vs. carriage of those without the parameter under consideration. 
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Table 4-9: disease location and NOD2/CARD15 carriage
At diagnosis p-value  2 year follow up p-value
Disease location
Oral 5.0% vs. 22.7% 0.08 7.1% vs. 25.0% 0.18
Oesophageal 0% vs. 21.0% 0.58 0% vs. 23.6% 1
Gastric antrum 12.8% vs. 21.7% 0.23 33.3% vs. 23.6% 0.48
Gastric body 16.7% vs. 21.3% 0.57 22.2% vs. 21.0% 1
Duodenal 17.4% vs. 21.9% 0.78 22.2% vs. 24.0% 1
Jejunal 36.3% vs. 17.5% 0.04 50% vs. 18.4% 0.01
Ileal 26.4% vs.11.8% 0.04 30.2% vs. 12.9% 0.06
Caecal 19.8% vs. 21.4% 0.84 25.9% vs. 23.8% 0.85
Rectum 19.6% vs. 20.6% 0.90 22.4% vs. 26.9% 0.64
Perianal 21.2% vs. 19.6% 0.80 21.6% vs. 23.8% 0.80
a. Only 2 colonic locations have been included as results for all colonic locations 
demonstrated similar results.
Table 4-10: Blood parameters and NOD2/CARD15 carriage
At diagnosis p-value  2 year follow up p-value
Variable
ESR>10mm/hr 20.6% vs. 25.0% 0.74 18.1% vs. 26.8% 0.54
Thrombocytosis 24.0% vs. 13.5% 0.12 26.5% vs. 23.1% 0.74
Anaemia  21.4% vs. 17.3% 0.54 31.4% vs. 18.4% 0.17
Raised CRP 25% vs. 9.5% 0.04 57.1% vs. 12.8% 0.0009
Albumin<35g/l 31.0% vs. 9.0% 0.001 33.3 vs. 22.0% 0.43
IBD Genetics in Scottish Children
NOD2 susceptibility and phenotype 99
4.4.2.3 Disease location
Using the Vienna classification (table 4-8), carriage of one or more NOD2/CARD15 
variant alleles was more common at diagnosis (50.0% vs. 18.2%, p=0.05) and a trend 
for the same association was also present at 2 year follow (60.0% vs. 21.1%, p=0.07) 
in patients with ileal disease using the Vienna classification. NOD2/CARD15 
carriage was also more common in those with ileal disease using the paediatric 
disease classification (table 4-9) at diagnosis (26.4% vs. 11.8%, p=0.04 OR=2.7 [1.0-
7.1]) and approached significance at 2 year follow up (30.2% vs. 12.9%, p=0.06). 
At disease diagnosis, the allele frequency of the R702W allele was more common in 
patients with jejunal disease activity compared to those with no jejunal activity 
(13.6% vs. 4.6%, p=0.02 OR=3.2 [1.1-9.7]). Carriage rates of one or more allelic 
variants of NOD2/CARD15 were higher in patients with jejunal disease at diagnosis 
and 2 year follow up compared to those with no jejunal disease (36.3% vs. 17.5%, 
p=0.04 OR 2.7[1.0-7.3] and 50% vs. 18.4%, p=0.01 OR=4.4[1.3-14.7] respectively). 
In patients who had both jejunal and ileal disease (n=14) carriage rates of one or 
more NOD2/CARD15 variant alleles were higher than in patients with no disease at 
either site, at diagnosis (42.9% vs. 10.9%, p=0.007 OR=6.2 [1.5-25.1]) and at 2 year 
follow up (50% vs. 10.7%, p=0.003 OR=9.7[1.9-49.1]). 
No association was found between other disease locations, using either disease 
classification systems and NOD2/CARD15 mutations at diagnosis or follow up.
4.4.2.4 Disease behaviour 
Possession of R702W mutants was less common in patients with purely 
inflammatory disease behaviour, compared to patients with complicated (stricturing 
or penetrating) disease behaviour (allele frequency 4.6% vs. 14.0%, p=0.01 
OR=0.3[0.1-0.8]). Carriage of any of the NOD2/CARD15 variant alleles was also 
less common in patients with inflammatory disease at diagnosis, compared to 
patients with complicated disease (17.0% vs. 33.3%, p=0.04 OR=0.4[0.2-1.0]) and 
showed a trend towards significance at 2 year follow up (16.7% vs.31.6%, p=0.07). 
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The presence of stricturing disease behaviour at diagnosis showed a trend towards an 
increase in carriers of NOD2/CARD15 variant alleles (42.9% vs. 18.7%, p=0.14), 
and became significant in this group by 2 year follow up (45.5% vs. 19.4%, p=0.05 
respectively).
4.4.2.5 Need for Surgery
In total 27% of patients in the study needed surgery for complications of Crohn’s 
disease. The median time from diagnosis to surgery was 1.83 years (Inter Quartile 
Range=0.3-4.4). Patients possessing the R702W or Leu1007fsInsC variants or 
possessing any one or more of the three NOD2/CARD15 variants were more likely 
to have a need for surgery for intestinal complications of CD compared to those who 
did not need surgery (11.5% vs. 4.3%, p=0.02 OR=2.8[1.1-7.6], 10.0% vs. 2.3%, 
p=0.003 OR=4.8[1.6-14.7] and 39.5% vs. 12.8%, p=0.0002 OR=4.45 [2.0-10.1] 
respectively).  
4.4.2.6 Blood parameters
The results are listed in table 4-10. Carriers of NOD2/CARD15 variant alleles were 
more likely to have a raised CRP at diagnosis and at 2 year follow up (25% vs. 9.5%, 
p=0.04 OR=3.2[1.0-10.0] and 57.1% and 12.8%, p=0.0009 OR=9.1[2.2-37.3] 
respectively) compared to patients who had normal values. At diagnosis, carriers of 
NOD2/CARD15 variants were more likely to have a low albumin (31.0% vs. 9.0%, 
p=0.001 OR=4.6[1.7-12.1]). No association was found between NOD2/CARD15 
carriage and abnormal ESR, platelets or haemoglobin at diagnosis or 2 year follow 
up.
4.4.2.7 Anthropometry
No significant relationship was found between weight, height or body mass index 
(BMI) centile at diagnosis using standard UK centile charts (© Child Growth 
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Foundation,1996). At 2 year follow up NOD2/CARD15 carriers were more likely to 
be in the lowest weight centile (<0.4th) compared to those not in this centile band 
(75.0% vs. 20.2 %, p=0.03 OR=3.7[1.8-7.5]) and the (2-9th) height centile compared 
to those not in this centile band (50.0% vs. 16.0 %, p=0.001 OR=5.2[1.7-16.0]). No 
relationship was demonstrated with BMI centile at follow up. 
4.4.2.8 Other variables 
There were 68.5% of CD patients who had granulomata present at diagnosis. Variant 
alleles of G908R and 1007fsInsC were both significantly lower in the patients with 
histological evidence of granulomas compared to those with no evidence of 
granulomas (0.4% vs. 6.1% p=0.001 OR=0.1[0.0-0.6] and 3.0% vs. 9.1% p=0.03 
OR=0.3[0.1-0.9] respectively). Carriage of one or more NOD2/CARD15 variants 
demonstrated the same relationship (13.8% vs. 30%, p=0.01 OR=0.4[0.2-0.8] 
respectively). 
In CD patients with extraintestinal manifestations (EIM’s) 10.1% had joint EIM’s 
and 12.0% skin EIM’s.  No associations were found between NOD2/CARD15 
mutations with the presence or absence of extra-intestinal manifestations. 
4.4.3 Multifactorial Analysis
Multifactorial analysis using binary logistic regression controlling for factors 
implicated on unifactorial analysis- disease location, disease behaviour, weight 
centile, granulomata, jejunal disease and albumin demonstrated NOD2/CARD15 
carriage was an independent risk factor for surgery for IBD (p=0.004, OR 4.9 95% 
CI:1.7-14.7).
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4.5 Discussion
This study reports the contribution of the three common NOD2/CARD15 mutations 
in a large Scottish paediatric cohort and, although, a series of studies has confirmed 
the high incidence of early-onset of IBD in Scotland,2;4;6 this study demonstrates a 
notably low variant allele frequencies of NOD2/CARD15 variants compared to the 
majority of published adult185 and paediatric series (table 4-11). 
In contrast to the wealth of published data in adults, there are only a small number of 
published studies looking at NOD2/CARD15 mutations  in exclusively paediatric 
IBD populations (table 4-11).186-194 The published studies performed to date have 
been of varying quality with four containing 100 or less Crohn’s disease 
patients186;187;189;191 and three containing no population controls.187;188;191 The major 
strengths of this study, in comparison to the majority of published studies are, the 
large number of early onset patients, a largely homogenous study population and 
rigorous disease phenotyping.
Despite the methodological problems noted, the majority of paediatric studies have 
replicated the association of mutations within the NOD2/CARD15 gene and 
susceptibility to Crohn’s disease.186;189-194 These studies in general have 
demonstrated similar allele frequencies to corresponding adult studies in the same 
population; the exception is one small study of 65 German patients from Saxony 
published by Sun et al. that demonstrated notably high carriage rates with two thirds 
of the patients having at least one NOD2/CARD15 mutation.191  The conclusions in 
this small selected population have to be treated with great caution however, as no 
population controls were analysed in the study.195
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This study 167 4.2% 6.4% 2.2%
Germany191 55 25.4%* 14% 5%
USA193 163 13.1%* 6.6% 6.0%
USA190 101 17%* 6% 11%
Canada192 167 9.6%** 8.4% 5.6%
Israel189 93 9.7%*** 8.6% 21.5%
Sweden187 58 1.7%**** 2.6% 0%
Italian194 134 7.1%**** 9.0% 7.8%
Italian186 54 7.4%**** 8.3% 8.3%
a. Refers to the number of Caucasian patients in each study
The age at diagnosis was  <18 years in the studies listed except for the Scottish 
patients that were diagnosed at < 16 years, Swedish <17 years and the second study
from the USA where age at disease onset was  not stated.
Chi- square p value of allele frequency of 1007fsInsC in Scottish CD patients 
compared to allele frequency in other populations: * p<0.00001, **p=0.006, *** 
p=0.08, **** p = not significant.
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The Scottish population had a statistically lower allele frequency of the 1007fsInsC 
in comparison to four of the other populations studied (German, USA and Canadian) 
190-193 and shows a strong trend towards significantly lower allele frequency in 
comparison to the 5th study population (Israeli).188 The Scottish and Swedish (a 
similar high disease incidence Northern European population) demonstrated no 
significant statistical difference between them. It is interesting to note that the two 
Italian paediatric populations,186;194 did not show any statistical difference when 
comparing the allele frequency of Leu1007fsinsC but did show a statistically higher
carriage of NOD2/CARD15 variants overall (p<0.001).
Overall allele frequencies are significantly lower in the Scottish paediatric CD 
population compared to the CD patients studied in the index populations (mixed 
child and adult) of Northern Europe and North America (p<0.00001).166;167 This 
observation provides a critical confirmation in the paediatric CD population of  the 
evidence for genetic heterogeneity in the contribution of  NOD2/CARD15 gene that 
was initially reported in the adult CD populations by Arnott et al.184 Thus, the low 
prevalence of NOD2/CARD15 variant alleles present in Northern latitudes of Europe 
in adults (Scotland, Norway, Iceland, Finland, Ireland, Denmark and Sweden),184;196-
201 is very consistent with the findings of this study and the smaller Swedish 
paediatric study (figure 4-2).187 This data contrasts with the higher allele frequency 
present in Southern European populations (France, Belgium, Germany, Spain, Italy, 
Hungary and Holland).115;166;198;202-204 This data have been confirmed in an 
independent European study looking at NOD2/CARD15 data in several different 
European studies that confirmed a statistically lower (p< 0.001) in patients from 
Scandinavia compared to patients in other European countries (Scottish patients were 
not included in the study).205
The widespread heterogeneity in NOD2/CARD15 carriage rates in adult and 
childhood CD patients extends throughout the world outside of Europe and North 
America. There is an absence of NOD2/CARD15 carriage reported in four adult 
Asian populations,206-209 and a low carriage rate has been reported in other non-
Caucasian childhood Crohn’s disease populations.210 This heterogeneity is reflected 
not only in allele frequency in cases but also in controls.211 The IBD International 
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Genetics Consortium has published data on the allele frequency of the common 3 
NOD2/CARD15 mutations in more than 3,500 healthy controls. This has 
demonstrated some of the lowest allele frequencies in control populations are 
Northern European from Finland and Scotland (together with Australia) and the 
highest frequencies are found in populations from Belgium and Canada.  
A recent  meta–analysis of 42 NOD2/CARD15 case control studies gives an 
increased relative risk (RR) of CD of 2.4  for heterozygotes and 17 for homozygotes 
in patients possessing variant alleles of these three common mutations.185 The overall 
population attributable risk for the 3 common NOD2/CARD15 mutations was 
between 12.7%-21.8% in the studies included in the meta-analysis. The PAR in this 
study was notably lower at 7.9%.
Comparisons between paediatric and adult genetic studies (direct or indirect) have 
been performed on the 3 common NOD2/CARD15 mutations. No studies have 
demonstrated a statistically higher frequency of NOD2/CARD15 mutations in the 
paediatric population, with the data in this current study almost identical to those of 
Arnott et al. in studies in the Scottish adult CD population.184 Two studies, one 
Italian186 and one Israeli188 have come close to statistical significance comparing 
NOD2/CARD15 carriage in children vs. adults (p=0.06 for both respectively) but 
further studies have confirmed no significant difference between adult and paediatric 
populations.212 Thus the notion that early onset patients have a higher genetic 
contribution to developing IBD has not been proven in this current study or so far in 
other published studies of the NOD2/CARD15 gene comparing child-adult study 
populations.
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Figure 4-2: Genetic heterogeneity across Europe
The numbers in the figure correspond to the allele frequency of the 1007fs 
NOD2CARD15 mutation in countries across Europe. The black line illustrates the 
divide between the low allele frequencies of northern Europe compared to the higher 
frequencies of Southern Europe.
This illustration was later adapted for publication in the Lancet (Gaya DR, Russell 
RK, Nimmo ER, Satsangi J. New genes in inflammatory bowel disease: lessons for 
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The relative contribution of each of the three common alleles in this dataset to 
disease susceptibility is consistent with the reported genotype relative risk data 
reported in most adult populations studied i.e. the Leu1007fsInsC confers the greatest 
risk and R702W the least.185 In an analysis of 42 case control studies from across the 
world Economou et al. demonstrated odds ratios for risk of CD of 2.20, 2.99, and 
4.09 for R702W, G908R and Leu1007fsInsC respectively in non-Jewish Caucasians. 
Notwithstanding the relatively low allelic frequencies in cases and controls in this 
current study the 1007fsInsC mutation was associated with susceptibility to CD both 
in the case control study and by TDT analysis; G908R variants were associated with 
CD susceptibility in case-control analysis only, with no role demonstrated for the 
R702W mutation. 
The case control data in childhood mirror the data in the adult population in Scotland 
where susceptibility was associated with Leu1007fsIsnC variants (p=0.003) and 
G908R variants (p=0.008) but not R702W(p=0.27).184 The TDT data mirror findings 
both  in a North American paediatric study and UK adult study.193;213 The carriage 
rates of mutant NOD2/CARD15 alleles in Scottish paediatric CD patients overall 
were similar to the Scottish adult CD population published by Arnott et al (19.7% vs. 
22.8% p =0.47 ).184
Thus the effect of the common NOD2/CARD15 mutations the Scottish paediatric 
IBD population on susceptibility, is definite but small, and these variants clearly do 
not explain the high incidence of early onset disease in Scotland.
The rigorous clinical phenotyping was a particular strength of this study and has 
allowed demonstration of several novel genotype phenotype relationships most 
notably a number of factors associated with Crohn’s disease severity. 
Surgery for IBD in this study was more common in those carrying NOD2/CARD15 
variants on unifactorial (39.5% vs. 12.8%, p=0.0002) and multifactorial analysis 
(p=0.004, OR 4.92 (1.65-14.66). This finding replicates data from published 
paediatric193 and adult series,200;202;203;214;215 that all demonstrate possession of 
NOD2/CARD15 mutant alleles to be associated with an increased need for surgery in 
Crohn’s disease. In a very similar study to this one, Kugathasan et al. demonstrated 
by regression analysis in a population of 186 paediatric CD patients that patients 
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carrying the 3 common NOD2/CARD15 mutations were at a significantly higher risk 
of having earlier surgery for their Crohn’s disease. 
In this present study, linked to the need for surgery and disease severity was an 
association between those carrying variants of NOD2/CARD15 disease and 
complicated (stricturing/penetrating) disease at diagnosis (33.3% vs. 17.0%, p=0.04) 
and specifically an association with stricturing disease at 2 year follow up (45.5% vs. 
19.4%, p<0.05). The   association of NOD2/CARD15 mutations and stricturing 
disease behaviour has been demonstrated in  paediatric,191;193 and several adult 
series,200;202;203;216-219 including the meta-analysis of 16 case-control studies that 
demonstrated increased risk for stenosing disease for NOD2/CARD15 carriers [OR = 
1.94, (95% CI: 1.61-2.34)].185
Several paediatric studies have demonstrated the presence of common abnormalities 
(anaemia, thrombocytosis, low albumin and raised CRP/ESR) in routine blood tests 
in  children with IBD and CD  at diagnosis.220-223 The present study is the first to 
demonstrate a relationship between abnormalities in these commonly performed 
blood markers and carriage of NOD2/CARD15 variants. A raised CRP at diagnosis 
and 2 year follow up was more common in NOD2/CARD15 carriers (25% vs. 9.5%, 
p=0.04 and 57.1% and 12.8%, p=0.0009 respectively). CRP is a very useful, easily 
available, marker of disease activity in patients with CD that correlates with other 
markers of disease activity including the Crohn’s disease activity index (CDAI) and 
faecal calprotectin.224
Similarly, an association between low serum albumin (<35 g/l) and NOD2/CARD15 
carriage at CD diagnosis (31.0% vs. 9.0%, p=0.001) was demonstrated. Both of these 
findings give strength to the case of NOD2/CARD15 carriage being associated with 
a severe disease phenotype in paediatric patients. This finding of an association with 
a severe disease phenotype is supported by the previously mentioned data on risk of 
surgery in this study and a North American study as well as data from a small 
German study also showing association of NOD2/CARD15 mutations with several 
markers of severe disease.225
Growth failure is a recognised feature of severe Crohn’s disease in children.189 An 
association between NOD2/CARD15 carriage and a low weight centile (<0.4th
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centile) as well as low height centile (2-9th centile) at 2 year follow up. This 
replicates the findings of Tomer et al,190 who demonstrated increased 
NOD2/CARD15 carriage at diagnosis with  a lower weight centile (<5th centile; 44% 
vs. 15%, p=0.003) in a population of 101 children with CD from the New York area, 
albeit our findings were at follow up and not diagnosis. These associations however, 
were not replicated in a second study performed by Wine et al. who studied 93 Israeli 
children with CD, perhaps because they used a more rigorous measure of growth 
using z-scores rather than centiles.189
A novel association in this study was demonstrated with NOD2/CARD15 carriage 
and jejunal CD involvement both at diagnosis and 2 year follow up (36.4% vs. 
17.5%, p=0.04 and 50% vs. 18.4%, p=0.01 respectively). In addition it was 
demonstrated NOD2/CARD15 carriage was very high in both jejunal and ileal 
disease combined at diagnosis (42.6% vs. 10.9%, p=0.007) and follow up (50% vs. 
10.7%, p=0.009). This demonstrates the limits of analysis using the Vienna 
classification and the potential benefits of using a more extensive phenotypic 
classification dividing disease location into more than four locations as described in 
this thesis. The association could also be explained by the marked phenotypic 
differences in disease distribution between paediatric and adult Crohn’s patients, 
with a greater proportion of proximal disease in children.79 This is illustrated  by 
comparing Scottish children with Upper GI disease (as defined by the Vienna 
classification) (46.1%)  with Scottish adults (9.8%), p<0.00001.184
The strongest and most consistent phenotypic association of NOD2/CARD15 
genotype-phenotype studies has been with ileal disease 
location.132;190;193;197;198;215;226;227 This well replicated association with 
NOD2/CARD15 variants and ileal disease that has been demonstrated in this study 
although only on unifactorial analysis. The relationship of NOD2/CARD15 variants 
with ileal disease was also demonstrated on meta-analysis of 16 case control studies 
that included genotype- phenotype data with an odds ratio of 2.5.185
Leading on from these consistent phenotypic associations, data from Wehkamp et al. 
has demonstrated that patients with ileal Crohn’s disease have an -defensin 
deficiency, most pronounced in NOD2/CARD15 mutants.228 In his study of 45 CD 
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patients (24 NOD2/CARD15 mutants and 21 with wild-type) and 12 healthy 
controls, -defensin production but not the production of other anti-bacterial 
products was decreased in patients with ileal CD as assessed by real time-PCR of 
biopsies.  There was a 50% reduction of -defensins in NOD2/CARD15 wild type 
patients compared to controls with a yet more pronounced effect in the 
NOD2/CARD15 mutants. In the same study, immunohistochemistry demonstrated 
that Paneth cells were the sole producers of -defensins in the ileal biopsies. This 
provides a coherent hypothesis whereby Paneth cells (which express both 
NOD2/CARD15 and -defensins) may be the common link for the occurrence of 
Crohn’s disease of the ileum. This finding is further supported by microarray data 
from  the NOD2/CARD15 knockout mouse model, where expression of cryptdins 
(the murine counterpart of defensins) is strongly influenced by genetic variants in 
NOD2/CARD15.229
Epitheliod granulomas are often considered to be a pathognomonic feature of 
Crohn’s disease. This is the first study to suggest that possessing NOD2/CARD15 
mutant alleles are protective against granulomata formation. A positive association 
between mutations of the R702W allele and granulomata formation has been 
demonstrated  in one previous study.218 A study specifically aimed to examine the 
relationship between granulomas and NOD2/CARD15 mutations in surgical 
resection specimens demonstrated no relationship.230 The findings of this study in 
contrast to other studies, may partly be explained by the greater tendency to form 
granulomas in younger patients.230
In conclusion, this study has demonstrated that the common three NOD2/CARD15 
mutations do make a contribution in susceptibility to Crohn’s disease in the high 
incidence early onset Scottish Crohn’s disease population but that the overall 
contribution is small (PAR 7.9%). The genetic susceptibility in this population 
should be further investigated by examining all mutations in the NOD2/CARD15 
gene (see chapter 5) to exclude an effect from other mutations outside the common 3 
mutations, before going onto to study other candidate genes located within the other 
IBD susceptibility loci (IBD2-9). In this study NOD2/CARD15 carriage was 
consistently associated with several markers of severe disease including the need for 
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surgery. Replication of these findings may allow for early stratification of treatment 
for Crohn’s disease in children. 
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5 Searching for population specific variants in the 
NOD2/CARD15 gene
IBD Genetics in Scottish Children
Searching for specific NOD2 variants 113
5.1 Summary
Aim: To sequence the whole NOD2/CARD15 gene, assessing the contribution to 
disease susceptibility of other mutations outside of the common three previously 
analysed (R702W, G908R and 1007finsC).
Subjects: 24 paediatric CD patients for stage 1 then 1478 subjects for stage 2 (320 
IBD patients <16 years [210 CD, 80 UC and 30 IC], 343 adult CD patients, 542 
parents and 273 populations controls).  
Methods: Primers were designed to sequence the 12 exons of the NOD2/CARD15 
gene in the 1st stage of the study. Two of the SNPs identified by sequencing were 
then genotyped in the 2nd stage of the study using the TaqMan system. The two SNPs 
were selected based on patterns of linkage disequilibrium plus the location of the 
SNPs within the NOD2/CARD15 gene.
Results: Sequencing identified 18 SNPs in total. Two non-synonymous coding 
mutations V955I and M863V were then genotyped in 1478 subjects. Carriage of 
M863V variants was not significantly higher in CD patients vs. healthy controls 
(1.35% vs. 0.37%, p=0.27).   Carriage of V955I variants was higher in IC patients 
(n=29) compared to healthy controls (n=253) (41.4% vs. 16.2%, p=0.001 OR= 3.65 
[1.62-8.21), but not compared to CD or UC patients (12.6% and 15.8% respectively). 
TDT analysis for V955I was negative. 
Conclusions: Sequencing of the NOD2/CARD15 gene and subsequent SNP analysis 
did not identify any new mutations in the NOD2/CARD15 gene that are associated 
with increased disease susceptibility in patients with CD. Candidate genes other than 
NOD2/CARD15 should be investigated to explain the genetic contribution in 
patients with CD within the Scottish Paediatric population.
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5.2 Introduction
The NOD2/CARD15 gene was the first gene described conferring increased 
susceptibility to Crohn’s disease.166;167 Since the two initial studies, three mutations 
within the NOD2/CARD15 gene (a frameshift Leu1007fsinsC  and two missense 
mutations R702W and 908R)  have been associated with increased susceptibility to 
Crohn’s disease in most Caucasian populations studied.185
The contribution of these mutations to disease susceptibility in the Scottish paediatric 
population is relatively modest, with an increased risk conferred by 2 of the 3 
common NOD2/CARD15 mutations (no increased risk for R702W) as described in 
chapter 4. The PAR in the Scottish paediatric and adult population is lower than most 
other populations studied at 8% and 11% respectively. Despite the small contribution 
to disease susceptibility NOD2/CARD15 variants are strong predictors of disease 
phenotype in children as demonstrated by an increased need for surgery in the 
Scottish paediatric study (chapter 4) replicating results from an North American 
Paediatric cohort.193
It is clear however that these three “common” NOD2/CARD15 mutations do not 
account for all of the contribution to disease susceptibility at the IBD1 locus. In a 
genome wide scan stratified for the common 3 mutations Shaw et al. demonstrated 
that less than half the genetic contribution at this locus was accounted for by these 
mutations, leading to a search for other mutations.231 These rarer NOD2/CARD15 
mutations have been identified in a large number of European patients. In this 
European study 50% of CD patients carried at least 1 NOD2/CARD15 mutation and 
17% carried two. There were 27 rare mutations identified representing 19% of 
disease-causing mutations in total. The 3 common polymorphisms (R702W, G908R, 
and 1007fs) represented 32%, 18%, and 31% of disease-causing mutations, 
respectively. In combination, 93% of all mutations were located in the Leucine Rich 
Region (LRR) of the gene. The LRR domain is critically important for interacting 
with luminal bacteria.232
Population specific variants have been identified in the Jewish population. Sugimura 
et al. sequenced the NOD2/CARD15 gene in 12 Ashkenazi Jewish, Crohn’s disease 
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patients and described a novel conserved variant (IVS8+158; JW1) which was found 
in Jewish but not non-Jewish patients.233 JW1 is a C to T substitution in the intron 8 
splicing region that it is almost always accompanied by the SNP P268S; the 
functional consequence of this variation has not been identified. Karban et al. could 
not replicate increased JW1 frequency in a population of Israeli Ashkenazi Jewish 
patients with CD but their study used UC patients as the controls instead of normal 
population controls.234 A second study in European based Jewish patients by Tukel et 
al. also failed to replicate the JW1 association.235
The apriori aim of this chapter was to sequence all 12 exons of the NOD2/CARD15 
gene to identify any potential novel disease causing mutations, focussing on 
mutations situated in the LRR then analyse the contribution of any potential 
mutations in a larger cohort of Scottish IBD patients comprising both children and 
adults. 
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5.3 Materials and Methods
Patients were recruited as described in chapter 2. Patient data and disease 
phenotyping was performed as previously described. 
5.3.1 Patients 
The patients included in this study are summarised in table 5-1. There were 320 IBD 
patients <16 years [210 CD, 80 UC and 30 IBDU] (cohort 1) and 343 adult CD 
patients (cohort 2) were studied together with additional samples from 542 parents 
(305 mothers, 237 fathers). There were a total of 221 (72.4%) completed family trios. 
5.3.2 Controls
A total of 253 healthy populations controls (101 local healthy control volunteers 
recruited directly by the gastrointestinal unit and 152 Scottish blood donors) were 
used for case-control analysis. 
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Table 5-1: Demographics of patients involved in the study
Cohort 1 Cohort 2
Sex (M/F) 175/145 137/206






Current Smoker 7/315 (2.2%) 94/333 (28.2%)
Family history 
of IBD
107/315 (34.0%) 66/343 (19.2%)
Caucasian (%) 313 (97.8%) 329/331 (99.4%)
Cohort 1 320 IBD patients <16 years at diagnosis; Cohort 2 343 CD patients from 
adult cohort
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5.3.3 Sequencing of the NOD2/CARD15 gene 
In the first stage of investigation, a total of 24 patients (<16 years at diagnosis) with 
CD were studied having been selected randomly from the patients collected as part of 
the wider genetics study. Primers were designed to sequence the exons of the 
NOD2/CARD15 gene together with intron/exon boundaries. To guide primer 
construction, the following methodology for primer design was used: 
1. The initial base sequence of the intron/exon, within the NOD2/CARD15 
gene, was found by searching in the Ensembl database (www.ensembl.org).
2. Primer construction was then performed in the Sigma genosys oligo website 
www.sigma-genosys.co.uk/oligo_custinfo.cfm, using a customer ID and PIN. 
3. An initial (forward) primer was not selected from first 50-60 bases of an 
intron leading into an exon to avoid incorporating potential splice sites.
4. Whenever possible a primer was selected from a position 80-120 bases from 
the start of the exon being sequenced.
5. Each primer was 18-25 bases long (17 was the absolute minimum used).
6. A 50% guanine (G)/cytosine (C) ratio was desirable, but not essential. 
7. Each primer finished with a guanine (G) or cytosine (C) base.
8. An annealing temperature of around 60°C (Tm) was aimed for.
9. Either a weak or no secondary structure was to be present.
10. There was no primer/dimer interaction.
11. The initial (forward) primer base structure was read backwards i.e. right to 
left and then the base structure reversed i.e. thymine (T) replaced by adenine 
(A) and guanine (G) by cytosine (C) and vice versa.
12. The second (reverse) primer was selected at around 600 bases from the site of 
the first (forward) primer site, with a minimum distance of 300 bases and 
maximum of 1000 bases.
13. If an exon was large enough to need more than 1 primer pair combination, the 
2nd forward primer was started at around 120 bases before the site of the first 
reverse primer.
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The primers documented in table 5-2 are those that were successfully used to 
sequence DNA. They do not represent all of the primer combinations tried as some 
were designed and failed to work, at which point a new set of primers were designed 
and tried. 
The basic PCR reaction used was: 25μl of 10x PCR buffer (160mM (NH4)2SO4, 
670mM Tris-HCI (pH8.8 at 25°C), 0.1% Tween-20), 25μl of each primer (10uM), 50 
mM Magnesium Chloride 7.5-15μl , 25uM dNTP 2.5-5μl, Taq polymerase 2.5-5μl 
(5U/μl, Bioline) and 156μl of water. This was mixed and 20ul aliquots used per 
reaction. Into the 20μl of each reaction 1μl (100nanograms) of DNA was then added. 
A temperature gradient was then performed on the PCR machine with annealing 
temperatures ranging from 53C to 65C. The PCR product was then run on a 
standard gel and the optimum annealing temperature estimated at the point where a 
single band appeared at its brightest on the gel 
After the optimum annealing temperature was obtained the basic PCR reaction was 
run again at the appropriate temperature using the 24 samples of DNA selected for 
analysis. After the PCR had been performed 5μl was removed from 3 of the 24 
samples and run on a standard gel to ensure the reaction had been successful. If a 
product was obtained the sample was then sent for sequencing.
Direct sequencing was performed and the samples run on the 7900 HT sequence 
detection system (Applied Biosystems, Foster City, Ca, USA) by the Technical 
Services section of the MRC Human Genetics Unit, Edinburgh. DNA sequence was 
read using Sequencher v4.5 (Gene Codes Corporation, Ann Arbor, MI, USA). 
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Table 5-2: Primers used in the sequencing of the NOD2/CARD15 gene
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5.3.4 Genotyping
TaqMan was used to genotype the 2 SNPs: V955I and M863V using assay on 
demand and assay by design methodology respectively. TDT analyses in this study 
were performed using Family Based Association Tests (FBAT) software (version 
1.7.3, available from http://www.biostat.harvard.edu/~fbat/fbat.htm). The results 
were reported using the methodology proposed by Kazeem & Farrall.236
5.4 Results
Sequencing of 48 chromosomes in 24 patients identified 18 SNPs in the 24 patients 
studied. The results are presented in table 5-3.The frequency of these SNPs in each 
of the 24 patients is listed in table 5-4.
In order to identify any novel potential disease causing mutations, SNPs were 
selected for further analysis if they caused an amino acid change in the LRR region 
of the protein. Four SNPs were identified but as two of these SNPs had been 
previously genotyped in chapter 4 the remaining two [Methionine863Valine 
(M863V) and Valine955Isoleucine (V955I)] were subject to further analysis in a 
larger population of patients to assess any contribution towards increased disease 
susceptibility.
An analysis of linkage disequilibrium between all 18 SNPs identified within the 
NOD2/CARD15 gene was performed (figure 5-1) using Haploview version 3.2 
(www.broad.mit.edu/mpg/haploview). The 2 SNPs selected for further analysis were 
not in strong linkage disequilibrium (pair wise D prime score 0.34).
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 Table 5-3: SNPs identified in sequencing of the NOD2/CARD15 gene
SNP SNP description rs number Exon number / base change
1 upstream rs5743264 Exon 1 promoter T/C
2 5  UTR(-59) rs5743266 Exon 1 G/A
3 intronic rs2076753 Exon 2 promoter  G/T*
4 Ser178Ser rs2067085 Exon 2 C/G
5 Ala211Ala rs5743269 Exon 3 C/T
6 Pro268Ser (SNP 5) rs2066842 Exon 4(1) C/T
7 Arg459Arg (SNP 6) rs2066843 Exon 4(2) C/T
8 Arg587Arg (SNP 7) rs1861759 Exon 4(2) T/G
9 ** Exon 4(2) C/T
10 Arg702Trp (SNP 8) rs2066844 Exon 4 (3)C/T
11 ** Exon 4 end + 10 bases A/C
12 Met863Val ** Exon 6 A/G
13 Gly908Arg (SNP12) rs2066845 Exon 8 G/C
14 Val955Ile rs5743291 Exon 9 G/A
15 ** Exon 10 (post exonic +1) T/A
16 Leu1007fsincC 
(SNP13)
rs2066847 Exon 11 c+/-
17 3  UTR rs3135499 Exon 12(1)  A/C
18 3  UTR rs3135500 Exon 12(2) G/A
* This is described in Lesage219 (and here) as an Exon 2 promoter mutation, 
numbered from the ATG in the 2nd exon that was thought to be the start of the 
NOD2/CARD15.  It’s actually in intron one/two.
** No rs number listed in Ensembl
IBD Genetics in Scottish Children
Searching for specific NOD2 variants 123
Table 5-4: Patient results of SNPs detected in sequencing 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
- - GG CC CT CC CC TT CC CC AA AA GG GG AA AA -
TT GA TG CC CC TT TT TT CC CT AA AA GG GG TT AA GG
TT GG GG CG CC CC CC GG CC CC AA AA GG GG TT CC AA
TT GG GG CG CC CC CC TG CC CC AA AA GG GA TA AC GA
TT GG GG CG CC CC CC TG CC CC AA AA GG GA TT CC AA
TT GA TG CC CC CT CT TT CC CC AA AA GG GG TA AA GG
TT GA TG CC CC CT CT TT CC CT AA AA GG GG TA AA GG
TT GA TG CC CC - CT TT CC CT AA AA GG GG TA AA GG
TT AA TT CC CC TT - - - CC AA AA GG GA TA AA GG
TT GG GG CG CC CC CC TG CC CC AA AA GG - TA AC GA
- - GG GG CC CC CC GG CT CT AA AA GG - TT CC AA
TT GA GG CG CC CC CC GG CC CC AC AA GG - TA CC AA
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TT GA TG CC CC CT CT TG CC CC AA AA GG GG TT AC GA
TT GA TG CC CC CT CT TT CC CC AA AA GG GG TA AA GG
TT GA TG CG CC CC CC TG CC CC AA AA GG GG TA AC GA
TT GA TG CG CC CT CT TG CC CC AA AA GG GG TT CC AA
TT GG GG CG CC CC CC TG CC CC AA - GG GA TA AC GA
TT GA TG CC CC CT CT TT CC CC AA AA GG GG TA AA GG
TT GA TG CG CC CT CT TG CC CC AA AA GG GG TT C+ AC GA
TT GA TG CG CC CT CT TT CC CC AA AA GC GC TA AA GG
TC AA TT CC CC TT TT TT CC CT AA AA GG GG TT AA GG
TT GA TG CG CC CT CT TT CC CC AA AA GG GG TA AA GG
TT AA TT CC CC TT TT TT CC CC AA AG GC GC TT AA GG
- - TG CG CC CT CT TG CC CC AC AG GG GG TT AC GA
The numbers of the SNPs (corresponding to those listed in table 5-3) are placed horizontally across the top of the table and the results for each of 
the 24 patients studied are then listed vertically; – indicates that sequence was not available for that SNP for the patient in question.
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Figure 5-1 : Linkage equilibrium across the NOD2/CARD15 gene
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5.4.1 Case-control analysis 
The results for case control analysis are presented in table 5-5.
5.4.1.1 V955I
There was no significant difference in carriage rates of the V955I variant in patients 
with Crohn’s disease or Ulcerative colitis compared to healthy controls (12.6% vs. 
16.2%,  p=0.18 and 15.8% vs. 16.2%, p=0.86 respectively). The carriage rate of 
V955I variants was significantly higher in patients with IC (n=29) compared with 
healthy controls (n=253) (41.4% vs. 16.2%, p=0.001 OR= 3.65 [1.62-8.21). 
5.4.1.2 M863V
Carriage of M863V variants was higher in patients with Crohn’s disease compared to 
healthy controls but this was not significant (1.35% vs. 0.37%, p=0.27). No variants 
were detected in patients with UC or IC.
5.4.2 TDT analysis
TDT analysis was only performed for the G955A SNP, given the relative rarity of the 
M863V SNP. TDT analysis did not demonstrate distortion of transmission of G955A
variants in patients with IBD, Crohn’s disease or ulcerative colitis (table 5-6). 
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Table 5-5: Comparison of carriage rates by case-control analysis in the different disease groups
The numbers of carriers of the variant form of the SNP analysed is compared to the 
number of patients successfully genotyped. 






p value cf. 
HC
V955I  variant 
carriage
p value cf. 
HC
HC 1/267 (0.37%) 41/253 (16.2%) 
CD children 2/207 (0.97%) 0.58 29/202 (14.4%) 0.29
CD adults 5/313 (1.6%) 0.22 36/305 (11.8%) 0.13
Both CD 7/520(1.35%) 0.27 64/506 (12.6%) 0.18
UC 0/80 - 12/78 (15.8%) 0.86
IC 0/30 - 12/29 (41.4%) 0.001
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Table 5-6: TDT results






2 p-value Allele 1 Allele 2 OR 95% CI
IBD 0.023 0.879 25 21 1.19 (0.67-2.13)
CD 0.182 0.670 14 11 1.27 (0.58-2.80)
UC 0.000 1.000 7 6 1.17 (0.39-3.47)
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5.5 Discussion
The data contained in this chapter demonstrates that there is unlikely to be a major 
contribution of other coding NOD2/CARD15 variants to CD susceptibility in the 
Scottish paediatric CD population. This is an important finding given the relatively 
small contribution of the three common NOD2/CARD15 mutations in the Scottish 
population that has been demonstrated in children (chapter 4) and previously by 
Arnott et al. in Scottish adults with Crohn’s disease.184
There is clear evidence in most Western Crohn’s disease populations that the three 
common mutations within the NOD2/CARD15 gene contribute to Crohn’s disease, 
but no other major disease associated mutations have been identified.101 A meta –
analysis of 29 case-control studies has shown an increased relative risk  for 
developing CD of 3 fold and 20 fold for heterozygous and homozygous mutant
carriers respectively.185   In the meta-analysis the Leu1007fsinsC mutation made the 
most significant contribution to increased disease susceptibility in comparison to the
other two common disease associated SNPs.185 This finding has been replicated in a 
pooled analysis of more than 7000 Crohn’s disease patients.237
The results from gene sequencing in the current study are similar to those found in 
previous studies. Lesage et al. were the first group to sequence the entire 
NOD2/CARD15 gene in a heterogeneous European cohort of 51 Crohn’s disease  
patients including patients from both Northern and Southern Europe.219 They 
identified 67 mutations of which 31 were potential disease causing mutations with 
93% of the 31 coding for amino acid changes in the LRR region of the 
NOD2/CARD15 protein. Of the mutations identified 9 had an allele frequency of 
>5% and 8 of the 9 were more frequent in a CD group of 453 adults compared with 
103 French controls (mostly spouses of patients). Three (of the nine) were the 
common variants (R702W, G908R and 1007finsC) and all of the other 6 were 
identified in the present study (SNPs 3, 4,6,7,8 and 14 listed in Table 5-3). This 
replication of data from the Lesage study validates the findings of the current study 
demonstrating the techniques were appropriate to identify any common 
NOD2/CARD15 variant that may have been present in the Scottish population. The 
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Lesage study however was limited by the heterogeneous mixture of CD patients (8 
different European countries were involved) and by the choice of controls.
As part of the sequencing study performed by Lesage et al both of the SNPs subject 
to detailed analysis within this present study were identified. The allele frequency of 
the V955I mutation was lower in CD patients than controls (63/906 (7.0%) vs. 
21/206(10.2%), p=0.11) with comparative figures from this present study remarkably 
similar (65/1012 (6.4%) vs. 43/506(8.5%), p=0.14). The allele frequency of the 
M863V allele was rare in the Lesage study found in 4/906 (0.04%) alleles compared 
to 7/1040 (0.06%) in the current study. The SNP was not found in any UC patients in 
either study and was found in only 1 healthy control in the Scottish study.
The current study was designed to identify any population specific NOD2/CARD15 
mutations in the Scottish population.  None were identified, but given the similar 
allele frequencies in other Northern European populations the negative data in the 
current study are supported by Medici et al. who sequenced the NOD2/CARD15 
gene in 91 Norwegian Crohn’s disease patients identifying 23 SNPs across the 
gene.238 They did not identify any NOD2/CARD15 mutations in this population that 
accounted for increased disease susceptibility, including the common three 
NOD2/CARD15 variants. However, it is important to note that the case-control study 
may have been underpowered as it was carried out in a relatively small cohort of 150 
patients and 236 population controls. The authors of this study then  went on to 
demonstrate the allele frequencies of the common NOD2/CARD15 mutations were 
less common in their Northern European (Norwegian) compared to Southern 
(German) of 309 CD patients as has been discussed in detail in chapter 4. 
This study was aiming to identify novel variants only present in an early onset 
population but did not identify any. In one previous study, the NOD2/CARD15 gene 
was sequenced in an exclusively paediatric population (<18years old at diagnosis) of 
55 Crohn’s disease patients from Saxony, Germany.191 This study identified 14 SNPs 
across the NOD2/CARD15 gene but only analysed the Leu1007finsC SNP further by 
case control analysis comparing allele frequencies with 101 healthy controls. In this 
small study they demonstrated extremely high rates of NOD2/CARD15 carriage, 
with 65% of the patients studied carrying at least one NOD2/CARD15 mutation. 
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This suggests that in early onset populations the population the patients are from, 
rather than the fact they the disease has an earlier age of onset is the predominant 
factor governing the NOD2/CARD15 mutations identified by sequencing.
The current study suggested for the first time that V955I variants increase 
susceptibility to developing IC. No analysis was carried out in patients with IC in the 
Lesage study or any other NOD2/CARD15 sequencing studies. The V955I mutation 
was selected for further study because it was identified as a non-synonymous coding 
SNP. A study by King et al. has subsequently suggested that V955I was not likely to 
be a disease causing mutation  based on sequencing of the NOD2/CARD15 gene in 
species other than humans. They suggested it was unlikely to be a non-synonymous 
coding SNP because of a lack of evolutionary conservation of this SNP.239
This current study and thesis is one of very few that has studied candidate genes in 
patients with IC with most groups choosing to exclude patients with this diagnosis 
from genetic analysis. Paediatric IBD populations may be particularly appropriate to 
study these patients, as proportionately they contain a larger number of IC patients 
than published adult series contributing up to 30% of all IBD presenting in 
childhood.4;240  Carvalho et al. described a series of 250 children presenting to the 
John Hopkins hospital 30% of whom had an initial diagnosis of IC.240 The research 
focus thus far in this group of patients has been limited to the study of serological 
rather than genetic markers (see chapter 8 for more detailed discussion of 
studies).241;242 This may in part relate to the small number of patients with this 
diagnosis and controversy about the exact disease definition.243 This is the first study 
to demonstrate a higher carriage of any NOD2/CARD15 mutation in patients with IC 
but this is preliminary data as the number of patients analysed is small (n=29) and 
would need to be replicated by other groups.
In conclusion, despite sequencing all exons of the NOD2/CARD15 no new mutations 
that contributed to increased disease susceptibility were identified. The major genetic 
determinants of disease susceptibility of the Scottish population and indeed other 
Northern European IBD populations remain to be answered. 
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6 The role of the IBD5 haplotype and OCTN genes
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6.1 Summary 
Aims: To study the role of the SNPs within the IBD5 locus looking at effects on 
disease susceptibility and phenotype.
Subjects: 299 children (200 CD, 74 UC and 25 IC) together with 502 parents (for 
TDT) and 256 healthy controls.
Methods: Genotyping for the OCTN1/2 variants (SLC22A4 1672C→T, SLC22A5 -
207G→C) and IBD5 marker SNPs (IGR2096a_1, IGR2198a_1, and IGR2230a_1) 
was performed by TaqMan. 
Results: All SNPs were in strong linkage disequilibrium (D >0.94). TDT analysis 
demonstrated association of the OCTN1 variant with IBD (p=0.01) and CD (p=0.04). 
Allele frequencies of the OCTN1/2 variants were significantly higher in IBD/CD 
cases (0.04 < p > 0.01). The homozygous mutant OCTN1/2 haplotype was 
significantly increased in IBD (24.3% vs. 16.1%, p=0.02) and UC patients (28.2% 
vs. 16.1%, p=0.02) compared with controls. 
Unifactorial analysis in CD patients demonstrated carriage of the TC haplotype (a 
combination of the variant alleles of OCTN1/2) was associated with lower weight, 
height and BMI centile (<9th centile) at diagnosis (87.9% vs. 67.3%, p=0.002 
OR=3.52[1.51-8.22], 84.1% vs. 68.4%, p<0.05 OR=2.44[1.00-5.99], 79.6% vs. 
61.1%, p=0.02 OR=2.49[1.14-5.44] respectively) and lower weight centile at follow 
up (87.5% vs. 64.6% p=0.03, OR=3.83 [1.03-14.24]). Multifactorial binary logistic 
regression analysis confirmed association of the TC haplotype with lower weight 
centile at diagnosis (p=0.02, OR 3.41[1.20-9.66]).
Conclusions: Variants within the IBD5 haplotype are associated with increased 
disease susceptibility in IBD patients and with decreased growth parameters in CD 
patients. The OCTN1/2 variants remain potential positional candidate genes, but 
require further analysis.
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6.2 Introduction
IBD starting in childhood can have profound effects on a child’s growth, pubertal 
development and education. Growth failure is a common feature of childhood IBD 
particularly in Crohn’s disease.8 Several factors have been linked to growth failure in 
CD including: delay to diagnosis,244 jejunal inflammation,39 disease severity,189 age 
at diagnosis245 and genotype.190
The IBD5 locus (5q31-33) was first identified in Genome Wide Scan of North 
American CD patients as detailed in Chapter 1.109;112 To summarise, Rioux et al. 
stratified the genetic data from the Canadian genome wide scan by age, and 
demonstrated the highest LOD score of 3.9 was found in CD patients diagnosed 
under 16 years of age.112
In a more detailed study of the IBD5 locus, Daly and colleagues reported strong 
linkage disequilibrium across the region, and derived a risk haplotype for Crohn’s 
disease that was represented by 11 marker SNPs in separate haplotype blocks that 
spanned the whole 250 kb interval of the locus.246 Heterozygotes for the IBD5 risk 
haplotype had a 2 fold increased risk of CD and homozygotes a 6 fold increase, but 
with no increased risk of UC.135 Several European studies have replicated the 
association of IBD5 variants with susceptibility to adult onset CD,247-250 and  
additionally, one study  has demonstrated an association with UC.247 Genotype-
phenotype studies in adult-onset disease have shown association with perianal CD249
and earlier age of disease onset.248 IBD5 epistasis has been demonstrated with the 
IBD6 locus116 and with NOD2/CARD15, for both CD248 and UC.247;251   
Peltekova et al. suggested two variants within the IBD5 interval are independently 
associated with CD; variant alleles of the OCTN1 gene (SLC22A4 C/T, missense 
mutation) and OCTN2 (SLC22A5 -207 G/C, promoter mutation).252 Both of these 
genes have been suggested to play a role in carnitine transport but critical expression 
and functional data in IBD patients are lacking. In the initial publication from 
Peltekova and colleagues, the resulting 2 allele risk (TC) haplotype was 
independently associated with susceptibility to CD when CD patients and controls 
who were homozygous wild type for marker SNP IGR2078a_1 were compared.252
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In this study apriori the contribution to disease susceptibility and phenotype of 3 
marker SNPs on the IBD5 haplotype together with the OCTN1/2 variants and the TC 
haplotype within the Scottish paediatric IBD population has been assessed. Post hoc, 
further detailed analysis was performed of the relationship between growth 
parameters and the five IBD5 SNPs as well as the TC haplotype. In addition, the 
study has specifically addressed whether the contribution of the OCTN1/2 genes to 
disease susceptibility is independent of other determinants within the IBD5 locus. 
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6.3 Patients and Methods
6.3.1 Patients
Two-hundred and ninety nine patients with IBD diagnosed at less than age 16 years 
were studied. Two hundred patients had an established diagnosis of Crohn’s disease, 
74 ulcerative colitis and 25 patients had indeterminate colitis. 
6.3.2 Parents and controls
Genotyping data from 502 parents were used to construct family trios for TDT 
analysis (71% of patients had complete family trios). Data from 256 healthy adult 
controls was also available for case-control analysis with the initial data in the 
healthy controls analysed by Noble et al.253
6.3.3 Disease phenotype
CD phenotype was assessed using the Vienna classification and a more extensive 
paediatric classification.36  Specifically relevant to the present study , peri-anal 
disease was defined by the presence of anal fissures, peri-anal abscesses, fistulae and 
peri-anal ulcers, and to allow for comparison with the results published by other 
groups that have analysed the IBD5 haplotype,249;254 the definition was adapted to 
use the above definition of perianal disease minus anal fissures.
6.3.4 Data collection
Disease phenotype was determined using a combination of patient questionnaire, 
interview and retrospective case note review as previously described in chapter 2.255
The phenotypic characteristics of the CD patients are presented in tables 6-1 and 6-2 
and UC patients in table 6-3. The phenotypic data for CD patients at diagnosis are 
based on 197 patients unless otherwise stated. In this CD patient group there were 
121 males, the median age at diagnosis was 11.2 years (IQR 8.6-13.0), 97% were 
Caucasian, 2% smoked and 34% had a positive family of IBD. The UC data refer to 
69 patients at disease diagnosis unless otherwise stated.
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Table 6-1: disease location and behaviour of CD patients at diagnosis 
Disease location 
Terminal Ileum (L1) 9 (4.6%)
Colon (L2) 48 (24.4%)
Ileocolon (L3) 38 (19.2%)
Upper gastrointestinal (L4) 93 (47.2%)
None 9 (4.6%)
Disease behaviour 
Inflammatory (B1) 163 (82.7%)
Stricturing (B2) 7 (3.6%)













*defined by the presence of fissures, perianal ulcers, abscesses or fistulae but not by 
the presence of skin tags alone; ** not by the presence of skin tags or fissures.
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Table 6-2: Anthropometry and atopic diseases in CD patients at diagnosis
Anthropometry Number with variable
Weight <9th Centile 71/185 (38.4%)
Weight <25th Centile 104/185 (56.2%)
Height <9th Centile 46/178 (25.8%)
Height <25th Centile 83/178 (46.6%)
BMI <9th Centile 66/178 (37.1%)
BMI <25th Centile 92/178 (51.7%)
Mean Weight z score with SD -0.68 +/- 1.55
Mean Height z score with SD -0.48 +/- 2.01





All 3 diseases 15/198 (7.9%)
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Table 6-3: Demographics of ulcerative colitis patients at diagnosis
Sex (M/F) 32/37
Median Age at diagnosis(y) 10.7 (IQR 8.5-12.9)
Current Smoker 1(1.4%)
Family history 20 (29.0%)
Caucasian (%) 66 (95.6%)
Disease extent
Pancolitis 36 (52.2%)
Extensive colitis 13 (18.8%)
Left-sided colitis 16 (23.2%)
Proctitis 4 (5.8%)
Extraintestinal manifestations (%) 7/67 (10.4%)
Anthropometric Measurements
Weight <9th centile 11/65 (16.9%)
Weight <25th centile 20/65 (30.8%)
Height <9th centile 9/59 (15.2%)
Height <25th centile 23/59 (39.0%)
BMI <9th centile 6/59 (10.2%)
BMI <25th centile 19/59 (15.2%)
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6.3.5 Genotyping
Three marker SNPs on the IBD5 haplotype were typed IGR2096a_1, IGR2198a_1 
and IGR2230a_1. The rs1050152 polymorphism of the OCTN1 gene (SCL22A4
exon 9 1672C→T) and the rs26313667 (SLC22A5 promoter, -207G→C) 
polymorphism of the OCTN2 gene were also typed. Genotyping was performed 
using TaqMan with all SNPs analysed using assay on demand methodology. The 
primers used for genotyping the SNPs are listed in table 6-4. The relative positions of 
these SNPs within the IBD5 locus is shown in figure 6-1.
The three NOD2/CARD15 mutations (Leu1007InsC, G908R and R702W) were 
genotyped as previously described in chapter 4.
6.3.6 Statistical analysis
Each of the 5 SNPs was analysed individually using allele frequencies and carriage 
rates for association with IBD, CD and UC. As the total number of patients with IC 
was small these data were included in IBD analysis overall but were not analysed as 
an individual disease group. Multifactorial analysis was performed using binary 
logistic regression analysis.  All SNPs in patients and controls were in Hardy-
Weinberg equilibrium.
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Table 6-4: Primers used to examine each of the 5 SNPs examined in this study











IBD Genetics in Scottish Children
Role of IBD5 142
Figure 6-1: Relative position of SNPs within the haplotype blocks 
4 5 6 7
Figure 6-1: The relative position within the haplotype blocks of the IBD5 
locus (as described by Daly et al, Nature Genetics 2001;29(2):229-32) of the 5 
SNPs within the haplotype examined in this study. Also shown is the marker 
SNP IGR 2078a_1 examined in the study by Peltekova et al, Nature Genetics 
2004;36(5):471-75. The corresponding rs numbers are given below each SNP 
examined in this study. In Daly’s original study 11 separate haplotype blocks 
were described the numbers shown here (4-7) are the ones referred to in the 
original publication. IGR 2222a_1 refers to the OCTN2 variant (-207G→C) 
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6.4 Results
6.4.1 Linkage disequilibrium
Strong linkage disequilibrium (LD) was seen between the 3 IBD 5 haplotype SNPs 
and the two OCTN variants, as shown below in figure 6-2. As shown in the figure
the pair wise D prime scores for all 5 markers was 0.94 or above. 
Figure 6-2: linkage disequilibrium across the IBD5 Haplotype 
Figure 6-2: The D prime scores of the 5 SNPs studied across the IBD5 haplotype are 
listed on the left in red with corresponding SNPs listed above. The most common 
haplotype frequencies are listed on the left.
A = Wild type, C= Mutant
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6.4.2 Transmission Disequilibrium Testing 
The Transmission Disequilibrium Testing results for IBD5 SNPs and OCTN variants 
in inflammatory bowel disease patients are shown in table 6-5. The TDT results were 
based on 293 patients with inflammatory bowel disease together with one or both 
parents (the numbers of informative trios were 271,197 and 74 for IBD, CD and UC 
respectively). The IBD5 Haplotype in this analysis refers to the homozygosity for 
mutants of IGR2096a_1, IGR2198a_1, and IGR2230a_1 combined. The TC 
haplotype in the table refers to homozygosity for the mutants of OCTN1/2 combined.
TDT analysis demonstrated the IGR2198a_1 allele was associated with susceptibility 
to IBD (p=0.01). Homozygosity for the mutant IBD5 haplotype was associated with 
susceptibility to CD (p<0.05). The OCTN1 variant was associated with susceptibility 
to both IBD and CD (p=0.01 and p=0.04, respectively). The homozygous OCTN1/2 
mutant haplotype was associated with susceptibility to IBD (p=0.01). 
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Table 6-5: TDT analysis 
IBD CD UCSNP
χ2 p value χ2 p value χ2 p value
IGR2230a_1 2.42 0.12 0.87 0.35 2.00 0.16
IGR2198a_1 5.57 0.02 2.24 0.15 4.03 0.06
IGR2096a_1 2.34 0.16 1.11 0.32 1.36 0.24
IBD5 haplotype 10.59 0.05 10.13 <0.05 4.07 0.42
OCTN1 7.54 0.01 4.21 0.04 3.54 0.06
OCTN2 1.57 0.23 0.47 0.52 1.54 0.18
TC Haplotype 12.92 0.01 6.59 0.11 7.72 0.21
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6.4.3 Case-control analysis
6.4.3.1 IBD 
Allele frequencies and carriage rates for variants in the IBD5 haplotype in IBD 
patients compared with healthy controls are listed in table 6-6. A total of 299 IBD 
patients were compared to 256 healthy controls. The allele frequencies were 
significantly higher in IBD patients for all 3 IBD5 SNPs and for the OCTN1/2 
variants than in healthy controls (p value 0.01-0.04). Homozygosity rates for the 
IBD5 variant alleles IGR2096a_1 and IGR2198a_1 as well as homozygosity rates for 
the mutant TC haplotype in patients with IBD were significantly higher when 
compared with healthy controls (24.4% vs. 15.2%, p=0.008 OR 1.79 [1.16-2.78], 
22.8% vs. 15.2%, p=0.03, OR=1.64 [1.06-2.54], 24.3% vs. 16.1%, p=0.02 OR=1.67 
[1.08-2.58] respectively).
Case control analysis in IBD patients using carriage rates demonstrated all 5 SNPs 
were associated with susceptibility to IBD. Homozygous carriage of IGR2096a_1, 
IGR2198a_1 and the TC haplotype were associated with susceptibility to IBD. The 
results for heterozygous carriage all failed to achieve significance and are not listed 
in the table.
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Table 6-6: case-control analysis in IBD patients
Allelic Frequency IBD vs. HC p value Odds Ratio
IGR2096a_1 49.6% vs. 42.0% 0.01 1.36 (1.07-1.73)
IGR2198a_1  48.4% vs. 41.0% 0.01 1.35 (1.07-1.72)
IGR2230a_1 53.8% vs. 47.5% 0.04 1.29 (1.01-1.64)
OCTN 1 50.0% vs. 42.9% 0.02 1.33 (1.05-1.69)
OCTN 2 54.5% vs. 47.9% 0.03 1.30 (1.03-1.66)
Homozygous Carriage
IGR2096a_1 24.4% vs. 15.2% 0.008 1.79 (1.16-2.78)
IGR2198a_1 22.8% vs. 15.2% 0.03 1.64 (1.06-2.54)
IGR2230a_1 27.0% vs. 21.2% 0.12 1.38 (0.92-2.05)
TC Haplotype 24.3% vs. 16.1% 0.02 1.67 (1.08-2.58)
Combined IBD5 carriage 21.3% vs. 14.7% 0.06 1.57 (0.99-2.49)
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6.4.3.2 CD
 The allele frequencies and carriage rates for variants in the IBD5 haplotype in 
Crohn’s disease patients compared with healthy controls are shown in table 6-7. A 
total of 200 CD patients were compared with 256 healthy controls. The frequencies 
of variant alleles in CD patients compared to healthy controls were significantly 
higher for IGR2096a_1 (49.2% vs. 42.0%, p=0.04 OR=1.34 [1.02-1.75]), 
IGR2198a_1 (47.7% vs. 41.0%, p=0.04 OR=1.31 [1.01-1.71] and OCTN2 (54.8% 
vs. 47.9%, p=0.04 OR=1.32 [1.01-1.72]). Homozygous carriage of mutant 
IGR2096a_1 was higher in CD patients compared to controls (23.6% vs. 15.2%, 
p=0.03, OR=1.72 [1.06-2.79]).The results for heterozygous carriage all failed to 
achieve significance and are not listed in the table.
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Table 6-7: Case control analysis in Crohn’s disease patients 
Allelic Frequency CD vs. HC p value Odds Ratio
IGR2096a_1 49.2% vs. 42.0% 0.04 1.34 (1.02-1.75)
IGR2198a_1 47.7% vs. 41.0% 0.04 1.31 (1.01-1.71)
IGR2230a_1 53.8% vs. 47.5% 0.06 1.29 (0.99-1.69)
OCTN 1 49.5% vs. 42.9% 0.05 1.30 (1.00-1.70)
OCTN 2 54.8% vs. 47.9% 0.04 1.32 (1.01-1.72)
Homozygous Carriage
IGR2096a_1 23.6% vs. 15.2% 0.03 1.72 (1.06-2.79)
IGR2198a_1 20.8% vs. 15.2% 0.12 1.46 (0.90-2.38)
IGR2230a_1 26.9% vs. 21.2% 0.16 1.37 (0.88-2.14)
TC Haplotype 22.2% vs. 16.1% 0.11 1.48 (0.91-2.40)
Combined IBD5 haplotype 19.2% vs. 14.7% 0.42 1.38 (0.82-2.32)
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6.4.3.3 UC
The allele frequencies and carriage rates for variants in the IBD5 haplotype in 74 
Ulcerative Colitis patients were compared with 256 healthy controls with the results 
listed in table 6-8.
The frequency of the IGR2198a_1 variant allele was higher in UC patients than 
controls (50.7% vs. 41.0%, p=0.04 OR=1.48 [1.02-2.15]). Homozygosity for the 
variant alleles IGR2096a_1 (27.9% vs. 15.2%, p=0.01 OR=2.16 [1.15-4.05]) and 
IGR2198a_1 (25.7% vs. 15.2%, p=0.04 OR=1.92 [1.03-3.58]) were higher in UC 
patients than controls. Homozygous carriage of the mutant TC haplotype and of a 
combined IBD5 haplotype (homozygosity for all 3 IBD5 marker SNPs variants) was 
also higher in UC patients than controls (28.2% vs. 16.1%, p=0.02 OR=2.04 [1.10-
3.78] and 26.6% vs. 14.7%, p=0.02 OR=2.10 [1.09-4.05] respectively). The results 
for heterozygous carriage all failed to achieve significance and are not listed.
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Table 6-8: Case control analysis in UC patients
Allelic Frequency UC vs. HC P value Odds ratio
IGR2096a_1 50.7% vs. 42.0% 0.07 1.42 (0.97-2.08)
IGR2198a_1 50.7% vs. 41.0% 0.04 1.48 (1.02-2.15)
IGR2230a_1 52.9% vs. 47.5% 0.25 1.24 (0.85-1.81)
OCTN1 52.1% vs. 42.9% 0.05 1.45 (1.00-2.10)
OCTN2 54.1% vs. 47.9% 0.18 1.28 (0.89-1.86)
Homozygous Carriage
IGR2096a_1 27.9% vs. 15.2% 0.01 2.16 (1.15-4.05)
IGR2198a_1 26.8% vs. 15.2% 0.04 1.92 (1.03-3.58)
IGR2230a_1 27.5% vs. 21.2% 0.26 1.41 (0.77-2.60)
TC Haplotype 28.2% vs. 16.1% 0.02 2.04 (1.10-3.78)
Combined  IBD5 Haplotype 26.6% vs. 14.7% 0.02 2.10 (1.09-4.05)
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6.4.4 OCTN genes, independence within the IBD5 haplotype?
The association between the OCTN1/2 TC Haplotype and disease susceptibility was 
not independent of other determinants within the IBD5 Haplotype as shown in table 
6-9. There was no independent association between the TC haplotype and 
susceptibility to IBD, CD or UC in individuals lacking the extended IBD5 risk 
haplotype markers (IGR2198a_1, IGR2230a_1 and IGR2096a_1). The data shown in 
table 6-9 do not show a significant difference between IBD, CD or UC cases 
compared with controls in carriage of the variant alleles representing the TC 
haplotype on a background of having no IGR2198a_1 risk alleles. Thus for Crohn’s 
disease only 4 out of 47 patients carried the TC haplotype but no IGR2198a_1 
variants compared with 10 out of 82 IGR2198a_1 variant negative controls (p=0.57). 
The same lack of association was also seen with the TC haplotype if either of the 2 
other variants (IGR2230a_1, and IGR2096a_1) were analysed similarly, or if all 3 
IBD5 SNPs were combined. These results are not listed in the table.
No independent effect was demonstrated if the OCTN variants 1 and 2 were 
considered individually rather than when combined as the TC haplotype. 
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Table 6-9: Comparison of patients and controls who are homozygous wild type for the 
IGR2198a_1 IBD5 haplotype marker SNP but have a risk allele in the TC haplotype
Number of subjects with no 
IBD 5 risk alleles.
No. of patients with 
TC haplotype but no 
IBD5 risk alleles.
Controls 82 10
IBD patients 72 5
χ2 p value comparing IBD patients to controls 0.27
CD patients 47 4
χ2 p value comparing CD patients to controls 0.57
 UC patients 18 0
χ2 p value comparing UC patients to controls 0.20
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6.4.5 Epistasis with NOD2/CARD15 mutations 
There was no evidence of epistasis between IBD or CD patients with regard to the 
TC haplotype and patients carrying the common NOD2/CARD15 mutations 
(Leu1007InsC, G908R and R702W) in NOD2/CARD15 carriers vs. non-carriers for 
IBD and CD  (70.3% vs. 76.8% p=0.39 and 71.0% vs. 76.9% p=0.49 respectively) as 
demonstrated in table 6-10.





























4 (12.9) 32 (23.9%) 0.18
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6.4.6 Genotype-phenotype analysis 
6.4.6.1 Unifactorial analysis
For clarity, the results presented in the genotype-phenotype analysis describe 
associations with the TC haplotype only, with the exception of growth parameters. 
The phenotypic associations with the TC haplotype generally reflected the genotype-
phenotype results for all SNPs analysed across the IBD5 haplotype (all SNPs were in 
close LD). The results presented in subsequent tables relate clinical features of the 
Crohn’s disease patients included in the study comparing carriage of the TC 
haplotype and homozygous TC haplotype showing the % carriage of each phenotypic 
variable compared to the % carriage of those without the phenotypic variable. All 
data are for phenotypic variables at diagnosis and p values for the comparison 
between the variables are listed in the table. The Odds ratios with 95% CI for 
significant results are then given in the text.
6.4.6.1.1 Disease Location 
The results for disease location and behaviour are listed in table 6-11. Homozygous 
carriage of the TC haplotype was associated with gastric antral Crohn’s disease, 
when comparison was made with patients assessed and found to have no antral 
disease at diagnosis (36.7% vs. 14.2%, p=0.006 OR=3.51 [1.40-8.83]). 
6.4.6.1.2 Disease Behaviour and need for Surgery
No association was seen between carriage of the TC haplotype and disease 
behaviour. In this study 26.9% of patients underwent abdominal surgery for Crohn’s 
disease during the period of analysis. Carriage of the TC haplotype was no higher in 
those patients needing surgery than those who did not (77.6% vs. 73.9% p=0.61).
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Table 6-11 : Genotype-phenotype analysis of disease location and behaviour
Disease location TC haplotype p value Homozygous TC p value
Colonic 77.8% vs. 75.9% 0.80 28.9% vs. 21.1% 0.28
Ileal 77.8% vs. 76.3% 0.92 44.4% vs. 21.9% 0.21
Ileo-colonic 67.6% vs. 78.4% 0.18 17.6% vs. 24.3% 0.40
Upper GI 78.3% vs. 74.7% 0.57 20.5% vs. 25.3% 0.45
None 85.7% vs. 76.0% 0.55 14.3% vs. 23.4% 1
Disease behaviour 
Inflammatory 74.8% vs. 83.9% 0.28 22.4% vs. 25.8% 0.68
Stricturing 83.3% vs. 76.2% 0.68 16.7% vs. 23.3% 1
Penetrating 84.0% vs. 75.2% 0.33 28.0% vs. 22.2% 0.52
Disease location
Oral 79.2% vs. 75.3% 0.68 20.8% vs. 18.1% 0.75
Oesophageal 83.3% vs. 75.3% 0.65 50% vs. 15.8% 0.06
Gastric antrum 86.4% vs. 71.7% 0.05 36.7% vs. 14.2% 0.006
Duodenal 86.9% vs. 74.6% 0.19 26.1% vs. 17.5% 0.33
Jejunal 78.6% vs. 76.8% 0.84 17.8% vs. 18.2% 0.96
Ileal 75.0% vs. 78.2% 0.65 23.0% vs. 18.2% 0.48
Caecal 75.2% vs. 79.3% 0.65 18.8% vs. 17.2% 0.84
Sigmoid 75.8% vs. 81.8% 0.46 22.6% vs. 18.2% 0.58
Rectum 77.6% vs. 73.7% 0.61 22.4% vs. 23.7% 0.86
Perianal* 78.9% vs. 74.0% 0.46 22.5% vs. 22.0% 0.93
Perianal** 83.3% vs. 75.3% 0.59 27.8% vs. 22.2% 0.45
 * defined by the presence of fissures, perianal ulcers, abscesses or fistulae.               
** defined by the presence perianal ulcers, abscesses or fistulae
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6.4.6.1.3 Growth parameters
A comparison was made between lowest 3 (<9th) centile groupings and the remaining 
7 (>9th) centiles for weight, height and BMI (table 6-12). Carriage of the TC 
haplotype was more common in patients with lower weight, height and BMI 
compared to those in higher centiles at diagnosis of Crohn’s disease (87.9% vs. 
67.3%, p=0.002  OR=3.52 [1.51-8.22], 84.1% vs. 68.4%, p<0.05 OR=2.44[1.00-
5.99] and 79.6% vs. 61.1%, p=0.02 OR=2.49 [1.14-5.44] respectively). 
If the analysis was done using median z scores comparing homozygous carriers of 
the TC haplotype with non-carriers a significant difference was demonstrated for 
BMI (-1.32 vs. -0.51 p=0.03) and a strong trend toward significance for weight (-
1.16 vs. -0.49, p=0.05) but not for height (p=0.89). At 2 year follow up the TC 
haplotype was more common in lower compared to higher weight centiles (87.5% vs. 
64.6% p=0.03, OR=3.83 [1.03-14.24]). 
 Table 6-12: Genotype-phenotype analysis of Anthropometric parameters 
Centile TC haplotype p value Homozygous TC p value
Weight <9th
centile
87.9% vs. 67.3% 0.002 28.8% vs. 16.8% 0.07
Height <9th
centile
84.1% vs.  68.4% <0.05 25.0% vs. 21.4% 0.62
BMI <9th centile 79.6% vs. 61.1% 0.02 27.8% vs. 16.8% 0.11
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6.4.6.1.4 Asthma, eczema, hayfever and atopy
Homozygosity for the TC haplotype was less frequently seen in patients with asthma 
compared to those without (11.5% vs. 26.9%, p=0.02 OR 0.35[0.14-0.90]), less 
common in patients with hayfever than those without (7.5% vs. 27.0% p=0.009 
OR=0.22[0.06-0.75]) and less common in patients who had all 3 atopic diseases 
combined (asthma, eczema and hayfever) compared to those without (0% vs. 25.3%, 
p=0.02) (table 6-13). 
Table 6-13: Genotype phenotype analysis of associated atopic disease
Atopic 
disease 
TC haplotype p value Homozygous TC p value
Eczema 69.8% vs. 77.3% 0.27 15.9% vs. 26.1% 0.12
Asthma 73.1% vs. 75.4% 0.74 11.5% vs. 26.9% 0.02
Hayfever 72.5% vs. 75.9% 0.66 7.5% vs. 27% 0.009
All atopy 60.0% vs. 76.3% 0.16 0% vs. 25.3% 0.02
No atopy 75.6% vs. 74.5% 0.86 29.1% vs. 17.7% 0.07
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6.4.6.1.5 Age at diagnosis
The median age at diagnosis of carriers of the TC haplotype was 11.6 years [vs. 10.9 
years for non-carriers (p=0.12)] and for TC homozygotes 12.1 years [vs. 11.3 years 
in non-carriers (p=0.06)]. 
6.4.6.1.6 Other phenotypic variables
 No association was seen with the TC haplotype and family history of IBD, extra-
intestinal manifestations granulomas, or with blood test abnormalities (FBC, ESR, 
CRP, or albumin concentration).
6.4.6.1.7 Ulcerative colitis
Carriers of the TC haplotype were more common in patients in lower height centiles 
at diagnosis (<25th centile compared to >25th) (85.7% vs. 55.9%, p=0.02 OR 
4.74[1.17-19.16] and showed a trend towards significance for weight centile (83.3% 
vs. 59.5%, p=0.07 OR=3.40[0.85-13.57]). Genotype-phenotype analysis in this group 
was limited by the small number of patients available for analysis (n=69). No 
relationships were found between the TC haplotype and age at diagnosis, 
extraintestinal manifestations, IBD family history, need for surgery and extent of 
disease.
6.4.6.2 Multifactorial analysis
Using multifactorial binary logistic regression considering weight centile as either 
less than or greater than the 9th centile, disease location and behaviour as defined by 
the Vienna classification, family history of IBD, erythema nodosum and gastric 
antral Crohn’s disease a low weight centile was predicted by carriage of the TC 
haplotype (p=0.02, OR 3.41[1.20-9.66]) and the presence of antral Crohn’s disease 
(p=0.003, OR= 4.02 [1.58-10.21]).
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6.4.6.3 Log-Linear model analysis
Using Log-Linear model analysis to compare propensity across all 11 weight centiles 
groupings i.e. not dichotomised into above/below 9th Centile, a very strong trend 
towards higher carriage of the TC haplotype at lower weight centiles and lower TC 
haplotype carriage at higher weight centiles (p=0.05) at CD diagnosis was apparent 
(table 6-14). Homozygous carriers of the extended IBD5 risk haplotype (patients 
who were homozygous mutants for all 3 IBD5 haplotype markers IGR2096a_1, 
IGR2198a_1, and IGR2230a_1) were more likely to lie within lower BMI centiles 
and less likely to be within the highest BMI centiles in a logistic regression model 
(p=0.04).
Table 6-14 : Log linear model analysis
Marker/ Factor Weight Centiles Height Centiles BMI Centiles
IGR 2096 0.525 0.713 0.300
IGR 2198 0.375 0.411 0.251
IGR 2230 0.180 0.300 0.194
IBD5 Haplotype 0.187 0.869 0.044
OCTN1 0.154 0.456 0.282
OCTN2 0.223 0.436 0.245
TC Haplotype 0.051 0.137 0.198
IBD Genetics in Scottish Children
Role of IBD5 161
6.5 Discussion
This study demonstrates a definite role for variants within the IBD5 locus in 
determining susceptibility to both early-onset Crohn’s disease and reports initial 
evidence of association in Ulcerative colitis. In addition, the first consistent 
genotype-phenotype data demonstrating these variants influence growth in both CD 
and UC. Additionally the study demonstrated that the OCTN1/2 variants do not act 
independently of variants within this region in determining disease susceptibility, 
emphasising the complexity of the IBD5 locus to disease susceptibility.
The most unique strengths of this study lies in the robust phenotypic data that 
accompany the genetic data and in the size of the childhood population studied. Such 
detailed growth parameters have not been compared in such a large childhood 
population in the published literature before. A very strong association between the 
IBD5 haplotype (and TC haplotype) for low weight and body mass index at
diagnosis of Crohn’s disease is evident, with a less significant association 
demonstrated with height centile. The relationship has been demonstrated on 
unifactorial and multifactorial analysis for weight centile (with the TC haplotype) 
and for homozygosity of the extended IBD5 haplotype with BMI. Although the 
relationship was stronger in Crohn’s disease the same relationship was also strongly 
suggested in patients with UC. Given the relatively small numbers of UC patients the 
study may be underpowered to fully assess this relationship. 
The relative weakness of the data presented is that there is a relatively short follow 
up period for most of the patients in the study as most were enrolled at, or soon after 
diagnosis. This means the effect of this relationship over time could not be tested to 
either support or refute these initial findings. It would be interesting to see whether 
the variants within the IBD5 locus do have a lasting influence on growth and whether 
they have an influence on adult anthropometry too, not just at diagnosis in children.
This data does represent some of the strongest to date relating genotype to abnormal 
growth variables in inflammatory bowel disease. Previous paediatric studies have 
tried to correlate patient genotype with growth parameters but overall results have 
been not been consistent between populations. Levine et al. in a study of 87 children 
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with Crohn’s disease suggested variant alleles of the -238 promoter polymorphism in 
the TNF- gene protect patients from height retardation.245 The children carrying 
TNF- -238 variant alleles had significantly higher mean height z scores compared 
to those carrying wild type alleles. Tomer et al. demonstrated a relationship between 
carriage of NOD2/CARD15 variant alleles and weight below the 5th centile (but not 
for height, BMI was not examined) in 87 Crohn’s disease at diagnosis.190 The data in 
Tomer’s study were not subjected to multifactorial analysis; the findings have been 
confounded by the strong relationship between NOD2/CARD15 carriers with ileal 
disease which in turn is associated with lower weight at diagnosis.256 Two 
subsequent publications analysing 93 and 65 CD patients respectively have failed to 
replicate these findings between carriage of NOD2/CARD15 variant alleles and 
growth parameters.189;225 The lack of agreement between some of these studies and 
this present study results from the fact differences “centile” cut offs are used in 
different IBD populations e.g.3rd, <5th and <9th centile. Harmonisation between 
studies would be improved if z-scores were used universally to examine growth 
parameters. After this became apparent the growth data collected for the study was 
refined to include z-scores following the example of Levine et al.
As detailed in chapter 4 the relationship of NOD2/CARD15 genotype with growth 
parameters in Scottish children with CD demonstrated no relationship at diagnosis, 
although at follow up carriers of NOD2/CARD15 variant alleles were more common 
in a low centile band for height (2-9th) and for weight (<0.4th) only. This relationship 
was present on unifactorial analysis only and growth z-scores were not analysed in 
NOD2/CARD15 genotype-phenotype analysis.
There is no universally accepted definition of growth failure or good evidence of 
how it should be treated.257 Growth failure nevertheless remains a common problem 
especially in paediatric Crohn’s disease that can persist into adult life.258 Markowitz 
et al. studied 48 young adults with IBD and found permanent growth failure to be 
present in 19-35% of patients, depending on the method used to define growth 
failure.  There is also evidence from prospective paediatric studies that the growth 
failure is “pre-programmed” strongly suggesting a genetic influence.259 Motil et al. 
prospectively followed growth in 69 patients with IBD over 3 years and 
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demonstrated that those with growth failure at the start of the study were the most 
likely to have growth failure at the end of the study, despite interventions including 
surgery. Although the data presented in this study do not demonstrate genotype 
predicts “growth failure” because the strongest growth associations are with weight 
and BMI not height, the data do demonstrate genetic markers may have the potential 
to be used to predict growth problems and in the longer term even perhaps determine 
treatment strategies. To further test this association longer term follow up would be 
needed in our cohort or analysis of growth parameters and IBD5 variants would need 
to be assessed in an adult cohort. 
The association of markers in the IBD5 haplotype with low anthropometric centiles 
signifying a more severe disease phenotype are entirely consistent with published 
findings in Scottish adults with CD.253 Noble et al. demonstrated possession of 
variant alleles of the TC haplotype in 374 Scottish adults with CD was associated 
with disease progression at follow up and on multifactorial analysis the need for 
surgery, both phenotypic variables representing a more severe disease phenotype. 
This cohort would have been very useful to test our hypothesis with growth 
parameters but this cohort as with most adult cohorts did not have their growth 
parameters recorded. This is one of the many reasons why studying childhood 
cohorts with IBD in addition to adult studies is important as genotypes affecting 
growth will be ignored by adult gastroenterologists. The association of IBD5 variants 
and more severe Crohn’s disease has also been demonstrated by investigators out 
with the Scottish adult population.260
This study describes a novel association between the TC haplotype and gastric antral 
Crohn’s disease. Previous investigators have linked possession of the TC haplotype 
with ileal,261 colonic262 and peri-anal 254 Crohn’s disease but none of these studies 
have considered a relationship with Crohn’s disease of the proximal gastrointestinal 
tract. The establishment of such a relationship gives some justification for using a 
phenotypic classification of Crohn’s disease location in this thesis that is more
extensive than the Vienna classification. The relationship of the antral disease in turn 
with low weight centile at diagnosis on multifactorial analysis is intriguing in light of 
previous prospective paediatric studies establishing a link between jejunal CD and 
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low weight centile at diagnosis.39 The relationship with antral disease would be 
considered more robust if it was present at disease follow up and if the findings could 
be validated by other groups. The difficulty for validation is that adult studies are 
unlikely to look for antral disease as most adult gastroenterologists will not perform 
an upper GI endoscopy that is needed to define disease at this site. 
The association between the IBD5 haplotype and susceptibility to CD has now been 
clearly demonstrated in adult studies247-250;253;262 but this data is the first from an 
exclusive early-onset population to replicate the findings in Rioux’s initial genome 
wide scan.112 These data also represent the first paediatric study to demonstrate IBD5 
variants increase susceptibility to UC. Giallourakis et al. have previously 
demonstrated increased susceptibility to UC in 187 German trios by TDT analysis.247
It is noteworthy that the index study published by Rioux et al. from Canada may 
have been underpowered to assess association between IBD5 and UC as it contained 
only 20 families with UC.112 This current dataset is considerably larger therefore than 
the index study, nevertheless is relatively small for a case-control association study, 
containing only 74 UC patients and therefore the data have to be interpreted carefully 
because of the small number of patients compared to controls. More recently the TC 
haplotype has been associated with CD susceptibility in 3 adult studies in Canadian, 
Scottish and German populations. 252;253;262 Waller et al. in a UK case control study 
of 512 UC patients and 750 controls have also demonstrated an association between 
the TC haplotype and UC.263  
Despite demonstrating an association between the OCTN1/2 variants and disease 
susceptibility, the data do not support these variants as independent predictors of 
disease when the IBD5 risk markers are removed. This finding is contrary to the 
findings of Peltekova’s study,252 but consistent with all subsequent 
publications.253;262;263 These apparent inconsistencies are likely to reflect  the 
haplotype block structure of the region as described by Daly et al (figure 6-1).246 The 
published studies to date outwith the studies in the Scottish IBD population have 
only studied one haplotype marker IGR2078a_1 (haplotype block 4) and examined 
the relationship to (or lack of it) with the OCTN1/2 genes (haplotype block 7).252;262
This study has examined markers in block 4 (IGR2096a_1), block 5 (IGR2198a_1) 
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and block 7 (IGR2230a_1) representing an extended haplotype across the region. 
Fischer at al. have examined data from over 1200 case-controls from four European 
populations and demonstrated lack of independence of the OCTN1/2 variants from 
the background IBD5 haplotype.264 Thus the apparent independent effect reported in 
Peltekova’s data may reflect an effect of recombination events between haplotype 
block 4 and 7 in the Canadian population. Silverberg et al. have further analysed the 
IBD5 locus in a cohort of 1879 offspring with IBD from the North American 
genetics consortium study.141 This study demonstrated that the IRF1, PDLIM, and 
P4HA2 genes within the IBD5 locus are as likely to be the causal genes from within 
IBD5 as OCTN1 (this study rejected a role for OCTN2).
Given this uncertainty about the identity of the causal gene within the IBD5 locus it 
remains pertinent to examine the role of other genes within the region:  Interleukin 4 
265-267, Interleukin-13 268 as well as Interleukins 3 and 5 together with GMCSF are all 
plausible candidate genes within the linkage interval.269;270
Given the data published in the Canadian genome wide scan demonstrated markers 
in the IBD5 locus had the highest frequency of the risk haplotype in patients with 
Crohn’s disease diagnosed under the age of 16 it is pertinent to see if this is true of 
this and other paediatric studies.112 This study together with a study by Babusukumar 
et al. from within the American early onset IBD populations have both demonstrated 
markers from within IBD5 haplotype are associated with increased susceptibility to 
CD,271  however this risk does not seem to be higher than that of the corresponding 
adult IBD populations.253;261 No association with IBD5 mutations and IBD 
susceptibility has been demonstrated in a smaller Italian study and a very small 
Hungarian study but both of these negative studies were probably 
underpowered.194;272 No genotype-phenotype associations were demonstrated in the 
American paediatric study. 
Direct comparison between this study and the study performed in the Scottish adult 
IBD population by Noble et al. has revealed very similar results. The genetic 
contribution to disease susceptibility in both populations is similar with a modest 
odds ratio in both studies, both studies have associated IBD5 variants with markers 
of disease severity and neither has supported an independent role for the OCTN 
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genes within the IBD5 locus. Similar findings have been found in adult and 
childhood populations in North America. It seems therefore that although the 
findings of Rioux initial GWS were correct in predicting a role for the IBD5 locus in 
childhood onset disease this risk has yet to be proven to be dependent on age at 
disease diagnosis.
The protective association of the homozygous TC haplotype with asthma, hayfever 
and atopy would be consistent with the evidence from genome wide scans that genes 
within the 5q31-33 region are not only important in IBD but also in asthma and 
atopy.273-276 The contrasting findings that the homozygous haplotype may be a risk 
factor for IBD while being protective for asthma are consistent with the contrasting 
effects of the NOD1/CARD4 gene shown for the same 2 diseases.277;278 Candidate 
genes associated with asthma and atopy within the 5q31-33 region include IL-12B 
gene279and IL-13.280
In summary this study has demonstrated evidence for genetic association between the 
OCTN1/2 variants within the IBD5 locus and susceptibility to IBD, CD and UC. Of 
note this study also describes novel and consistent phenotypic associations with low 
anthropometric centiles. However, the effect of the OCTN1/2 variants is not 
independent of the extended IBD5 region and further investigation of these and other 
candidate genes within the IBD5 linkage interval are necessary. This study has 
demonstrated similar results in the Scottish childhood and adult IBD populations.
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7 The role of Drosophila Discs Large Homologue 5 (DLG5) 
in disease susceptibility and phenotype
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7.1 Summary
Aims: To study allelic frequencies of the Drosophila Discs Large Homologue 5 
(DLG5) gene 113G/A variant in childhood-onset IBD and additionally, match 
genotype with phenotypic characteristics at disease presentation.
Subjects: 296 children (197 CD, 73 UC, and 26 IC) with IBD were studied, together 
with 260 healthy controls. TDT analysis was performed on 270 IBD trios.
Methods: The DLG5 113G/A variant was genotyped by TaqMan®. Full clinical 
phenotypes including growth and social class (DepCat score) data were also 
collected. 
Results: TDT analysis demonstrated a significant association of this variant with 
IBD (p = 0.045). On unifactorial analysis, 113 G/A variant carriage was associated 
with: 1) higher social class (DepCat 1 compared to 2-7 and 1-2 compared to 3-7) 
(66.7% vs. 22.6% p=0.0005 OR 6.84[1.99-23.55] and 37.2% vs. 22.2% p=0.03, OR 
2.08[1.04-4.17] respectively) 2) higher height centile (>75th centile vs. <75th centile) 
(42.9% vs. 23.1%, p=0.01 OR 2.50[1.18-5.28]  3) male sex in CD (29.3% vs. 16.9%, 
p=0.04 OR 2.04[1.01-4.11].  Multifactorial analysis demonstrated that higher social 
class (DepCat 1) was independently associated with carriage of variants of 113 G/A 
(p=0.001, OR=6.92[2.24-21.33]).
Conclusions: The DLG5 113 G/A mutation is associated with susceptibility to IBD.
We have identified several phenotypic characteristics that are more common in 
carriers of variant alleles.
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7.2 Introduction
A strong genetic basis for inflammatory bowel disease has been suggested by 
evidence from: twin studies, prevalence rates of IBD in families of an IBD proband, 
and differing prevalence rates of IBD between ethnic groups as discussed in detail in 
chapter 1.45 Additionally several genes have been associated with susceptibility to 
inflammatory bowel disease including NOD2/CARD15166;167 as discussed in chapters 
4 and 5, IBD5(OCTN1/2)252 as discussed in chapter 6, as well variants within the 
MDR1,281 and the NOD1/CARD4 genes.278 The disease model that has evolved over 
the past decade is that ulcerative colitis and Crohn’s disease are related polygenic 
diseases sharing some but not all susceptibility genes.76 Although the studies 
presented in chapters 4 and 6 demonstrate NOD2/CARD15 and IBD5 variants are 
strong determinants of disease phenotype they do not account for most of the genetic 
susceptibility risk in the Scottish childhood IBD population.
7.2.1 Deprivation and IBD
A rising incidence of childhood onset inflammatory bowel disease in Scotland has 
been documented over the past 3 decades by observers within Scotland 3;6 and 
independently by the British Paediatric Surveillance Unit.4 Furthermore, within the 
Scottish population Armitage et al. have noted an association between susceptibility 
to early-onset Crohn’s disease both with Northern latitudes and with relative 
affluence.12 In a study of 580 incident IBD cases over the period 1981-95, the 
incidence of Crohn’s disease in the North of Scotland was significantly higher than 
in the South, 3.1 compared to 2.1 cases per 100,000 population (p<0.001).12
Additionally, the relative risk of developing IBD and CD, analysed by Poisson 
regression analysis was significantly increased in areas of relative affluence, 
compared to areas of socio-economic deprivation (p=0.02 and p=0.03 respectively). 
The deprivation category (DepCat) score, has been used and validated, in several 
Scottish studies as a marker of socioeconomic status.282 The DepCat score is used to 
assess social class and is scored 1-7, where 1 equates to the least deprivation and 7 
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the maximum deprivation. Although this measure of affluence has not previously 
been studied extensively in IBD , associations with other indirect measures of 
childhood deprivation in patients with IBD such as hygiene have been proposed.16
 In other childhood studies, lower DepCat scores have been associated with increased 
rates of both dental caries and Helicobacter pylori infection.283;284 Radford et al. 
demonstrated dental caries was more common in Scottish 1 year olds from the lowest 
DepCat categories (6 and 7) compared to higher scores (1-5). Malcolm et al. 
presented data showing Helicobacter pylori carriage was significantly higher in 
children from DepCat categories 6 and 7(34%) compared to DepCat 3-5(22%) and in 
turn higher than categories 1 and 2 (16%).
7.2.2 The DLG5 gene
Hampe et al. performed a genome-wide scan in an European population of 353 IBD 
sibling pairs (162 CD, 114 UC, 77 mixed) that included UK IBD patients, and 
identified an area on Chromosome 10 that achieved the criteria for “suggestive 
linkage” with a LOD score of 2.3 for IBD.108;285 Despite its relatively modest LOD 
score the chromosome 10 locus was the highest ranking chromosomal region in this 
GWS leading the authors to pursue further investigation that eventually lead to 
candidate gene identification within the locus. 
Stoll et al, (in a similar manner to Hugot et al. had used to identify NOD2/CARD15 
at the IBD1 locus), used a positional cloning approach to narrow the linkage region 
in the chromosome 10 locus.166;286 Fine mapping of the linkage region led to the 
suggestion that variants of the Drosophila, discs large homolog 5 (DLG 5) gene 
situated within this locus may be associated with increased susceptibility to Crohn’s 
disease.286 Stoll’s group identified four common haplotypes within the DLG5 gene in 
the German IBD population. Haplotype D was significantly over-transmitted in IBD 
patients and the haplotype was identified by a 113G/A coding SNP. The 113G/A 
variant (a missense mutation from within exon 30 of the DLG5 gene) which encodes 
for the amino acid substitution at position 30 from Arginine to glutamine (R30Q) 
was associated with increased susceptibility to IBD and Crohn’s disease.286
Haplotype A was tagged by 8 marker SNPs including the marker SNP DLGe_26 was 
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a protective haplotype against IBD and CD, thus this SNP and the other 7 marker 
SNPs were significantly under-transmitted in IBD trios in this study. 
Initially Stoll’s group found the 113G/A variant was significantly over-transmitted in 
TDT analysis of 457 German trios with IBD (302 CD and 155 UC), p=0.004 for IBD 
and p=0.04 for CD. They then replicated these findings in a European case control 
cohort (538 CD and 548 controls) p=0.001 for IBD. They were not however able to  
replicate these finding in a separate cohort of 485 IBD trios (reported in the same 
publication) where they were only able to demonstrate a trend towards significance 
for IBD and CD (p=0.09 and p=0.07 respectively). Evidence of epistasis between the 
113G/A variant of DLG5 and NOD2/CARD15 variants was also observed in the CD 
cohort in Stoll’s study.
DLG5 is a member of the membrane-associated Guanylate kinase (MAGUK) 
family.287 MAGUKs are known to form scaffolds for proteins involved in 
intracellular signal transduction. DLG5 is important in maintaining the epithelial 
structure, and the genetic variants in DLG5 could therefore interfere with the 
epithelial barrier function and in turn lead to increased permeability of the mucosa in 
the gastrointestinal tract.287;288 In silico analysis suggests that the 113G/A (R30Q) 
variant may impair DLG5 scaffolding function, but as yet no expression or functional 
studies in IBD patients have been conducted.286
This is the first study of the DLG5 gene in childhood onset inflammatory bowel 
disease. A priori we examined the contribution of the DLG5 113G/A mutation with 
respect to disease susceptibility and phenotype. The results demonstrate a statistically 
significant but overall relatively modest increase in disease susceptibility for carriers 
of the variant alleles of DLG5 113 G/A. We identified several phenotypic factors 
associated with variant carriage viz. sex, height and social class.
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7.3 Patients and methods
7.3.1 Patients
Two hundred and ninety six patients (197 CD, 73 UC, and 26 IC) with IBD were 
studied. The demographics of the 197 Crohn’s disease patients are presented in table 
7-1. There were 116 males, the median age at diagnosis was 11.21 years (IQR 8.61-
13.02), 2.6% were smokers, 98% were Caucasian and 35% had a positive family 
history of IBD. A total of 17/189 (9.0%) had joint extraintestinal manifestations and 
21/189 (11.1%) had Erythema Nodosum. Examining growth centiles (75-91st) at 
diagnosis there were 8/186 (4.3%) in this category for weight, 21/179 (11.7%) for 
height and 15/179 (8.4%) for BMI.
The demographic data for the 73 ulcerative colitis patients studied are shown in 
Table 7-2.
7.3.2 Parents and controls
In 69% of IBD patients family trios were available for TDT analysis. There were also 
data from 260 adult healthy controls (129 males and 131 females) that had been 
previously genotyped and reported by Noble et al. available for case-control 
analysis.289
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Table 7-1: Demographics of Crohn’s disease patients 
Disease location 
Terminal Ileum (L1) 9 (4.6%)
Colon (L2) 48 (24.3%)
Ileocolonic (L3) 38 (19.3%)
Upper gastrointestinal (L4) 93 (47.2%)
None 9 (4.6%)
Disease behaviour 






Gastric antrum 49/168 (29.2%)
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Table 7-2: Demographics of ulcerative colitis patients
Sex (M/F) 35/38
Median Age at diagnosis(y) 10.58 (IQR 8.42-12.83)
Current Smoker 1 (1.4%)
Family history 21 (28.7%)
Caucasian (%) 71 (97.3%)
Disease extent
Extensive Colitis 52 (71.2%)




Erythema Nodosum 4 (5.5%)
Anthropometric Measurements
Weight 75-91st centile 7/64 (10.9%)
Height 75-91st  centile 5/58 (8.6%)
BMI 75-91st  centile 7/58 (12.1%)
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7.3.3 Deprivation status
Socioeconomic status based on the patient’s postcode was allocated using the 
Carstairs score. This score is a measure of socioeconomic deprivation derived from 
levels of male unemployment, head of the household’s social class, the level of 
overcrowding in households, and car ownership generated from census data.282  Data 
used to calculate the scores for this study were based on the UK 2001 census data. 
The Carstairs score was then assigned a numerical deprivation category (DepCat 
score) based on the postcode, scored 1-7; where a score of 1 is associated with no 
deprivation and a score of 7 equals maximum deprivation. The data for the DepCat 
score were not calculated as part of this study; the DepCat scores were merely 
matched with the patient postcode. The DepCat scores and matching postcodes were 
obtained from the Edinburgh University data library and were supplied by Robin 
Rice, librarian. In cases where a patient’s postcode fell between two different DepCat 
categories, no score was allocated. Thus, this score is derived from a person’s 
postcode and reflects the socioeconomic status of the area in which a patient lives 
rather than an individual case-specific score. The methodology used to define North 
and South Scotland was also based on a patients’ postcodes.12
7.3.4 Genotyping
The SNP 113G/A (rs1248696) and DLGe_26 (rs2289311) were genotyped using the 
TaqMan system assay on demand methodology with primers shown in table 7-3. The 
genotyping methods used for the 3 NOD2/CARD15(Gly908Arg, Arg702Trp and 
Leu1007fsinsC) mutations have been described previously in chapter 4. 
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Table 7-3 : DLG5 SNP primers
Table 7-4: Transmission Disequilibrium Testing results for the DLG5-113 mutant allele 
Observed Expected Variation (O-E) χ2 p value
IBD 68 58.543 22.272 4.01 0.045
CD 48 42.453 15.991 1.92 0.178
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7.4 Results 
The DLGe_26  (rs2289311) was not satisfactorily assayed with > 45% failure rate, so 
further analysis was not undertaken and thus the results presented are for the DLG 
113G/A SNP only.
7.4.1 TDT Analysis 
The results are presented in table 7-4. TDT analysis based on 270 families 
demonstrated an association of allelic variants of the 113G/A allele with IBD 
(χ2=4.01, p=0.045) but not Crohn’s disease or ulcerative colitis.
7.4.2 Case-control analysis
The results are presented in Table 7-5 for 296 IBD patients, 197 CD and 73 UC 
patients compared to 260 healthy controls. There was no significant difference in 
overall allele frequencies or carriage rates of 113G/A variant alleles in patients 
compared with healthy controls.  The 113G/A SNP was in Hardy-Weinberg 
equilibrium in patients and controls. 
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Table 7-5: Case control analysis



























1.5% 1.0% 1.0% 0%
*p value compared to healthy controls
Table 7-6: DepCat scores in IBD patients and DLG5 carriage
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7.4.3 Genotype-phenotype analysis: unifactorial analysis
7.4.3.1 Association with affluence 
The results are presented in table 7-6 matching a patients DepCat score with carriage 
of DLG5 variants. A higher rate of carriage of the 113G/A variant was present in the 
patients with DepCat score 1 (n=12) compared to those with DepCat score 2-7 
(n=252) (66.7% vs. 22.6% p=0.0005 OR 6.84[1.99-23.55]) and in comparing allele 
frequency between the two groups (33.3% vs. 13.3% p=0.006 OR=3.26(1.34-7.92). 
A higher carriage of 113G/A variants was also demonstrated if patients with DepCat 
scores 1 and 2 were analysed together (n=43), and compared to patients with DepCat 
scores 3-7(n=221) (37.2% vs. 22.2% p=0.03 OR 2.08[1.04-4.17] respectively). All 
patients in DepCat 1 were Caucasian and consisted of 7 males and 5 females. There 
was no significant difference between Northern (n=35) and Southern latitudes 
(n=259) in the carriage of variant 113G/A alleles (34.4% vs. 23.9%, p=0.20 
respectively).
7.4.3.2 Growth centiles
Carriage of variants of the 113G/A allele were associated with the higher height 
centiles (>75th centile) for IBD and CD (42.9% vs. 23.1%, p=0.01 OR 2.50[1.18-
5.28] and 40.7% vs. 18.9%, p=0.01 OR 2.95[1.23-7.04] respectively). Higher 
carriage of 113G/A variants was highest in the 75-91st centile for weight and height 
at diagnosis for patients with IBD compared to those in other centiles (56.2% vs. 
23.4% p=0.004, OR 4.20[1.49-11.81] and 48.0% vs. 22.4% p=0.006 OR 3.19[1.36-
7.47] respectively). 
The same centile associations (75-91st) were also demonstrated for CD patients 
(62.5% vs. 21.8% p=0.008, OR 6.01[1.37-26.29] and 50% vs. 21.8% p=0.002 OR 
4.20[1.6-11.00] respectively). There was no association demonstrated with Body 
Mass Index centiles or if z scores were used instead of centiles.
IBD Genetics in Scottish Children
DLG5 180
7.4.3.3 Sex
In males with Crohn’s disease the carriage rate of 113G/A variant alleles was higher 
than in females with Crohn’s disease (29.3% vs. 16.9%, p=0.04 OR 2.04[1.01-4.11]  
and there was a trend towards higher allele frequency (15.1% vs. 9.0%, p=0.07 OR 
1.79 [0.94-3.40]). There was no difference between allele frequency and carriage 
rates of 113G/A variants in patients with UC or IBD.
7.4.3.4 Other variables
The carriage of 113G/A variant alleles was uncommon in patients with joint disease 
or joint symptoms but did not reach statistical significance (13.0% vs. 25.9%, p=0.21 
OR 0.42[0.12-1.49] respectively). There was no difference in the median ages at 
diagnosis of carriers of 113G/A variant alleles vs. non-carriers for patients with CD 
at 11.4 years vs. 11.2 years (p=0.91) and with IBD at 11.3 years vs. 10.9 years 
(p=0.73).  There was no difference in allele frequency or carriage rates of this 
113G/A DLG5 variant in disease location or behaviour in patients with either 
Crohn’s disease or Ulcerative colitis at diagnosis.
7.4.4 Multifactorial analysis
Binary logistic regression analysis combining family history of IBD, sex, weight, 
height and BMI centile (as either 75th –91st or other), social class (as either DepCat 
score 1 or 2-7) together with joint disease in all patients with IBD was performed. 
Carriage of the 113G/A variant was associated with DepCat score 1 taking into 
account all of the above factors (p=0.001, OR=6.92[2.24-21.33]). If the same model 
was run combining DepCat 1 and 2 together compared to 3-7 and with all other 
factors the association between higher socio-economic class and 113G/A carriage 
was confirmed (p=0.02, OR=2.49  [1.13-5.47]). 
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7.4.5 DLG5-NOD2/CARD15 interaction 
There was no difference in carriage of the DLG5 113G/A variants when patients 
were stratified based on carriage of at least one of the three common CARD15 
variants (Gly908Arg, Arg702Trp and Leu1007fsinsC).  The carriage of CARD15 
variant alleles compared to non-carriage in patients with IBD or CD patients was 
(14.0% vs. 20.5%, p=0.30 OR 0.63 [0.26-1.53] and 14.7% vs. 20.5% p=0.43 OR 
0.66 [0.23-1.88] respectively).
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7.5 Discussion
The overall association of the DLG5 113G/A variant alleles with early-onset IBD in 
the Scottish population appears relatively modest. Carriage of variants was more 
common in males, taller children and those in the highest social classes. These 
findings are interesting given that no clear genotype-phenotype relationship has been 
published previously but require replication in a larger numbers of patients in other 
populations before they can be accepted as true findings.262;289
An association between higher social class (DepCat 1) and early onset IBD in 
Scotland by Poisson regression analysis in a study of 580 IBD patients has been 
demonstrated by Armitage et al; these data clearly demonstrated that the relative risk 
of IBD and CD in Scottish children is decreased in areas of socio-economic 
deprivation.12 The association of Crohn’s disease with affluence has also been 
demonstrated in other childhood populations outside Scotland.290 Blanchard et al. 
demonstrated an association between affluence also using postcodes and census data 
in a childhood CD population from Manitoba, Canada. In a follow up study also 
based in Manitoba, Green at al. demonstrated an association of IBD with higher 
social class and a negative correlation with rates of enteric infections.291
The reason for these associations with affluence remain unclear but the role of water 
quality,16 diet (cold-chain hypothesis), hygiene and infection rates 17 are potentially 
plausible. Gent et al. studied 133 patients with CD and matched them with 
population controls demonstrating CD patients were significantly more likely to have 
a hot water tap and a separate bathroom. No association was seen in the 231 UC 
patients and population controls when studying these measures of hygiene reported 
in the same study. Hugot et al. proposed the rise in Crohn’s disease in the 20th
century was due to the increased use of refrigeration.17 He proposed that 
psychotropic bacteria that exist particularly at refrigeration temperatures e.g. listeria, 
yersinia were responsible for interaction with peyers patches and thus involved in 
Crohn’s disease aetiology. These observations are yet to be replicated.
The most provocative data from this study proposes that individuals within these 
affluent regions may also possess a risk genotype. The association with relative 
IBD Genetics in Scottish Children
DLG5 183
affluence in the present study is present when DLG5 113G/A carriage rate is 
compared between patients with DepCat score 1 and DepCat 2-7 and when patients 
resident within DepCat 1 and 2 are compared to those with DepCat scores 3-7. 
Moreover the association holds on multifactorial analysis. The major limiting factor 
in this data however is the small number of patients in DepCat 1 alone at 12. The 
lack of a trend in the data over the social classes outside DepCat 1 suggest that this 
finding only relates to the most affluent of children or it is a false positive result 
created by the relatively small numbers of patients in this group. The data need to be 
replicated by other groups before broader conclusions can be drawn from analysis of 
this small patient group.
Assuming these results were found to be true  the potential mechanisms whereby 
DepCat 1 children should differ from children with other DepCat scores and how this 
influences the development of IBD remain uncertain and a matter for investigation, 
but it is interesting to note some of the differences highlighted from published 
studies. Children from lower DepCat scores have higher rates of dental caries, are 
more likely to be colonized with yeasts, and have higher rates of Helicobacter pylori 
infection.283;284 Breastfeeding incidence and duration are highest in DepCat 1 and 2 
together in one study,292 and they are higher in DepCat 1 compared with 2 and other 
categories in a second study.293 Strange et al. demonstrated the highest breast feeding 
rates in Lothian in the period 2002-03 at 6-8 weeks of age in mothers who were 
DepCat 1 and 2 at a rate of 70% higher than all other DepCat categories. Smith et al. 
demonstrated breast feeding rates in Argyle and Clyde in the period 1995-99 were 
significantly higher in DepCat 1 at 51% compared in a stepwise decreasing rate to 
other DepCat scores with DepCat 7 demonstrating a breastfeeding rate of only 17%. 
These data present a possible mechanism of how DepCat score, environment, and 
genotype could all interact.
Growth and development are critical aspects of childhood onset inflammatory bowel 
disease that are often overlooked in adult practice.294 Many series have now reported 
linear growth failure in series of children developing Crohn’s disease in childhood.295
Growth failure is a severe manifestation of CD that has been robustly linked to 
carriage of disease associated variants from within the IBD5 locus as discussed in 
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chapter 6. In the present study the association of DLG5 variants is not with growth 
retardation but rather with higher height and weight centiles leading to the 
hypothesis that this variant may act in the opposite manner, and in fact confer a 
protective effect against growth failure. A similar protective role has been previously 
suggested for the –238 TNF-α variant in a paediatric Crohn’s disease population.245
Levine et al. have described an association between the -238 TNF-α polymorphism 
and a higher height z-score in Israeli children with CD. Thus, the anthropometric 
data complement the associations described with affluence providing indirect support 
for the concept that this growth variant leads to disease expression in children 
lacking socio-economic deprivation. 
The 113G/A variants were commoner in males compared to female children with 
Crohn’s disease in this study. It has been reported that the DLG5 113G/A variant is  
more common in males.156 Friedrichs et al. combined data from Stoll’s original study 
and added the data from the Italian and Canadian populations (but not the UK) 
described by Daly et al. The overall odds ratio for risk of CD for the 113G/A variant 
in this combined study group was 1.52 but when calculated for men and women 
separately gave OR of 2.49 and 1.01 respectively. This effect is driven by a 
significantly lower carriage rate of the 113G/A in male control populations. In a 
separate study, Biank et al. studied 281 children with CD and demonstrated a 
significant negative association between DLG5 113G/A carriage and female sex and 
subsequent to this finding demonstrated a significant difference in carriage between 
males and females. Thus, it seems entirely plausible that studies in early onset 
populations may be more likely to give positive results when studying DLG5 
variations because of the male predominance in childhood onset Crohn’s disease in 
contrast with the female predominance in adult populations.8;11
What then of the overall contribution of this DLG5 variant to disease susceptibility? 
The results of this study and how it compares to other published TDT studies of the 
DLG5 gene are shown in Table 7-7. The TDT analysis in this study (p=0.045) 
reveals similar data to those of Stoll et al. in Germany and subsequent publications, 
which have suggested a weak overall association of variant alleles of DLG5 113G/A 
with IBD.286;296 In Stoll’s original study, initial TDT analysis was performed on 457 
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IBD trios (302 with CD) and demonstrated association for IBD (p=0.004) and CD 
(p=0.04).286 In a replication cohort of 485 IBD trios (reported in the same 
publication) Stoll and colleagues were only able to demonstrate a trend towards 
significance for IBD and CD (p=0.09 and p=0.07 respectively). Daly and colleagues 
have reported TDT data on the 113G/A variant in two further populations; one 
reporting a significant association for IBD in a UK population of 124 IBD patients 
(p=0.02), and in the second no evidence of association in a Canadian IBD population 
of 182 patients.296 No p value results were reported in Daly’s TDT analysis for 
patients with Crohn’s disease. In the Flemish population, in contrast to results 
published by other investigators, Vermeire et al. reported  significant 
undertransmission of 113G/A variants in TDT analysis of 373 IBD trios.254 Thus of 
the disease populations studied a modest effect on IBD susceptibility has been seen 
in 3 independent populations out of 6 studied and only one study286 has demonstrated 
significant association with Crohn’s disease. Given this modest effect this present 
study was probably underpowered to fully explore any association with Crohn’s 
disease and was certainly underpowered for ulcerative colitis.
The case-control data in this current study do not support Stoll’s initial findings of a 
significant difference between cases and controls in possession of variants of the 
113G/A allele, this is despite demonstrating very similar allele frequencies of 
113G/A variants in this study cases compared to Stoll’s, 13.0% and 13.2% 
respectively. The results from all case control studies are presented in table 7-8.286
Other case-control studies have yielded inconsistent  results.262;286;289;296 Noble et al. 
demonstrated no increased risk in 374 Scottish adult CD patients carrying 113G/A 
variants using a similar group of controls than used in this present study. Torok et al. 
studied the 113G/A variant in 625 German CD patients and demonstrated no 
association. Daly et al. performed two case control studies in three different 
populations.296 In the first study a combined Canadian/Italian population of 339 IBD 
(207 CD and 90 UC) patients and 207 controls a significant association was 
demonstrated with 113G/A with both CD and UC. However, in a much larger study 
in a UK population of  689 IBD patients (353 CD 336 UC) and 493 controls 
published in the same paper no association was demonstrated. Thus there has been a 
wide variation in the allele frequency of variants of the DLG5 113A allele in the 
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different populations studied in both cases and controls. A significant association has 
only been demonstrated in 2 out of the 6 populations studied. 
Table 7-7: TDT analysis in published studies






This study 270 0.045 0.18
German286 457 0.004 0.04
German/UK286 485 0.09 0.07
Canada 296 182 NS* not given
UK 296 124 0.017 not given
Pooled UK/Canada 296 306 0.018 not given
Belgium254 373 0.01** 0.006**
* Exact value not stated; ** significant undertransmission of 113A
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 Table 7-8: published case control studies










































* Cases were European, controls were German only;** These were the same group 
of control patients
# Personal communication CL noble
1. All numbers of patients or controls quoted are taken directly from the results tables 
in the relevant publications rather than the numbers quoted in other areas of the 
publications which often are not the same.
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Indeed, in the published studies to date it would seem that heterogeneity amongst 
controls more than cases in the frequency of 113G/A variant alleles may help explain 
the major differences between study populations.297 Tenesa et al. performed a meta-
analysis of adult data from the studies of Stoll, Noble and Daly and demonstrated 
statistically significant heterogeneity between the different study populations more so 
among population controls than among cases. The heterogeneity described between 
different study populations matches that shown in the Scottish population for other 
IBD genes NOD2/CARD15 as discussed in chapter 4 and TLR4.184;255;298
The analysis in this study (with positive TDT analysis yet a negative case-control 
analysis) and the conflicting data from the several other series now reported are 
nonetheless consistent with the hypothesis that DLG5 may represent a gene of 
relatively modest effect in IBD, as evidenced by the relatively low odds ratio of 1.62 
in the original study and lower still values in replication studies e.g. OR= 1.3 in 
Daly’s study.286;296 The different results between populations overall may be 
explained by a combination of factors- heterogeneity between geographically and 
ethnically distinct populations; as well as heterogeneity within subgroups of IBD 
patients with specific differences in the sex and age of cases. It is interesting to note 
that in this study of the Scottish childhood population using TDT analysis, a method 
that protects against the problems of population stratification to an extent, a positive 
association with IBD has been demonstrated when case-control results have been 
negative.95 An adequately powered case-control study to prove beyond doubt a 
definite role for DLG5 variants in IBD aetiology may necessitate studies of greater 
size than any yet carried out in Crohn’s disease or Ulcerative colitis, requiring 
several thousand patients and controls.296 This strategy is similar to that applied to 
many other polygenic diseases, in which genetic determinants of low genotype 
relative risk have been identified.91
The results of this study are therefore consistent with those published to date with a 
modest effect on disease susceptibility and association with male sex. The 
associations of variant carriage with affluence and protection from growth 
retardation, while awaiting replication in other study populations need to be 
interpreted with relative caution given the small numbers of patients analysed.
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8 The role of Anti-Saccharomyces cerevisiae antibody in 
predicting disease susceptibility and phenotype
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8.1 Summary
Aims: To determine Anti-Saccharomyces cerevisiae antibodies (ASCA) status and 
its relationship with disease phenotype in childhood onset IBD.
Subjects: 301 Scottish early onset IBD patients [197 CD, 76 UC and 28 IC]. 
Methods: ASCA status (IgA, IgG) was determined using an ELISA kit. ASCA status 
was then matched with Crohn’s disease (CD) phenotype at diagnosis. 
Results: CD patients had a higher prevalence of ASCA antibodies compared to UC 
patients and healthy controls (41.6% vs. 15.8% Odds Ratio (OR) =3.80[1.93-7.50] 
and 41.6% vs. 7.7% OR= 8.56 [3.55-20.62] respectively).
Unifactorial analysis of disease phenotype in CD patients demonstrated a positive 
ASCA was associated with oral (68.0% vs. 38.6% OR 3.39[1.38-8.34]) and perianal 
(50.6% vs. 35.2% OR 1.89[1.04-3.44]) disease location as well as markers of disease 
severity: raised CRP (48.9% vs. 24.5% OR 2.95[1.36-6.37]), hypoalbuminaemia 
(51.8% vs. 27.0% OR 2.28[1.19-4.37]), surgery (55.1 vs. 36.6% OR 2.11[1.10-4.06]) 
and the presence of granulomata (47.7% vs. 28.8% OR 2.25[1.13-4.48]). On a 
multifactorial analysis the presence of oral disease (adjusted p = 0.001, OR 
22.22[3.41-142.86]) and hypoalbuminaemia (adjusted p = 0.01 OR 4.78[1.40-16.39]) 
were found to be independently associated with ASCA status. 
Conclusions: CD patients had a higher prevalence of ASCA than other IBD patients. 
ASCA status defines CD patients with a specific phenotype, showing association 
with markers of disease severity and oral CD involvement.  
.
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8.2 Introduction
The data on the presence of specific serologic markers in IBD patients, including 
children date back many years.299;300  In 1988, Main et al. reported serum titres of 
both IgA and IgG antibodies directed against the oligomannan component of 
Saccharomyces cerevisiae (ASCA) were higher amongst patients with CD compared 
to controls.301  In subsequent paediatric studies, patients with CD have been found to 
have a higher prevalence of  ASCA antibodies (50-70%) compared to UC patients 
(10-15%) and healthy controls (<5%).302;303 ASCA has been linked to various 
Crohn’s disease phenotypes including disease location, disease behaviour and need 
for surgery.214;304-308 The presence of ASCA antibodies seems to pre-date clinical 
symptoms and their presence has been demonstrated before the diagnosis of CD.309
Whether the development of ASCA antibodies represents an adaptive immune 
response to an unknown environmental exposure or represents a genetic 
predisposition to developing Crohn’s disease remains contentious.310
An association between ASCA status and the presence of NOD2/CARD15 variants 
also been inconsistently replicated with a number of studies supporting 214;311;312  or 
failing to support this association.216;305;308 No associations have been suggested with 
other IBD genes. ASCA and p-ANCA are well established serological markers in 
IBD having associations with CD and UC respectively.313
Apriori this study aimed to determine the prevalence of ASCA antibodies in the 
cohort of patients with early onset IBD and assess relationships with disease 
phenotype. Post hoc analysis also examined the interaction of ASCA status with IBD 
candidate genes examined in earlier chapters of this thesis NOD2/CARD15 (chapter 
4), IBD5/ OCTN (chapter 6) and DLG5 (chapter 7).
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8.3 Patients and Methods
8.3.1 Patients and controls
There were 301 IBD (197 CD, 76 UC, and 28 IC) patients analysed. Of the 197 CD 
patients analysed there were 115 males (58.4%), the median age at diagnosis was 
11.25 years (IQR 8.75-13.00) and 35.1% had a positive family history of IBD.
Data previously analysed by Walker et al. examining ASCA status in 78 Scottish 
adult blood donors who acted as healthy controls, were also available to use in the 
study.305
8.3.2 Crohn’s Disease Phenotype
The presenting phenotype of patients with CD is shown in table 8-1.Of particular 
note in the analysis of this study oral Crohn’s disease was defined by macroscopic 
changes (mucosal tags, deep linear ulceration, cobblestoning, lip swelling and 
fissuring) after examination by a paediatric dentist or oral medicine specialist and/or 
the presence of granulomata on buccal biopsy. The presence of oral Crohn’s disease 
as stated by the patients physician was not taken as acceptable evidence of the 
presence of disease, based on findings from previous studies that have demonstrated 
a physicians assessment is unreliable.314
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Raised CRP 90/139 (64.7%)
Albumin≤35g/l 85/159 (53.5%)
ESR >10 141/152 (92.8%)
Platelets >400 117/176 (66.5%)
Anaemia 87/178 (48.9%)
IBD Surgery 49/196 (25.0%)
Granulomata 32/184 (71.7%)
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8.3.3 ASCA enzyme-linked immunosorbent assay (ELISA) method
Blood samples were collected from subjects when recruited as part of the early onset 
genetics study. Plasma was isolated at the time of lymphocyte extraction and samples 
were stored at -80oC until analysis. The ASCA combi kit® (Generic Assays, 
Dahlewitz, Germany) was used to measure ASCA IgG and IgA in patient samples, 
according to the manufacturer’s instructions. The optical density (OD) of the 
developed assay was measured using a spectrophotometric Enzyme-Linked 
Immunosorbent Assay (ELISA) reader at 450nm wavelength. 
Results were interpreted by calculating the binding index (BI) with the formula: BI= 
ODsample/ODcut-off control. The cut-off control, positive and negative control samples 
were provided in the kit. A BI of ≥1 was considered to be a positive result, and <1 
was considered to be a negative result. In keeping with standard ELISA practice each 
patient sample was analysed in duplicate.
8.3.4 Statistical Analysis
The χ2 test was used for analysis of selected discrete variables. A multifactorial 
analysis of ASCA status compared with all variables with p<0.25 was carried out 
using a binary logistic regression analysis. The variable was considered independent 
if a result of p<0.05 was generated. Data were analysed using SPSS® Statistical 
Software, version 11.5. 
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8.4 Results
8.4.1 ASCA prevalence in patients and controls 
CD patients had a higher ASCA positivity rate at 41.6% compared to UC patients 
(15.8%, p=0.0001 OR=3.80[1.93-7.50]), IC patients (0% p< 0.00001 OR=∞) and 
healthy controls (7.7%, p<0.0001 OR 8.56[3.55-20.62]). These results are 
summarised in table 8-2.
The sensitivity of ASCA in predicting CD was 41.6% with a specificity of 88.6%, 
positive predictive value of 86.3% and negative predictive value of 47.0%. Using 
likelihood ratios, patients who were ASCA positive were approximately 7 times 
more likely to have CD than UC.
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P value and odds 
ratio*
CD (n=197) 82 (41.6%) 115 (58.4%) -
UC (n=76) 12 (15.8%) 64 (84.2%) p= 0.0001, 
OR=3.80[1.93-7.50]
IC  (n=28) 0 (0% ) 28 (100%) p< 0.00001, 
OR=∞
HC (n=78) 6 (7.7%) 72 (92.3%) p< 0.00001, 
OR= 8.56[3.55-20.62]
* compared to Crohn’s disease
IBD Genetics in Scottish Children
Role of ASCA 197
8.4.2 Unifactorial Analysis in Crohn’s Disease patients 
8.4.2.1 Age at diagnosis
There was no significant difference in age at diagnosis in patients who were ASCA 
positive compared to those who were ASCA negative 11.7 years vs. 11.4 years 
respectively (p=0.28). 
8.4.2.2 Disease location and behaviour
The results summarising ASCA status and disease phenotype are listed in table 8-3. 
ASCA status was compared in all locations throughout the GI tract using a 
“paediatric” phenotype as well as using the locations defined in the Vienna 
classification. Only selected locations that reached statistical significance are 
presented in table 8-3 for the paediatric phenotype although all locations were 
analysed. Significant associations were seen with oral and perianal disease (68.0% 
vs. 38.6%, p= 0.008 OR=3.39[1.38-8.34] and 50.6% vs. 35.2%, p=0.04 
OR=1.89[1.04-3.44] respectively). 
In patients who did not have a disease location fitting into the Vienna classification 
classified as “none” a higher ASCA positivity rate was demonstrated (88.9% vs. 
40.4% p=0.02 OR=11.76[1.44-100.00]). As described in the methods section, these 
are patients with oral or peri-anal disease or a combination of both (see chapter 2 for 
further details). No associations were seen between disease behaviour at diagnosis 
and ASCA status.
8.4.2.3 Blood results
A positive ASCA was more common in patients with hypoalbuminaemia (<35g/l) 
(51.8% vs. 29.0% p=0.01, OR=2.28[1.19-4.37] and raised CRP (48.9% vs. 24.5% 
p=0.006, OR=2.95[1.36-6.37]). No relationship was seen with raised ESR, 
thrombocytosis or anaemia (table 8-4).
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8.4.2.4 Surgery
A positive ACSA status was present in Crohn’s disease patients undergoing surgery 
(55.1% vs. 36.6% p=0.03 OR=2.11[1.10-4.06]).
8.4.2.5 Other variables
Patients with granulomata present at diagnosis had a higher rate of positivity than 
those without granulomata (47.7% vs. 28.8% p=0.02 OR=2.25[1.13-4.48]). No 
associations were seen with growth parameters, extra-intestinal manifestations or the 
presence of atopic disease.
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Table 8-3: Univariate analysis of Crohn’s disease phenotype






p-Value, with Odds Ratio 
and 95% Confidence Interval
Disease location 
Ileal 5 (55.6%) 77 (42.1%) 0.43, OR=1.72 (0.45-6.62)
Ileocolonic 12 (33.3%) 70 (44.9%) 0.21, OR=0.61 (0.29-1.32)
Colonic 19 (39.6%) 63 (43.8%) 0.61, OR=0.84(0.43-1.64)
Upper GI 38 (42.2%) 44 (43.1%) 0.90, OR=0.96(0.54-1.71)
None 8 (88.9%) 74 (40.4%) 0.02, OR=11.76(1.44-100.00)
Disease behaviour
Inflammatory 66 (41.3%) 16(48.5%) 0.44, OR=0.75(0.35-1.48)
Stricturing 1(14.3%) 81(43.5%) 0.12, OR=0.22 (0.03-1.83)
Penetrating 15 (57.7%) 67 (40.1%) 0.09, OR=2.04 (0.88-4.70)
Disease location
Oral 17 (68.0%) 59 (38.6%) 0.008, OR=3.39 (1.38-8.34)
Jejunal 15 (53.6%) 53 (39.8%) 0.19, OR=1.74 (0.77-3.95)
Perianal 39 (50.6%) 38 (35.2%) 0.04, OR=1.89 (1.04-3.44)
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ASCA +ve  
Without Variable
p-Value, with Odds 
Ratio and 95% 
Confidence Interval
Raised CRP 44 (48.9%) 12 (24.5%) 0.006, OR=2.95(1.36-
6.37)
Albumin≤35 44 (51.8%) 20 (29.0%) 0.01, OR=2.28(1.19-
4.37)
Raised ESR 60 (42.6%) 2 (18.2%) 0.14, OR=3.29(0.69-
15.87)
Raised Platelets 53 (45.3%) 19 (32.2%) 0.10, OR=1.74(0.90-
3.36)
Anaemia 40 (46.0%) 33 (36.3%) 0.25, OR=1.50(0.82-
2.73)
IBD Surgery 27 (55.1%) 54 (36.6%) 0.03, OR=2.11(1.10-
4.06)
Granulomas 63 (47.7%) 15 (28.8%) 0.02, OR=2.25(1.13-
4.48)
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8.4.3 Multifactorial Analysis 
The results of this analysis are presented in table 8-5. A multifactorial binary logistic 
regression analysis was performed for ASCA status on the all variables with a p-
value of <0.25. Of these the presence of oral disease and hypoalbuminaemia were 
related to a positive ASCA status (adjusted p=0.001, OR 22.2[3.4-142.8] and 
adjusted p=0.01, OR 4.78 [1.40-16.39] respectively). 
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Table 8-5: Multifactorial binary logistic regression analysis









Oral Disease 0.008 3.39 1.38-8.34 0.001 22.22 3.41-142.86
Jejunal Disease 0.185 1.74 0.77-3.95 0.109 2.96 0.79-11.11
Perianal Disease 0.036 1.89 1.04-3.44 0.597 1.29 0.50-3.33
BMI <9th 
Centile 
0.237 1.45 0.78-2.71 0.184 1.99 0.72-5.49
Raised CRP 0.006 2.95 1.36-6.37 0.754 1.24 0.32-4.78
Albumin <35 0.013 2.28 1.19-4.37 0.012 4.78 1.40-16.39
Platelets 0.097 1.74 0.90-3.36 0.746 1.24 0.33-4.67
Granulomata 0.021 2.25 1.13-4.48 0.297 1.88 0.58-6.10
  * Adjusted
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8.4.4 ASCA and interaction with IBD genes
The carriage rate of the 3 common variants of NOD2/CARD15 (R702W, G908R and 
1007finsC) was not significantly different in ASCA positive and negative patients 
(21.5% vs. 22.3% respectively, p=0.90). There was no evidence of any association 
with DLG5 113A variants or the TC haplotype in ASCA positive and negative 
patients (27.8% vs. 20.4%, p=0.23 and 77.9% vs. 68.3% p =0.15 respectively).
8.4.5 Childhood vs. adult data
The data for CD patients in this study were compared to that previously published by 
Walker et al that provided data the Scottish adult cohort for ASCA status. 305 The 
ASCA positivity rate in children with CD from this current study 82/197 (41.6%) 
was significantly lower when compared to adults with CD 81/143 (57%) (p=0.006, 
OR=0.55[0.35-0.84]). There was no significant difference ASCA positivity between 
children and adults with UC 12/76 (15.8%) compared to 14/75 (18.7%) p=0.64. 
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8.5 Discussion
In this study the previously described association of increased ASCA positivity in 
CD patients has been replicated in the largest paediatric IBD cohort studied to date. 
Additionally, using rigorous phenotypic analysis an association of ASCA status has 
been demonstrated with markers of disease severity and a novel association has been 
described with oral Crohn’s disease.  
The incidence of oral Crohn’s disease is higher in Scottish children than in children 
from other parts of the UK.39 It is interesting therefore that in this study a positive 
ASCA status acted as an independent risk factor for oral involvement in Scottish CD 
patients. No association has been demonstrated with oral disease involvement in the 
genetic studies described in this thesis in previous chapters (NOD2/CARD15, 
OCTN1/2, and DLG5). In this study a positive ASCA serology predicted oral 
involvement in CD patients with a sensitivity of 68.0% and specificity of 61.4% 
compared to CD patients without oral involvement. 
In the only other published study examining ASCA status and oral CD, Savage et al. 
demonstrated higher salivary ASCA IgA in 26 patients with oral CD compared to 22 
CD patients with no oral involvement (p<0.02).315 This finding was independent of 
intestinal inflammation elsewhere in the gastrointestinal tract in the 26 patients with 
oral CD (12 of the patients had inflammatory changes on colonoscopy, 14 did not). 
In contrast to the findings in this study Savage et al. described a raised serum ASCA 
in CD patients with inflammation elsewhere in the GI tract but not in those patients 
with oral inflammation only. The findings of this present study are however more 
robust, bearing in mind Savage et al. examined a much smaller number of patients 
overall and the findings of the study were only subject to unifactorial analysis.
Previous studies in adult CD cohorts have found that positive ASCA status is found 
predominantly in those with more ‘proximal’ disease e.g. small intestine.305;316
Walker et al. in a previous study of 143 Scottish adult CD patients demonstrated 
ASCA was associated with gastro-duodenal and small bowel CD compared to 
colonic CD. In a study of 100 CD patients Quinton et al. demonstrated ASCA was 
more common in CD patients with small bowel involvement. ASCA status has been 
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linked with ileal disease, 151;214;306;316 and the upper GI disease(L4) location of the 
Vienna classification by other groups.305;317 Lack of replication of association with 
oral CD involvement as demonstrated in this study could be accounted for by the 
under-representation of patients with oral CD in other studies (it is not recognised as 
a disease location in the Vienna classification).36 It is also possible that the 
contribution of oral CD to ASCA status was missed due to difficulties in the 
diagnosis of oral involvement if expert opinion was not sought.314 In a prospective 
study of 48 CD patients Harty et al. demonstrated paediatric dentists were experts in 
diagnosing oral manifestations of CD but paediatric gastroenterologists missed the 
diagnosis in around half of cases. This current study has addressed the problems 
highlighted by previous studies by using an extensive description of disease 
phenotype, using only well defined cases of oral involvement by selecting cases 
where granulomata have been demonstrated on buccal biopsy or diagnosis has been 
confirmed by a paediatric dentist only, in addition to using a large study population.  
ASCA status in CD patients has been associated with increased disease activity 
(measured by Paediatric Crohn’s Disease Activity Index [PCDAI]) and disease 
severity.305;318 In the present study ASCA status is a marker of severe CD with 
unifactorial associations with raised CRP, low albumin and surgery (replicating 
findings for NOD2/CARD15 mutations, chapter 4) and additionally in this study 
with hypoalbuminaemia on multifactorial analysis. The association between positive 
ASCA status and the need for surgery304-306;308;319;320 and NOD2/CARD15 status and 
need for surgery193;321 has also been demonstrated by other groups. Other groups 
have clearly demonstrated ASCA positivity is associated with more rapid disease 
complications with higher rates of stricturing and penetrating disease independent of 
any NOD2/CARD15 associations.322;323 In a small study of 34 UC patients 
undergoing pouch surgery post operative complications were more common in 
patients who were ASCA positive.324
Several antibodies to other antigens have been described to be higher in patient with 
CD : OmpC (antibodies to the outer-membrane porin C of E.Coli), I2 (antibodies 
against a pseudomonas fluorescens-associated sequence) and cBir1(anti-flagellin 
antibodies).325;326 Most recently a number of antiglycan antibodies have also been 
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described to occur more frequently in CD patients.327 Positivity to not only ASCA 
but to the other microbial antigens has been shown to be a predictor of disease 
progression in a recent large paediatric study.328 Dubinsky et al. studied 196 
paediatric Crohn’s disease patients and determined their anti-I2, anti-OmpC, anti-
CBir1 as well as their ASCA status. Progression of disease behaviour to penetrating 
or stricturing type was predicted by positivity to one or more serum markers with 
greatest risk in those patients who were positive to all four markers.
Routine blood tests (FBC,ESR,CRP and albumin) will be abnormal in most children 
with IBD and so performing serological markers has little additional diagnostic 
benefit.223;329 Beattie et al. demonstrated in 39 IBD patients and 37 controls at least 
one of these routine blood tests was likely to be abnormal. Khan et al. studied 90 
IBD patients and studied ASCA and p-ANCA in addition to the previously 
mentioned routine blood tests and found little additional diagnostic benefit when 
serology was performed. 
The results of this study demonstrated similar sensitivity and specificity to ASCA 
assays used in other published paediatric and adult studies as highlighted in table 8-6. 
However the lack of sensitivity demonstrated in this and other studies with increased 
ASCA prevalence found in other diseases like Behçet’s disease, primary biliary 
cirrhosis, autoimmune hepatitis, and coeliac disease, has prevented ASCA status -
becoming a useful diagnostic tool in UK clinical practice.330
Thus although ASCA has questionable clinical benefit as a diagnostic tool it does 
seem to characterise a specific more severe disease phenotype and thus could be used 
clinically in stratifying treatments in future studies in patients with Crohn’s disease.
Why should ASCA be higher in patients with oral Crohn’s disease in particular? It 
has recently been suggested that that the immunogen for the production of ASCA is 
Candida albicans.331 Candida colonises the entire gastrointestinal tract but initial 
exposure will happen first in the mouth and the proximal gastrointestinal tract. With 
the similarities described between disease phenotypes predicted by NOD2/CARD15 
and ASCA it could be argued they are representing the same disease mechanism. 
NOD2/CARD15 mutations represent a defect in the innate immune system triggered 
by specific ligands on bacterial cell walls.101 ASCA may represent a specific, 
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genetically determined breakdown in a mechanism to innate tolerance to yeast or 
fungal molecular patterns, to which the intestinal epithelium is exposed. Evidence for 
ASCA representing a defect in the innate immune system has been demonstrated by 
its association with lower levels of mannose binding lectin(MBL), a component of 
the innate immune system.332 Seibold et al. determined ASCA status plus screening 
for MBL variants in 58 CD patients, 18 UC patients and 47 healthy controls. ASCA 
positive patients were more likely to have MBL mutations and additionally were 
found to have lower serum MBL levels compared to ASCA negative patients.
Other investigators have demonstrated an association between ASCA status and the 
presence of NOD2/CARD15 variants214;311;312 with demonstration of a gene dosing 
effect in one study.311 This relationship however has not been universally replicated 
and as well as this study other groups including Scottish adult patients have been 
unable to replicate these findings.216;305;308 The most recent study to address this issue 
has demonstrated patients and unaffected relatives who possess NOD2/CARD15 
mutations are more likely to demonstrate positivity to one or more of the panel of 
microbial antigens.333 The lack of replication in this study may in part be explained 
by the lower carriage of the NOD2/CARD15 in the Scottish population,255 “under 
powering” investigation of any such relationship. 
The role of ASCA serology in defining patients who are more likely to have CD than 
UC is demonstrated robustly in this study. The more interesting data however were 
with regard to the small group of patients (n=28) with IC none of whom had a 
positive ASCA, replicating previous paediatric data (n=7 patients) published by 
Gupta et al.320 This data also replicates studies from Joosens et al. in a larger adult 
series of 97 IC patients that demonstrated patients who are ASCA negative tend to 
retain their diagnosis of IC over time, with a median follow up time of ten years in 
Joosens study.242 Indeed in a follow up study of the same patient group if a wider 
panel of antibodies are determined (anti-I2 and anti-OmpC) a significant number of 
patients appear to be negative to all antibodies and remain so over an extended 
follow up period.241
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Table 8-6: Sensitivity and specificity of ASCA in previous publications 
Study Sensitivity Specificity CD Population 
Description
Present study 41.6% 88.6% Scottish paediatric 
cohort (n = 197)
Canani et al 2004318 58.8% 92.5% American paediatric 
cohort (n=102)
Zholudev et al 2004306 44% 98-100%* American paediatric 
cohort (n=81)
Ruemmele et al 1998302 55% 100% Canadian paediatric 
cohort (n=130)
Walker et al 2004 305 57% 87% Scottish adult cohort 
(n= 143)
Vermeire et al 2001334 41-76%** 86-98%** Belgium adult cohort 
(n=100)
Quinton et al 1998335 57% 97% French adult cohort 
(n=100)
Koutroubakis et al 
2001336
39% 89% Greek adult cohort 
(n=56)
*The specificity figures quoted was for ASCA IgA and ASCA IgG respectively.
** >1 form of ASCA assay was used in this study. 
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In conclusion ASCA prevalence is increased in patients with CD compared to 
patients with other types of IBD and healthy controls. Detailed phenotypic 
examination has allowed demonstrated of novel phenotypic association with oral CD 
on multifactorial analysis. The challenge now facing researchers and clinicians is 
how to incorporate these findings into the current model of disease pathogenesis and 
to explore the clinical applications of ASCA serology in treating patients with IBD. 
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9 Implications, further and future work
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9.1 Implications
This thesis set out to investigate the contribution of several genes and their effect on 
disease susceptibility and phenotype in children with IBD. I was successful in 
collecting a suitable cohort of children to study the genetics of inflammatory bowel 
disease and collecting one of the largest such cohorts available in the world for such 
studies in children. After the childhood cohort was collected along with parental 
DNA the major genes implicated in disease susceptibility at the start of, and during 
the course of, the thesis were studied. The contribution of the NOD2/CARD15 gene 
which has been implicated in Crohn’s disease populations throughout the Western 
world was thoroughly assessed and this gene does not explain the major genetic 
contribution to disease susceptibility in Scottish children. Subsequent studies of 
IBD5 and DLG5 did demonstrate a role in increasing susceptibility to IBD but their 
overall contribution was in a similar manner to NOD2/CARD15, relatively modest.
9.2 Regression analysis of relative contribution of CD susceptibility 
genes in Scottish childhood onset IBD
To clarify the exact contribution each gene made to disease susceptibility in the 
Scottish early onset population a regression analysis was undertaken. Applying a 
forward-Likelihood Ratio Stepwise regression model, genotypes and/or carriage 
status of the candidate genes studied in this thesis were analysed, namely: the 3 
common NOD2/CARD15 polymorphisms (R702W, G908R and Leu1007fsinsC), 
OCTN1/SLC22A4 1672 C/T, OCTN2/SLC22A5 –207 G/C as well as 3 SNPs in the 
extended IBD5 haplotype (IGR2096a_1, IGR2198a_1, and IGR2230a_1), DLG5 113 
G/A,  together with a NOD1/CARD4 SNP (NOD1+32656)337 and several TNF-
promoter SNPs (–1031T/C/-863C/A/-857C/T/-806C/T )338 studied subsequent to the 
conclusion of this thesis. All SNPs were analysed in the Scottish early onset 
population for their relative contribution to CD susceptibility. Only one, the 
NOD2/CARD15 Leu1007fsinsC contributed significantly to CD susceptibility 
(p=0.009 OR 7.71 CI 1.65-35.98). This clarifies that further work is needed, 
continuing on from the findings of this thesis to determine the major genetic 
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influences in the Scottish early onset population that determine susceptibility to 
Crohn’s disease.
The data contained within the thesis has explained very little of the genetic 
contribution to either Ulcerative colitis or indeterminate colitis. This is as a result of 
several inter-related factors: Crohn’s disease from family studies has the largest 
genetic contribution to disease susceptibility compared to the other two types of IBD; 
48 the number of patients in childhood IBD populations is proportionately less than 
the number of patients with Crohn’s disease with double the number of CD patients 
compared to UC and 6 times more CD than IC. To explore susceptibility in these 
groups thoroughly, a much larger cohort of patients with these disease types would 
have to be collected.  
Despite these limitations novel associations have been identified, homozygous 
carriage of the TC haplotype was found to be more common in UC patients, a result 
consistent with the fact associations with IBD5 and UC have been demonstrated by 
several other research groups.247;263;339
The only association found in the thesis for patients with indeterminate colitis was 
increased susceptibility in patients carrying V955I variants of the NOD2/CARD15 
gene. This association has not been examined by any other research group to date 
and has to be interpreted cautiously given that that were only a small number of 
patients (n=28) in the IC group.  
The successful replication of the three candidate genes within this thesis 
(NOD2/CARD15, IBD5 SNPs and DLG5) has been based on calculations using
standard statistical values with a p value of <0.05. All three candidate genes have 
achieved this level of significance but the weakness of these findings was they were
based on pragmatic numbers of patients recruited to the study rather than working to 
previously calculated power calculations. This traditional statistical threshold is 
therefore scientifically lenient in studies that are examining the genetics of complex 
chronic diseases. 
The “winners curse” has been demonstrated many times in such studies where a 
candidate gene identified in an index study has not been replicated in larger 
subsequent studies, suggesting the initial finding was a false positive thus 
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demonstrating the weakness of employing traditional statistical modelling.340 To 
avoid such problems Wacholder et al. proposed analysing candidate gene studies 
using the false positive report probability, where in addition to the p-value generated 
in the study consideration is also placed on the prior probability of genetic 
association and a power calculation.341 This will become an even more important 
consideration as candidate genes generated by genome wide association studies (see 
below) are described where the generated odds ration for candidate genes in some 
studies has been less than 1.5. The strength of replication of candidate genes within 
this thesis is that the results have been replicated in many different populations,342
and as such are likely to represent true genetic associations rather than the fact they 
reached the “traditional” statistical threshold when analysed in the Scottish childhood 
IBD population.
9.3 Novel methods for identification of candidate genes
9.3.1 Genome wide association studies
Most recently, catalysed in part by technological advances allowing cheaper 
genotyping, and the completion of the HapMap project, genome wide association 
studies have been used to identify IBD genes.343 In these studies a large number of 
SNPs are studied across the whole genome in disease cases and compared to healthy 
controls providing a collection of hypothesis free candidate genes.344 The first such 
IBD study to be performed was in the Japanese IBD population where Yamazaki et 
al. studied 80,000 SNPs across the genome. They reported an association between 
CD and the TNFSF15 (Tumour Necrosis Factor Superfamily, member 15) on 
9q33.345 They then replicated their findings in cohorts of European IBD patients.
Duerr et al. performed a genome-wide association study testing 308,332 SNPs in 547 
ileal CD patients and 548 controls of non-Jewish European ancestry. This study 
implicated germline variations of interleukin-23 Receptor (IL23R) on Chromosome 
1p31.346. Replication was obtained in a Jewish-ancestry ileal CD case-control cohort 
and by transmission disequilibrium testing in 883 families with IBD, the later
demonstrating association for all types of CD as well as UC. 
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Although the IL23R gene data were published first the full GWAS that the IL23R 
data were derived from, with results for other candidate genes were published 
subsequently.347 Rioux et al. analysed 304,413 SNPs in the patient group described in 
the IL23R study with ileal CD containing subjects with both Jewish and non-Jewish 
ancestry. This studies most significant results suggested a role for an intergenic area 
on 10q and for the ATG16L1 gene (see below).
In a German-British collaboration, Hampe et al. studied 19,779 SNPs in 735 Crohn’s 
disease patients and 368 controls.348 They demonstrated an association with a coding 
variant of ATG16L1 (Autophagy-related 16-like 1) gene, on 2q37.1 and replicated 
their findings in a family based association study and in an independent case control 
cohort. 
In a further GWAS study from Belgium, Libioulle et al analysed 311,882 SNPs in 
579 Belgian CD patients and 928 French and Belgian controls.349 This study 
replicated the findings for NOD2/CARD15 and IL23R but described a novel CD 
susceptibility locus at 5q13 at the site of a gene desert. This large 250kb area is 
devoid of genes and separated into 5 haplotype blocks with the strongest signal 
located in block 3. The association with CD was replicated in an independent case-
control cohort and within family trios. The authors presented some provisional data 
to suggest that a gene located at the edge of the gene desert was the important 
candidate gene from within this susceptibility locus namely the prostaglandin 
receptor EP4 gene.
The Wellcome trust case consortium have performed a GWAS of 7 common diseases 
of which Crohn’s disease was one. 350 This study has replicated the findings of 
previous studies and presented evidence for novel candidate genes. This study 
examined 500,568 SNPs in 16,179 subjects of whom 2000 had Crohn’s disease 
(collected from 5 UK centres- Cambridge, Oxford, London, Newcastle and 
Edinburgh) and 3,000 of whom were healthy UK population controls. This study 
replicated data for candidate genes identified by GWS (NOD2/CARD15 and 
IBD5)106;109 and data from published GWAS (IL23R, ATG16L1, the 10q21 
intergenic region and the 5q13 gene desert).347-349;351  
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The study also presented preliminary data on four novel candidate genes immunity 
related guanosine triphosphatase (IRGM), bassoon (BSN) gene, a cluster of SNPs 
around chromosome 10q24.2 and an area on chromosome 18p11upstream of  the 
protein tyrosine phosphatase, nonreceptor type 2 (PTPN2) gene. Interestingly the 
PTPN2 gene was also identified in patients with type 1 diabetes and to a lesser extent 
in patients with Rheumatoid arthritis. In a subsequent publication, Parkes et al. 
examined the data on the four novel regions identified in the scan and examined 
them in independent case control studies.352 These extension studies have provided 
further data supporting a role for IRGM and PTPN2 genes, as well as several other 
genes including IL12B a key player in the IL23/IL12 pathway.
While these studies represent a great advance in identifying genes important in IBD 
and other common disease they will not identify rare variants. Future efforts to 
capture all variants could be addressed by performing whole genome resequencing in 
cases and controls, but currently these studies are technologically and financially 
unachievable.353
9.3.2 Gene wide association studies
During the lifetime of the thesis researchers have moved away in the majority of 
cases from studying single or several SNPs within genes, to haplotype-tagging based 
approaches to comprehensively assess the gene-wide contribution to the disease 
being studied. The use of a gene-wide haplotype-tagging strategy has already proven 
successful in the analysis of other IBD candidate genes, in which equivocal evidence 
had been provided by single SNP analyses in different populations. This method of 
gene assessment has become feasible only since the full publication of the HapMap 
project data.343
Applying this approach to capture the haplotypic variations of the Multi Drug 
Resistance 1 (MDR1) gene, Ho et al. observed a highly significant association in the 
Scottish adult population between the common haplotypes of MDR1 and UC (p=4.22 
x 10(-7)) but not CD (p=0.22).354 These data provided really clear evidence of an 
important contribution to susceptibility and phenotype, in the face of inconsistent 
reports from other populations, and have been supported by publication of a 
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subsequent MDR1 meta-analysis.355 Ho and colleagues also confidently refuted the 
role of the pregnane X receptor gene (PXR/NR1I2) in IBD susceptibility in the same 
population, after application of a gene-wide haplotype tagging approach.356  
 In a further application of this technique in the study population collected for this 
thesis, Van Limbergen et al. has used this approach to move on from single SNP 
analysis in the NOD1/CARD4 gene,337 to comprehensively refute a role for this gene 
in the Scottish early onset population.357 McGovern et al. initially suggested the 
association of the deletion variant of a complex intronic insertion*2/deletion*1 
polymorphism (32656) of NOD1/CARD4 with susceptibility to IBD using a 
combination of TDT and case-control analysis.358 However, well-designed 
replication studies involving large numbers of IBD patients in four different 
populations have been negative, casting doubt on the contribution of this 
NOD1/CARD4 SNP and gene.337;359;360 In support of these negative susceptibility 
studies, a gene wide association study was performed in 356 Scottish children with 
IBD using 9 marker SNPs based on HapMap data, with no association demonstrated 
using three complementary methods of statistical analysis namely, single and 
multiple marker case-control analysis, TDT analysis and log-likelihood analysis.
9.3.3 Yeast two hybrid studies
The yeast two-hybrid is a disease model that investigates protein-protein interactions 
and has also been employed to try and identify new genes important in IBD.100 When 
investigating these ‘protein- protein’ interactions, a single “bait” protein is used to 
search for interaction with a library of proteins fused to the activation “prey” 
domain.361 In studies of IBD genes an intestinal cell library has been used. This yeast 
two hybrid model has been used successfully in IBD, identifying interactions with 
the NOD2/CARD15 gene. Barnich et al. identified the GRIM19 protein interacting 
with NOD2/CARD15,362 while Yamamoto-Furusho et al. identified Centaurin 
[beta]1 that interacts with both NOD1/CARD4 and NOD2/CARD15.363
IBD Genetics in Scottish Children
Implications, further and future work 217
9.3.4 Microarray Studies 
Gene expression technology using gene microarrays allows a comprehensive picture 
of gene expression at the tissue and cellular level, thus helping understand the 
underlying physiological and pathological processes in IBD patients.364 In these 
studies RNA is isolated from the tissue sample or cells that are to be examined e.g. 
intestinal tissue, and this is then used to generate cRNA or cDNA. These samples are 
then mounted on a “chip” and the arrays are fluorescently labelled so that they can be 
analysed by confocal laser scanning.364
In one of the first IBD micro-array studies, Lawrance et al.  examined global gene 
expression profiles of inflamed colonic tissue in IBD patients.365 They identified 
several hundred genes with altered expression both increased and decreased, that had 
not previously been linked to IBD. The results demonstrated distinct gene profile 
differences between patients with CD and UC. In further microarray studies, again 
using biopsy samples, Wu et al. have demonstrated different gene expression profiles 
when comparing inflamed and non-inflamed IBD samples, different gene profiles 
between non-inflamed IBD samples and healthy controls and again demonstrated 
distinct gene expression patterns between inflamed CD and UC samples.366 In further 
microarray studies in the healthy adult colon, the gene expression profiles differ 
markedly between the left and right side of the colon, this effect is primarily driven 
by genes involved in developmental pathways (Noble CL, unpublished work).
9.4  A Northern European founder gene?
It is possible that any gene identified in the Scottish childhood (or adult) IBD 
populations in Scotland may be important not only for Scottish patients but also 
patients from other Northern European countries. Clear heterogeneity exists in 
carriage of NOD2/CARD15 variants in Northern Europe compared to Southern 
Europe where carriage rates are significantly higher.101 It is intriguing, and indeed,  
may seem superficially  paradoxical that the countries of Northern Europe where the 
incidence of Crohn’s disease and Inflammatory bowel disease in children are 
highest,9;10;12;367 have the lowest carriage of the commonest disease susceptibility 
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gene identified thus far- NOD2/CARD15. However, this means the identification of 
a “Northern European” founder gene currently remains a distinct possibility.  
9.4.1 Genetic studies in the Swedish IBD population
In collaborative work with Swedish colleagues, (Dr L Torkvist, Karolinska institute, 
Stockholm) the contribution of genes in a second Northern European IBD population 
has been studied. The contribution of the three common NOD2/CARD15 mutations 
to disease susceptibility was studied in 178 Swedish adult CD patients and 143 
healthy controls.201 The results produced were very similar to the Scottish IBD 
population with a population attributable risk (PAR) of 11% matching the equivalent 
figure in the Scottish adult population and similar to the Scottish childhood 
population figure of 8%.184;201
Beyond studies of the NOD2/CARD15 gene the role of two further genes have been 
analysed in the Scottish and Swedish populations. Variants of OCTN1/2 together 
with IBD5 marker SNPs were studied in 178 CD patients and 143 controls and 
demonstrated susceptibility to CD, again with a similar degree of magnitude to that 
of the Scottish population.253;368 The NOD1/CARD4 +32656 insertion/deletion SNP 
has been implicated in IBD susceptibility by McGovern et al,278 has demonstrated no 
contributions to disease susceptibility respectively in 1791 IBD patients compared to 
1649 healthy controls in a study that included both Scottish and Swedish adults with 
IBD and 313 Scottish children with IBD.337
Thus the data in two Northern European IBD cohorts are remarkably similar and 
have yet to explain the majority of genetic risk within either of these two Northern 
European populations.
9.4.2 Searching for a major Northern European susceptibility gene 
The lack of genome wide scans in Northern European populations (with the 
exception of a small UC dominated Finnish scan)369 means other methods of 
identifying candidate genes will need to be employed. Since commencing this thesis 
the methods available for identifying IBD genes have progressed rapidly, as already 
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discussed. So, rather than conducting a genome wide scan in a large Northern 
European population of relative pairs, as would have seemed logical at the start of 
the thesis, it would now be technically possible, and scientifically more robust to 
perform a genome wide association scan using Northern European populations of 
IBD patients and population controls. A genome wide association scan would seem 
to offer the best chance of novel gene identification in Northern Europe based on 
both current scientific knowledge and on practical numbers of subjects available to 
study. 
An alternative approach would be to perform a genome wide association scan in an 
exclusive early onset population. This would mean collaboration between several 
groups of investigators in order to get an appropriately powered study, especially if 
the aim was to identify novel UC genes. An appropriately powered study to identify 
genes of modest effect would need to study at least 1000-2000 children with IBD 
plus controls.
9.5 Childhood vs. adult studies
One of the major hypotheses explored in this thesis was looking for a genetic 
difference between the childhood and adult IBD populations. There was preliminary 
evidence from family studies that disease starting in childhood had a stronger genetic 
contribution,48 and evidence for the first two genes studied in the thesis IBD1 and 
IBD5, that children would be expected to have a higher mutation frequency.94;112
This hypothesis has not been supported by the data in this thesis with respect to 
NOD2/CARD15 as no difference has demonstrated between adult and paediatric CD 
populations in Scotland (table 9-1). The same lack of effect is demonstrated for IBD5 
and DLG5 by comparison of published figures for the childhood and adult 
populations in Scotland. It is interesting to note however that the ASCA prevalence 
was significantly lower in the childhood CD population although this serological 
marker clearly does not definitely reflect a genetic susceptibility towards disease 
development.
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The similarities in genotype contrast starkly with disease phenotype which differs 
markedly between both populations. Childhood onset CD is a male dominated 
disease, more likely to result in Crohn’s disease of the upper GI tract. Children also 
very clearly have more extensive ulcerative colitis than adults. Further examination 
of these differences should be explored by examining further candidate genes in both 
populations, standardising methods of investigation and comparing disease 
phenotypes in both populations over time. 
As Rioux et al demonstrated for the analysis of the genome wide scan investigating 
the IBD5 locus it is possible to stratify the results of a scan by age at diagnosis.112
The same technique could be applied to the GWAS that have been performed to date 
either using results from an individual scan or combining the results into a meta-
analysis. 
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Table 9-1: Childhood vs. adult studies 
Genetic/serological 
marker 
Carriage rate of variant 
alleles  
p value children vs. 
adults
NOD2/CARD15184;255 19.8% vs. 22.6% p=0.48
IBD5253;370 82.7% vs. 76.8% p=0.14
DLG5289;371 23.3% vs. 18.4% p=0.15
ASCA305;372 42% vs. 57% p=0.006
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9.5.1 Future genetic studies and further work
This thesis has produced exciting data based on studies of the NOD2/CARD15, 
IBD5 and DLG5 genes in the Scottish early onset population. The relatively low 
numbers of patients in the thesis means all of the data would need to be replicated in 
other populations before the findings could be considered scientifically robust, this is 
despite the fact that the collection of patients presented in this thesis is one of the 
largest such collections collected in the world to date. 
Further work to fully assess the genetic contribution to IBD could focus on the genes 
of the innate immune system given the rapid progress in understanding the 
importance of innate immune defects in IBD development,102 performed after the 
detailed studies of the NOD2/CARD15 gene e.g. NOD1/CARD4, RIPK2/RICK and 
the TLR genes. 
As mentioned further candidate genes could be identified by employing 
complementary gene finding strategies e.g. genome wide association studies, yeast 
two hybrid analysis and microarray studies. These human studies can be 
complemented by animal models of IBD using knock in and knock out mice to study 
the role of specific candidate genes.
Whatever methods of gene detection are employed it is clear collaboration between 
interested groups will be needed to study further candidate genes in detail. In the era 
of GWAS this means studying 2000-3000 patients and so will only happen in 
paediatric IBD studies with international collaboration between at least 4-6 national 
projects.
9.5.2 Disease site in Crohn’s disease and relationship to genetic/serological 
markers 
A summary of the relationship between the Crohn’s disease locations within the 
gastrointestinal tract and the genes/serological markers studied in this thesis is shown 
in figure 9-1. The proposed phenotypic classification for use in paediatric genetic 
studies allows the description of both well recognised and novel genotype-
phenotype associations. 
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Thus patients who carried one or more of the common variants of NOD2/CARD15 
(Chapter 4) were more likely to have disease located in the small bowel, both jejunal 
(novel) and ileal (well recognised) but particularly with both sites combined (novel). 
Similarly Crohn’s disease patients who possessed the TC haplotype, within the IBD5 
locus (Chapter 6), were more likely to have disease in the gastric antrum, another 
novel observation. No relationship with disease location was demonstrated for DLG5 
variants described in chapter 7. Patients with positive ASCA serology were more 
likely to have oral Crohn’s as described in chapter 8. 
Further studies in the Scottish early onset population by co-workers have added to 
this description of disease markers linked to specific sites of disease. Van Limbergen 
has demonstrated that the complex insertion deletion of the NOD1/CARD4 maybe 
associated with disease located in the gastric body ,337 and in other work lead by the 
same author TNF-α promoter mutations have been linked with colonic disease 
location.338
9.5.3 Genetic associations with disease location, true finding or false 
association?
The description of association between sites of disease activity for most of the genes 
studied in this thesis, begs the question as to whether these are true findings or 
simply represent statistical flaws from multiple testing. The NOD2/CARD15 
association with ileal disease is widely described and likely to be true, having been 
described in many studies and in a subsequent meta-analysis.185 This is further 
supported with the description of the association of NOD2/CARD15 mutations with 
Paneth cells and defensin production which are located within the ileum.228 Whether 
the association is only with ileal disease or whether it extends to jejunal disease as 
described in chapter 4 remains to be seen, but given the functional similarities 
between the ileum and jejunum this remains a plausible association that needs to be 
explored in other CD populations. The relative inaccessibility of the jejunum to 
biopsy means relying on assessing disease presence by the rather “blunt” method of 
small bowel follow through and perhaps this can only be fully explored when capsule 
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endoscopy that will pick up more subtle lesions, is used commonly in clinical 
practice.373
The association of IBD5 variants with gastric antral disease is a unique finding of 
this thesis in contrast to the well replicated evidence of NOD2/CARD15 mutations 
with ileal Crohn’s disease. Paradoxically, the IBD5 association was described on 
multifactorial analysis (p=0.003, OR= 4.02 [1.58-10.21]) in contrast to the 
NOD2/CARD15 that was only described in this thesis, at least, by unifactorial 
analysis so statistically speaking the association is actually more robust. As the exact 
gene within the IBD5 locus is yet to be determined is harder to speculate at present 
as to the physiological basis of any such association. 
In a similar manner to IBD5 the association of positive ASCA serology with oral 
Crohn’s disease location is described on multifactorial analysis. ASCA serology has 
been associated with a variety of disease locations most notably with small bowel 
disease in several studies. Few investigators have described an association with oral 
Crohn’s disease as patients with oral Crohn’s disease were not analysed as part of 
their studies. The one publication that did investigate this association was a small 
study of 26 patients that did describe a positive correlation between a positive 
salivary IgA ASCA and oral CD.374
There are some limitations to the data that have been presented here because of the 
multiple testing of different disease sites with the various candidate genes. The 
robustness of these findings are discussed individually but without replication these 
could still be chance findings. Applying corrections for multiple testing like a 
Bonferroni correction has been considered too strict for genotype-phenotype analysis 
by many investigators because of the interdependency of the variables being 
examined. In the thesis to fully explore possible relationships no corrections were 
made for multiple testing initially but any findings on unifactorial analysis were 
further examined by multifactorial analysis. In reality the true validity of the findings 
will only become apparent when they are examined in independent groups of patients 
with childhood onset IBD.
Thus the associations of genes with specific disease locations form an emerging body 
of evidence that demonstrates Crohn’s disease has many sub-phenotypes 
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characterised by specific genes or serological markers. These findings need to be 
further explored in independent cohorts with accompanying rigorous phenotypic data 
to allow these interesting data to be confirmed or refuted.
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9.6 Moving towards a uniform paediatric phenotype
There is as yet no recognised disease classification system for children with IBD.37
Childhood onset CD does not fit well into the adult phenotypic classifications 
devised to date. The hierarchical disease classification designed for use in adults 
(Vienna) has resulted in most paediatric patients with a disease location that fell into 
the upper GI (L4) category potentially disguising any underlying genotype 
phenotype relationships.36 The shortcomings of the Vienna classification have to 
some extent been addressed in the newer Montreal classification, which includes 
adoption of a non-hierarchal system and specific recognition of a separate early onset 
disease category (<17 years).35 Despite the relative shortcomings of these phenotypic 
classifications when applied to paediatric CD populations, they have set standard 
definitions for disease location and disease behaviour making preliminary steps 
towards uniformity of reporting for genotype–phenotype analysis in paediatric 
genetic studies.
These classification systems however do not incorporate one of the major phenotypic 
variables present in childhood studies, namely growth.  There is a strong argument to 
be made for an agreed and validated paediatric phenotypic classification, especially 
for Crohn’s disease. The lack of an agreed system means in practice that many 
genetic studies in children do not report disease phenotype or report it in a variable 
and inconsistent manner making replication of the findings between different studies 
difficult. 
The first steps towards a paediatric phenotypic classification have been taken in 
Europe at least with agreement on a good practice for investigation of new patients 
with IBD (the Porto criteria)158. All patients are recommended to be investigated with
an upper GI endoscopy, ileo-colonoscopy and a barium follow through. In this thesis 
the studies were reported using an adult classification system35;36 plus a specifically 
devised paediatric classification that is more extensive but as yet remains unvalidated 
in other paediatric studies.255;370;371
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9.6.1 A framework for developing a paediatric disease phenotypic 
classification
9.6.1.1 IBD
Before designing a phenotypic framework for children it would have to be agreed 
what a “child” is. There are, as previously mentioned in chapter 2, many different 
age definitions, but in the absence of strong evidence it would seem sensible to fall in 
line with the Montreal classification and use age <17 years at diagnosis. The question 
as to whether within childhood age should be further subdivided is not directly 
addressed in this thesis. However, given the strong evidence produced by Heyman et 
al.41 and Meinzer et al. 164 complemented by the data in this thesis about a different 
disease phenotype at age eight and below, it would seem dividing age at diagnosis 
into two age groups, 0-8 years and 9-16 years is reasonable. 
All patients with IBD should then have some general phenotypic parameters noted. 
The classification should incorporate growth parameters using z- scores for weight, 
height and BMI. An assessment of puberty should be made using a standard pubertal 
classification system, although we failed to do this well in the thesis simply because 
the data was not recorded. Surgery should be recorded as any operation, excluding an 
EUA but the type of surgery performed should also be noted e.g. drainage, resection 
etc.
9.6.1.2 CD specific
A basis for a paediatric CD phenotype based on this thesis would involve defining 
Crohn’s disease sites throughout the GI tract individually based on evidence from 
endoscopy, at the time of surgery, biopsy or barium follow through and would be 
independent of disease activity elsewhere in the GI tract. The disease behaviour 
classifications used in the Montreal classification would be satisfactory. This 
phenotypic classification is vindicated by the description of disease correlations with 
genetic markers that would have been missed by only sticking to either the Vienna or 
Montreal classifications. These novel correlations (as mentioned) include the 
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association of IBD5 variants with indices of growth in children with CD370 and the 
association of NOD2/CARD15 mutations with jejunal disease location.370
9.6.1.3 UC specific
In assessing disease location it seems sensible to include the three disease locations 
in the Montreal classification of proctitis, left sided disease and extensive disease but 
also include a fourth category of pancolitis with inflammation of the entire colon 
given that this is such a common phenotype in children.
The thesis has not been able to assess the minimum period over which to re-assess 
changes in disease phenotype, given that IBD and especially Crohn’s disease is 
dynamic over time. This study adopted a 2 yearly assessment in Crohn’s disease 
patients, but the time interval which will adequately reflect changes in disease 
phenotype over time has not yet been well studied in paediatric patients. This 
question can only be addressed by long term follow up of the patients in this study 
and is beyond the time scale of this thesis.
No disease classification would be perfect but any classification adopted by the 
paediatric IBD community could be modified once used in clinical studies in a 
similar manner to the Vienna classification being modified into the Montreal 
classification.
9.6.2 Clinical implications
The translation of basic scientific into clinical practice is the biggest challenge facing 
clinician scientists involved in IBD genetics, none more so than those studying 
disease with onset in childhood. At present the aspiration of using genetics to 
influence diagnosis or treatment in IBD has not yet been fulfilled. The use of a good 
clinical history and a simple set of blood investigations is enough to screen children 
with suspected IBD in most cases. Patients are keen for translation of IBD genetics 
into clinical practice with 90% of 250 IBD patients interviewed expressing 
enthusiasm for genetic testing of both themselves and their children.375 A genetic 
panel in combination with known environmental factors has been proposed by some 
groups but is not likely to be widely useful in clinical practice.376 Attempts at 
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predicting response to medications used in IBD have generally been disappointing 
with negative or unreplicated results being common place thus far. 
The work described within this thesis has definitely added to the data and evidence 
for stratifying Crohn’s disease into different subtypes. NOD2/CARD15 variants were 
clearly associated in this thesis with markers of severe disease most notably with a 
defined clinical outcome-surgery. This finding has also been consistently replicated 
by other investigators. The association with surgery has been very clearly 
demonstrated in another paediatric study in the USA in a similar study group size to 
the Scottish paediatric study and with remarkably similar results.193 These findings of 
association with NOD2/CARD15 variants and increased need for surgery have also 
been replicated in adult studies.215;321;377
The TC haplotype in the IBD5 locus also demonstrated association with a more 
severe disease phenotype manifest as lower weight/BMI at diagnosis and follow up. 
These data demonstrating association with growth parameters have not been 
replicated, however adult studies have replicated the association of IBD5 locus 
variants, with a more severe disease phenotype.253;260 So, these mutations could 
potentially, at least, be used to stratify treatments in paediatric Crohn’s disease 
studies with those carrying variant alleles being given 
immunosuppressants/biological treatments earlier in the disease course.
In summary, this thesis marks the end of the beginning in developing an 
understanding of the genes that underlie genetic susceptibility and disease phenotype 
in IBD patients in the Scottish childhood population. A fuller understanding of the 
genetic contribution to disease development will be gained by further studies 
examining other candidate genes recognised by the growing array of methods being 
used for gene identification followed by studies confirming changes in gene 
expression and function. Genome wide association studies look to be the most 
exciting method for identifying novel genes at present. Evermore studies in single 
disease populations are becoming less common and as further groups undertake such 
research studies in the childhood population only by collaboration between research 
groups will knowledge of importance to all children with IBD be truly fulfilled.
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10 Appendices
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10.1 Appendix 1: Lennard-Jones Criteria-check list
Study Number
Chronic granulomatous lip        1 Yes / No / Unknown
Pyloroduodenal disease Yes / No / Unknown
Small bowel disease Yes / No / Unknown
Chronic anal lesion Yes / No / Unknown
…………………………………………………………………………….
Discontinuous lesions          2 Yes / No
…………………………………………………………………………….
Fissuring ulcers          3 Yes / No
Abscess Yes / No
Fistula Yes / No
…………………………………………………………………………….
Strictures              4                             Yes / No
…………………………………………………………………………….
Aphthoid ulcers      5           Yes / No / Unknown
Lymphoid aggregates Yes / No / Unknown
…………………………………………………………………………….
Colonic mucin retention 6            Yes / No / Unknown
…………………………………………………………………………….
Granulomata 7       0 / 1-2 / 2-5 /6-10 / > 10
……………………………………………………………………………..
Number of section criteria met
Total number of criteria met
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10.2 Appendix 2: Patient information leaflet
The Genetic Influence In the development of Crohn’s disease and colitis in 
children
We invite you to participate in research which we think may be important. The 
information which follows tells you about it. Try to make sure you understand what 
will happen to you if you decide to take part. Whether or not you do take part is 
entirely your choice. Please discuss this with your family and ask any questions you 
want to about the research and we will try our best to answer them.
 We would like to understand more about why people especially children develop 
Crohn’s disease and colitis. These diseases are becoming more common in children 
especially teenagers and we want to try and work out why this is. We know that 
having a relative (either a parent or brother or sister) with Crohn’s disease or colitis, 
gives you a higher chance of getting the disease. We want to examine the things that 
are passed onto you by your parents (your genes) and how these may result in the 
development of Crohn’s disease or colitis.
You are going to undergo tests on your blood having been seen by one of the doctors 
in the clinic. 
What we are asking
We would like to ask your permission to collect some extra specimens (two to four 
teaspoons of blood) which we can use for research in our laboratories. We are also 
asking both of your parents for blood samples too.
What are we going to do with them?
We are going to use these specimens to help research into your genes and the part 
they play in the development of Crohn’s disease and colitis. Some of these 
specimens will be tested in the laboratory soon after being taken while others may be 
stored in a freezer before testing. Any specimens stored will only be used for studies 
which examine your genes and the development of Crohn’s disease and colitis.
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All our research is intended to increase understanding of how and why these diseases 
occur, how treatments work and how we may be able to improve treatments in the 
future. 
We also plan to study how genetic make-up may lead to children getting Crohn's or 
colitis and whether this make-up can alter how effective the treatments are.
How will this affect me?
We will always collect specimens needed for your planned tests before any research 
specimens. If there are any problems during the collection of these specimens i.e. in 
collecting blood then the doctors will not collect specimens for research.
Taking extra blood will not cause you any problems. The research itself is not 
relevant to your care. If in the future we would like to perform research that may be 
directly relevant to you we will contact you to see if you agree.
Do the specimens have my name on them?
The people in the laboratory will not know your name as your specimens will have a 
number. Only Dr Russell or ward or outpatient staff supervised by him will be able 
to know this and link it to specimens collected. 
What if I don't want to be included or change my mind?
You are entirely free to decide not to participate or drop out at any time and this will 
not affect your care in any way. If a specimen has been collected and you change 
your mind it will be destroyed at your request.
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10.3 Appendix 3: Parent information sheet
Parent/Carer's Invitation to participate in a research study: The Genetic 
Influence In the development of Crohn’s disease and colitis in children
We invite your child to participate in research which we think may be 
important. The information which follows tells you about it.  It is important that you 
understand what is in this leaflet. It says what will happen if you take part and what 
the risks might be. Try to make sure you know what will happen to you if you decide 
to take part. Whether or not you do take part is entirely your choice. Please ask any 
questions you want to about the research and we will try our best to answer them.
The Department of Paediatric Gastroenterology at Royal Hospital for Sick Children 
together with the Department of Gastroenterology at the Western General Hospital 
and other paediatric gastroenterology units in Scotland have a major role in leading 
research into diseases of the bowel in children. Diseases which we see often in the 
clinics and have on-going research interest include inflammatory bowel disease 
namely Crohn's disease and ulcerative colitis. 
Your child is due to undergo tests involving collection of a blood sample as part of 
their on going care. 
What we are asking
We would like your permission to collect extra blood (up to 20 ml = 4 teaspoons) 
which we will use for ongoing projects within our laboratories. Some of these 
specimens may be stored in a freezer for future projects. If specimens are stored they 
will only be used for studies relating to genetics and Crohn’s disease and ulcerative 
colitis. We will also collect and store important and relevant clinical details (e.g. age, 
sex, medication, disease, findings from the test) for analysis with the specimens.
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How will this affect my child?
Priority will always be given to collecting specimens needed for our planned tests. If 
there are any difficulties during the collection of these specimens e.g. in collecting 
blood then the doctors will not collect specimens for research. Taking extra blood 
will not mean any significant extra risk or harm to your child. 
What research is being done?
Broadly speaking we are planning to study how the genetic make-up of children with 
inflammatory bowel disease (Crohn's disease or Colitis) may lead to them getting the 
disease. 
The research included within this application will not have any impact on the care of 
your child (including any direct benefit or harm). All our research is aimed to 
increase understanding of how and why diseases occur, how treatments work and 
how we may be able to improve treatments in the future. If any studies may affect the 
care of individual children then a separate consent form will be produced.
Can I help too?
Yes you can by giving blood too. We would like wherever possible to collect blood 
from both parents as well as your child to help get maximum information from your 
child’s blood sample.  Your blood sample will expand the potential information we 
will gain from taking your children’s blood. We appreciate your help with the study 
and so will arrange to take blood samples at a time and place that is convenient to 
you.
Feedback As the information found is not of any clinical relevance to your child we 
will not routinely be feeding back any information to you directly. We will however 
feed the collective results back at local support group meetings (CICRA).
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Is this anonymous? 
While collection of these specimens will not be anonymous only doctors or nurses 
involved in his/her clinical care will have access to his/her name. This allows us to 
go back to the hospital notes if we need to identify important and relevant 
information later on. Within the laboratory anonymity will be maintained by 
allocating a number (rather than his/her name) to the specimens. Only Dr Russell or 
other staff from the wards/clinics under his supervision will be able to link his/her 
name to the specimen. 
What happens if I or my child are not keen or change our minds?
You and your child are entirely at liberty to decide not to participate or drop out at 
any time and this will not affect his/her care in any way. If after specimens have been 
collected you change your minds contact us and the specimens will be discarded if 
they have not already been used.
Is this ethical?
We have gained approval from the Lothian Regional Ethics Committee for the 
collection and storage of these specimens and data and each individual projects. 
Any other Questions? 
Any other questions can be addressed by writing to Dr Russell at the Dept of 
Paediatric Gastroenterology, Sciennes Road , Edinburgh or by contacting his 
secretary (0131 536 0615).
We also have an independent adviser Dr Steve Cunningham, a consultant 
paediatrician who can answer any concerns you have. Dr Cunningham is based at the 
Royal Hospital for Sick Children in Edinburgh but is not a member of the research 
team. 
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10.4 Appendix 4: Patient consent form
CHILD'S INVITATION TO PARTICIPATE IN A RESEARCH STUDY: CONSENT
THE GENETIC INFLUENCE IN THE DEVELOPMENT OF CROHN’S DISEASE
AND COLITIS IN CHILDREN
Name of Patient/Volunteer:
Address:
 I HAVE READ AND KEPT THE INFORMATION SHEET…
 SPOKEN TO THE DOCTOR AND MY FAMILY AND ASKED ANY 
QUESTIONS I WOULD LIKE…
 I REALISE I DO NOT HAVE TO DO THIS …
 I REALISE ANY BLOOD SAMPLE STORED WILL ONLY BE USED TO 
STUDY THE EFFECTS OF GENES ON CROHNS DISEASE AND COLITIS 
…
 AND CAN STOP OR WITHDRAW AT ANY STAGE WITHOUT 
AFFECTING MY TREATMENT….
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10.5 Appendix 5: example of parent consent form
PARENT/ GUARDIAN WRITTEN CONSENT FORM:
Title of research proposal: THE GENETIC INFLUENCE IN THE 
DEVELOPMENT OF CROHN’S DISEASE AND                    
COLITIS IN CHILDREN
GREC Number: GREC 03/0273
Name of Patient/Volunteer:
Address:
• The study organisers have invited my child to take part in this research.   Yes/No
• I understand what is in the leaflet about the research. I have a copy            Yes/No                 
of the leaflet to keep.
• I have had the chance to talk and ask questions about the study. Yes/No
• I know what my child's part will be in the study and I know how long it will take. Yes/No
• I know my child will gain no direct benefit from taking part in the study. Yes/No
• I know how the study may affect my child. I have been told if                             Yes/No              
there are possible risks. 
• I understand that my child should not actively take part in more                         Yes/No               
than 1 research study at a time.
• I know that the local Grampian Research Ethics Committee has seen                    Yes/No             
and agreed to this study.
• I understand that personal information is strictly confidential:  I know the only people who 
may see information about my part in the study are the research team or an official 
representative of the organisation which funded the research. Yes/No
• I freely consent for my child to be a subject in the study. Yes/No                                         
No-one has put pressure on me.
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• I know that my child can stop taking part in the study at any time. Yes/No     
• I know if my child does not take part he/she will still be able to have                    Yes/No               
their normal treatment.
• I understand that the sample may be stored and held for future research aimed at 
understanding the genetic influence on inflammatory bowel disease (Crohn's disease and 
inflammatory bowel disease) only, and not for other studies without my permission.
Yes/No
• I know that if there are any problems, I can contact: Yes/No
Dr Russell Tel. No.    0131 536 0615
Parent/Carer's Signature:........................................................
Date:........................................................
The following should be signed by the Clinician/Investigator responsible for 
obtaining consent
As the Clinician/Investigator responsible for this research or a designated deputy, I 
confirm that I have explained to the patient/volunteer named above the nature and 
purpose of the research to be undertaken.
Clinician’s Name: .....................................
Clinician’s Signature:.....................................     
Date: .......................................
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10.6 Appendix 6: Patient/parent questionnaire
Genetics of Inflammatory Bowel Disease
Confidential
QUESTIONNAIRE FOR PATIENTS WITH IBD
Patient Identification Number Sex:  Male   /   Female         
Date of Birth: Hospital ID:
Ethnic origin
White European  Hispanic 
Jewish  Afro-Caribbean 
Japanese  Asian 
Other/Unknown 
Postcode:
Name of present hospital consultant: Hospital:
Diagnosis: Ulcerative Colitis/ Crohn’s disease / indeterminate Colitis/OFG
Date at symptom onset (month/year)
Date of diagnosis: (month/year)
Age at diagnosis:
Year of diagnosis
Years of disease at assessment:
School year:
Other medical problems:




Does patient smoke cigarettes? YES NO
If Yes, How many cigarettes a day?
What age did you start smoking?
If No, Have you ever smoked? YES NO
How many cigarettes a day?
What age did you start smoking? (Year) What age did you stop?  (Year)
2. Mother: 
Did you smoke during pregnancy? YES NO
If Yes, How many cigarettes a day?
Where you smoking when patient born? YES NO
If Yes, How many cigarettes a day?
Do you currently smoke cigarettes? YES NO 
If Yes, How many cigarettes a day?
What age did you start smoking?
If No, Have you ever smoked? YES NO
How many cigarettes a day?
 3. Father: 
Did you smoke during pregnancy? YES NO
If Yes, How many cigarettes a day?
Where you smoking when patient born? YES NO 
If Yes, How many cigarettes a day?
Do you currently smoke cigarettes? YES NO 
If Yes, How many cigarettes a day?
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What age did you start smoking?
If No, Have you ever smoked? YES NO




Was patient breast-fed at all? YES NO 
If so for how long? (Months)
Vaccinations
Have you given your child the following vaccinations? (Tick all that apply)
DPT HIB MMR
Hep B Men c
Family History
Do you have? 
Coeliac disease? YES NO
Colon cancer? YES NO
Autistic spectrum disorder? YES NO
Asthma/eczema/hay fever/food allergy? YES NO
Does your mother or father have? (List affected family members/age of onset)
Crohn’s disease? YES  NO
Ulcerative colitis? YES NO
Coeliac disease? YES NO
Colon cancer? YES NO
Autistic spectrum disorder? YES NO
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Brothers and sisters
1. In total, how many brothers and sisters do you have?
Sibling rank
Have you ever shared a bedroom ? YES NO
Do your brother or sisters have?(List affected family members/age of onset)
Crohn’s disease? YES NO 
Ulcerative colitis? YES NO
Coeliac disease? YES NO
Colon cancer? YES NO
Autistic spectrum disorder? YES NO
Do your grandparents, aunts, uncles, or cousins have? (List affected family 
members and age of onset)
Crohn’s disease? YES  NO
Ulcerative colitis? YES NO
Coeliac disease? YES NO
Colon cancer? YES NO
Autistic spectrum disorder? YES NO
Swimming pools
Do you use a swimming pool? Frequently/rarely/never
Family estimate of number of disease relapses:
Surgery  
Has patient had any operations for IBD? YES  NO
If yes, please list below, with year if possible.
Date of surgery Type of operation
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Have you had your tonsils removed?     YES  NO
If yes, when? Age/year
Have you had your appendix removed?  YES  NO
If yes, when? Age/year
Any other surgery? YES  NO
Have you had any broken bones? YES  NO
If yes, how many?
Medications
Have you been treated with the following?
Steroids YES / NO / don’t know
Nutrition YES / NO /  don’t know
Azathioprine YES / NO /  don’t know
6MP YES / NO /  don’t know
Infliximab? YES / NO / don’t know 
Methotrexate YES / NO / don’t know
Number of steroid courses
Family estimate
Charted
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10.7 Appendix 7: Crohn’s disease phenotypic data collection form
Study Number
Crohn’s disease site Presentation / Follow-up Year
Site       Behaviour      
Oral Inflammatory  B1
Oesophagus Stricturing        B2
Gastric body Penetrating       B3
Gastric antrum Give details below
Duodenal Strictures
Jejunal           Abscesses









DEXA   yes / no 
EIM’s yes / no                give details
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10.8 Appendix 8: UC/IC phenotypic data collection form
Study Number
Presentation / Follow-up Date of Last Follow-up Clinic:
Date of last investigation:
Extent of UC
Examination       satisfactory / unsatisfactory
Examination type        colonoscopy / sigmoidoscopy
Examination stopped at
Ulceration   yes / no
Crypt abscesses   yes / no
Cryptitis   yes / no
Goblet cell depletion   yes / no
Disease years
Extent changed   yes / no          
Colectomy   yes / no
Comments
DEXA yes / no
EIM’s yes / no     give details
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10.9 Appendix 9 : Laboratory data collection form
 Study Number









For CRP please choose from  - normal or raised.
Clinic Date: Age at Diagnosis:
Height : Ht centile/Z-score
Weight: Wt centile/Z-score
BMI: BMI centile/Z-score
Puberty progressing normally / delayed / not assessed / not appropriate
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10.10 Appendix 10: The salting out method
All steps were performed having taken universal precautions before handling blood 
and all stages were then performed in an appropriate “hood” within the laboratory.
1. 10 mls of whole blood collected previously into an EDTA tube were added 
into a 50ml conical tube. 
2. 40 mls of red cell lysis buffer (RCLB) were then added to the conical tube.
3. The resulting mixture was then mixed and re-suspended for 5 minutes. 
4. The solution was centrifuged at 3000 rpm for 10 minutes.
5. The supernatant was then removed leaving a pellet in the “cone” of the tube.
6. The pellet was re-suspended with a further 40 mls of RCLB and then re-
centrifuged at the same speed for a further 5 minutes. 
7. The resulting “white blood cell” pellet was then further re-suspended in 3 mls 
of nuclear lysis buffer and sodium dodecyl sulphate. 
8. To this solution 1ml of 6M sodium chloride and 3mls of chloroform were 
then added.
9. The resulting mixture was then aggressively agitated to allow mixing.
10. The solution was then centrifuged at 3000 rpm for 20 minutes. 
11. The solution then separated into 3 layers. The middle layer was then carefully 
pipetted out to avoid mixing with the other 2 layers. 
12. The layer was added to 20 mls of 100% ethanol resulting in precipitation of 
DNA. 
13. This DNA pellet was removed from the alcohol and dried in room air for 5 
minutes. 
14. The DNA was transferred into 0.5 mls of TE and stored at 4ºC until dissolves. 
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